IMAX (IMAX) 10-Q 28 Jul 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2020shares
Document Information [Line Items]
Entity Registrant Name	IMAX Corporation
Entity Central Index Key	0000921582
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock Shares Outstanding	58,857,436
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	Z4
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	IMAX
Security Exchange Name	NYSE
Entity File Number	001-35066
Entity Tax Identification Number	98-0140269
Entity Address, Address Line One	2525 Speakman Drive
Entity Address, City or Town	Mississauga
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	L5K 1B1
City Area Code	(905)
Local Phone Number	403-6500
Other Address [Member]
Document Information [Line Items]
Entity Address, Address Line One	902 Broadway, Floor 20
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Country	US
Entity Address, Postal Zip Code	10010
City Area Code	(212)
Local Phone Number	821-0100

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Assets
Cash and cash equivalents	$ 318,986	$ 109,484
Accounts receivable, net of allowance for credit losses	54,839	99,513
Financing receivables, net of allowance for credit losses	123,865	128,038
Variable consideration receivable, net of allowance for credit losses	39,397	40,040
Inventories	60,179	42,989
Prepaid expenses	12,008	10,237
Film assets	13,147	17,921
Property, plant and equipment	287,220	306,849
Investment in equity securities	13,192	15,685
Other assets	24,575	25,034
Deferred income tax assets	46,826	23,905
Other intangible assets	28,204	30,347
Goodwill	39,027	39,027
Total assets	1,061,465	889,069
Liabilities
Bank indebtedness	297,765	18,229
Accounts payable	13,668	20,414
Accrued and other liabilities	108,917	112,779
Deferred revenue	104,311	94,552
Deferred income tax liabilities	18,475
Total liabilities	543,136	245,974
Commitments and contingencies
Non-controlling interests
Non-controlling interests	4,237	5,908
Shareholders' equity
Capital stock common shares — no par value. Authorized — unlimited number. 58,878,749 issued and 58,857,436 outstanding (December 31, 2019 — 61,362,872 issued and 61,175,852 outstanding)	405,583	423,386
Less: Treasury stock, 21,313 shares at cost (December 31, 2019 — 187,020)	(329)	(4,038)
Other equity	172,690	171,789
Accumulated deficit	(134,395)	(40,253)
Accumulated other comprehensive loss	(4,180)	(3,190)
Total shareholders' equity attributable to common shareholders	439,369	547,694
Non-controlling interests	74,723	89,493
Total shareholders' equity	514,092	637,187
Total liabilities and shareholders' equity	$ 1,061,465	$ 889,069

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Shareholders' equity
Common stock, par value
Common stock, shares issued	58,878,749	61,362,872
Common stock, shares outstanding	58,857,436	61,175,852
Number of treasury shares held in trust for future settlement of share based awards	21,313	187,020

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues
Revenues, total		$ 8,855	$ 104,797	$ 43,757	$ 184,995
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total		16,543	45,244	46,359	80,302
(Margin loss) gross margin	[1]	(7,688)	59,553	(2,602)	104,693
Selling, general and administrative expenses		29,796	32,136	58,432	59,785
Research and development		1,232	1,222	3,432	2,358
Amortization of intangibles		1,344	1,218	2,665	2,293
Credit loss expense		1,440	927	11,657	1,358
Asset impairments		0	0	1,151	0
Exit costs, restructuring charges and associated impairments		0	0	0	850
(Loss) income from operations		(41,500)	24,050	(79,939)	38,049
Gain (loss) in fair value of equity securities		2,025	(4,544)	(2,514)	(2,053)
Retirement benefits non-service expense		(130)	(160)	(246)	(320)
Interest income		891	572	1,256	1,142
Interest expense		(1,581)	(636)	(2,229)	(1,317)
(Loss) income before taxes		(40,295)	19,282	(83,672)	35,501
Income tax benefit (expense)		10,248	(5,308)	(5,257)	(8,956)
Equity in losses of investees, net of tax		0	(138)	(529)	(222)
Net (loss) income		(30,047)	13,836	(89,458)	26,323
Less: Net loss (income) attributable to non-controlling interests		4,080	(2,439)	14,137	(6,661)
Net (loss) income attributable to common shareholders		$ (25,967)	$ 11,397	$ (75,321)	$ 19,662
Net (loss) income per share attributable to common shareholders - basic and diluted:
Net (loss) income per share — basic and diluted		$ (0.44)	$ 0.19	$ (1.26)	$ 0.32
Technology Sales [Member]
Revenues
Revenues, total		$ 2,687	$ 19,694	$ 8,349	$ 34,894
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total		2,546	11,939	6,415	21,374
Image Enhancement and Maintenance Services [Member]
Revenues
Revenues, total		3,799	56,662	24,520	100,809
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total		7,244	26,781	25,060	46,024
Technology Rentals [Member]
Revenues
Revenues, total		(137)	25,863	5,834	44,033
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total		6,753	6,524	14,884	12,904
Finance Income [Member]
Revenues
Revenues, total		$ 2,506	$ 2,578	$ 5,054	$ 5,259
[1]	IMAX DMR gross margin includes marketing cost of $nil and $2.4 million for the three and six months ended June 30, 2020, respectively (2019 — $9.5 million and $13.4 million, respectively). JRSA gross margin includes advertising, marketing and commission expense of less than $0.1 million and $0.6 million for the three and six months ended June 30, 2020, respectively (2019 —$0.2 million and $0.3 million, respectively). IMAX Systems gross margin includes marketing and commission costs of $0.2 million and $0.4 million for the three and six months ended June 30, 2020, respectively, (2019 — $0.4 million and $0.9 million, respectively). Film Distribution segment gross margin includes marketing expense of less than $0.1 million and $0.2 million for the three and six months ended June 30, 2020, respectively (2019 — less than $0.1 million and $0.6 million, respectively).

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	$ (30,047)	$ 13,836	$ (89,458)	$ 26,323
Unrealized net gain (loss) from cash flow hedging instruments	1,334	297	(1,526)	365
Realized net loss from cash flow hedging instruments	337	374	695	693
Foreign currency translation adjustments	496	(1,257)	(615)	(172)
Defined benefit and postretirement benefit plans	4		17
Other comprehensive income (loss), before tax	2,171	(586)	(1,429)	886
Income tax (expense) benefit related to other comprehensive (loss) income	(442)	(177)	253	(278)
Other comprehensive income (loss), net of tax	1,729	(763)	(1,176)	608
Comprehensive (loss) income	(28,318)	13,073	(90,634)	26,931
Less: Comprehensive (loss) income attributable to non-controlling interests	3,930	(2,040)	14,323	(6,607)
Comprehensive (loss) income attributable to common shareholders	$ (24,388)	$ 11,033	$ (76,311)	$ 20,324

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating Activities
Net (loss) income	$ (89,458)	$ 26,323
Adjustments to reconcile net (loss) income to cash from operating activities:
Depreciation and amortization	27,182	29,804
Credit loss expense	11,657	1,358
Write-downs	6,806	508
Deferred income tax (benefit) expense	(4,878)	1,296
Share-based and other non-cash compensation	10,850	11,710
Unrealized foreign currency exchange loss (gain)	312	(14)
Loss in fair value of equity securities	2,514	2,053
Equity in losses of investees	529	222
Changes in assets and liabilities:
Accounts receivable	36,971	489
Inventories	(16,887)	(3,226)
Film assets	(4,057)	(8,214)
Deferred revenue	9,799	(1,355)
Changes in other operating assets and liabilities	(12,220)	(12,437)
Net cash (used in) provided by operating activities	(20,880)	48,517
Investing Activities
Purchase of property, plant and equipment	(594)	(4,175)
Purchase of equipment for joint revenue sharing arrangements	(3,908)	(22,235)
Acquisition of other intangible assets	(1,221)	(1,121)
Investment in equity securities		(15,153)
Net cash used in investing activities	(5,723)	(42,684)
Financing Activities
Increase in credit facility borrowings	280,244	35,000
Repayment of credit facility borrowings		(50,000)
Credit facility amendment fees paid	(959)
Settlement of restricted share units and options	(2,757)	(7,619)
Treasury stock repurchased for future settlement of restricted share units	(329)	(1,575)
Repurchase of common shares, IMAX China	(36,624)	(1,258)
Taxes withheld and paid on employee stock awards vested	(251)	(219)
Common shares issued - stock options exercised		2,379
Issuance of subsidiary shares to non-controlling interests (net of return on capital)		1,106
Dividends paid to non-controlling interests	(2,118)	(2,266)
Net cash provided by (used in) financing activities	235,674	(41,265)
Effects of exchange rate changes on cash	431	293
Increase (decrease) in cash and cash equivalents during period	209,502	(35,139)
Cash and cash equivalents, beginning of period	109,484	141,590
Cash and cash equivalents, end of period	318,986	106,451
IMAX China
Financing Activities
Repurchase of common shares, IMAX China	$ (1,532)	$ (16,813)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Capital Stock [Member]	Other Equity [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Non-controlling Interests [Member]
Balance, beginning of period at Dec. 31, 2018		$ 421,539	$ 179,595	$ (85,385)	$ (3,588)
Movement of Shareholders' Equity
Change in shares held in treasury		(659)
Employee stock options exercised		1,728
Amortization of share-based payment expense - stock options			4,488
Amortization of share-based payment expense - restricted share units			7,253
Restricted share units vested			(7,294)
Cash received from the issuance of common shares in excess of par value			651
Fair value of stock options exercised at the grant date		97	(97)
Common shares repurchased and retired		(604)		(1,105)
Common shares repurchased, IMAX China			(16,813)
Stock options exercised from treasury shares			(1,551)
Net (loss) income attributable to non-controlling interests	$ 19,662			19,662
Other comprehensive (loss) income, net of tax	608				662
Balance, end of period at Jun. 30, 2019		422,101	166,232	(66,828)	(2,926)
Balance, beginning of period at Dec. 31, 2018						$ 80,757
Movement of Shareholders' Equity
Net (loss) income attributable to non-controlling interests	6,661					7,035
Other comprehensive income (loss), net of tax	(54)
Dividends paid to non-controlling shareholders						(2,266)
Balance, end of period at Jun. 30, 2019						85,472
Balance, beginning of period at Mar. 31, 2019		418,907	176,587	(77,120)	(2,562)
Movement of Shareholders' Equity
Change in shares held in treasury		2,632
Employee stock options exercised		1,092
Amortization of share-based payment expense - stock options			2,382
Amortization of share-based payment expense - restricted share units			4,842
Restricted share units vested			(1,392)
Cash received from the issuance of common shares in excess of par value			484
Fair value of stock options exercised at the grant date		74	(74)
Common shares repurchased and retired		(604)		(1,105)
Common shares repurchased, IMAX China			(15,046)
Stock options exercised from treasury shares			(1,551)
Net (loss) income attributable to non-controlling interests	11,397			11,397
Other comprehensive (loss) income, net of tax	(763)				(364)
Balance, end of period at Jun. 30, 2019		422,101	166,232	(66,828)	(2,926)
Balance, beginning of period at Mar. 31, 2019						85,434
Movement of Shareholders' Equity
Net (loss) income attributable to non-controlling interests	2,439					2,703
Other comprehensive income (loss), net of tax	(399)
Dividends paid to non-controlling shareholders						(2,266)
Balance, end of period at Jun. 30, 2019						85,472
Movement of Shareholders' Equity
Total shareholders' equity	604,051
Total shareholders' equity	637,187
Balance, beginning of period at Dec. 31, 2019	547,694	419,348	171,789	(40,253)	(3,190)
Movement of Shareholders' Equity
Change in shares held in treasury		3,709
Amortization of share-based payment expense - stock options			1,103
Amortization of share-based payment expense - restricted share units			7,762
Amortization of share-based payment expense - performance stock units			793
Restricted share units vested			(7,225)
Common shares repurchased and retired		(17,803)		(18,821)
Common shares repurchased, IMAX China			(1,532)
Net (loss) income attributable to non-controlling interests	(75,321)			(75,321)
Other comprehensive (loss) income, net of tax	(1,176)				(990)
Balance, end of period at Jun. 30, 2020	439,369	405,254	172,690	(134,395)	(4,180)
Balance, beginning of period at Dec. 31, 2019	89,493					89,493
Movement of Shareholders' Equity
Net (loss) income attributable to non-controlling interests	(14,137)					(12,466)
Other comprehensive income (loss), net of tax	(186)
Dividends paid to non-controlling shareholders						(2,118)
Balance, end of period at Jun. 30, 2020	74,723					74,723
Balance, beginning of period at Mar. 31, 2020		404,164	168,892	(108,428)	(5,759)
Movement of Shareholders' Equity
Change in shares held in treasury		1,090
Amortization of share-based payment expense - stock options			505
Amortization of share-based payment expense - restricted share units			4,948
Amortization of share-based payment expense - performance stock units			506
Restricted share units vested			(1,520)
Common shares repurchased, IMAX China			(641)
Net (loss) income attributable to non-controlling interests	(25,967)			(25,967)
Other comprehensive (loss) income, net of tax	1,729				1,579
Balance, end of period at Jun. 30, 2020	439,369	$ 405,254	$ 172,690	$ (134,395)	$ (4,180)
Balance, beginning of period at Mar. 31, 2020						79,508
Movement of Shareholders' Equity
Net (loss) income attributable to non-controlling interests	(4,080)					(2,817)
Other comprehensive income (loss), net of tax	150
Dividends paid to non-controlling shareholders						(2,118)
Balance, end of period at Jun. 30, 2020	74,723					$ 74,723
Movement of Shareholders' Equity
Total shareholders' equity	$ 514,092

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	1. Basis of Presentation Accounting Principles IMAX Corporation, together with its consolidated subsidiaries (the “Company”), prepares its financial statements in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. In the Company’s opinion, the unaudited Condensed Consolidated Financial Statements reflect all adjustments of a normal recurring nature that are necessary for a fair statement of the results for the interim periods presented. The interim results presented in the Company’s Condensed Consolidated Statements of Operations are not necessarily indicative of results for a full year, particularly in this interim period due to the impacts of the COVID-19 global pandemic. (See Note 2.) The Company’s Condensed Consolidated Financial Statements Condensed Consolidated Financial Statements In the first quarter of 2020, the Company updated certain account names within Revenues and Costs and Expenses Applicable to Revenues in its Condensed Consolidated Statements of Operations to better describe the nature of its revenue-generating activities and related costs. Principles of Consolidation These Condensed Consolidated Financial Statements include the accounts of the Company, except for subsidiaries which have been identified as variable interest entities (“VIEs”) where the Company is not the primary beneficiary. All intercompany accounts and transactions, including all unrealized intercompany profits on transactions with equity method investees, have been eliminated. The Company has interests in ten film production companies, which have been identified as VIEs. The Company is the primary beneficiary of five of these entities as it has the power to direct the activities that most significantly impact the economic performance of the VIE, and it has the obligation to absorb losses or the right to receive benefits from the respective VIE that could potentially be significant. The majority of the assets relating to these production companies are held by the IMAX Original Film Fund (the “Original Film Fund”) as described in Note 17(b). The Company does not consolidate the other five film production companies because it does not have the power to direct their activities and does not have the obligation to absorb the majority of the expected losses or the right to receive expected residual returns. The Company uses the equity method of accounting for these entities, which are not material to the Company’s Condensed Consolidated Financial Statements. A loss in value of an investment that is other than temporary is recognized as a charge to the Condensed Consolidated Statements of Operations. Total assets and liabilities of the Company’s consolidated VIEs are as follows: June 30, December 31, 2020 2019 Total assets $ 7,010 $ 9,677 Total liabilities $ 15,494 $ 15,528 Estimates and Assumptions In preparing the Company’s Condensed Consolidated Financial Statements, management makes judgments in applying various accounting policies. The areas of policy judgment are consistent with those reported in the Company’s 2019 Form 10-K, with the exception of the adoption of the estimate of current expected credit losses that became effective January 1, 2020, which also involves significant judgment and estimation, and is described in Note 4 below. In addition, management makes assumptions about the Company’s future operating results and cash flows in deriving critical accounting estimates used in preparing the Condensed Consolidated Financial Statements. As disclosed in the Company’s 2019 Form 10-K, such sources of estimation include estimates used to determine the recoverable amounts of receivables, inventory, film assets, long-lived assets (including assets used to support joint revenue sharing arrangements), goodwill and deferred tax assets, as well as estimates of variable consideration related to future box office performance. To date, the Company’s operations have been significantly impacted by the COVID-19 pandemic, as described in Note 2. There continues to be significant ongoing uncertainty surrounding the extent and duration of the impacts that the pandemic will have on box office results and the installation of IMAX Theater Systems, as well as the Company’s customers, suppliers, and employees. There is heightened potential for future credit losses on receivables, inventory write downs, impairments of film assets, impairments of long-lived assets (including the theater system equipment supporting the Company’s joint revenue sharing arrangements), impairments of goodwill, valuation allowances against deferred tax assets, and the reversal of variable consideration receivables that are based on future box office performance. In the current environment, assumptions about box office results, IMAX Theater System installations, and customer creditworthiness have greater variability than normal, which could in the future significantly affect the valuation of the Company’s assets, both financial and non-financial. The Company’s cash flow estimates for testing the recoverability of certain long-lived assets are based on a longer time horizon due to the long-term nature of its underlying contracts, allowing time for a recovery of the cash flows associated with the underlying assets groups, which management has factored into its estimates. The accuracy of management’s estimates is dependent, in part, on the timing of the reopening of theaters in the IMAX network, and on the release of new films by production studios. These theater reopening and film release scenarios are highly uncertain and have been factored into management’s cash flow estimates. As an understanding of the longer-term impacts of COVID-19 on the Company’s customers and business develops, there is a heightened potential for changes in management’s estimates over the remainder of 2020.

Impact of COVID-19 Pandemic

Impact of COVID-19 Pandemic	6 Months Ended
	Jun. 30, 2020
Impact Of Coronavirus Nineteen Pandemic [Abstract]
Impact of COVID-19 Pandemic	2. Impact of COVID-19 Pandemic In late-January 2020, in response to the public health risks associated with the novel coronavirus and the disease that it causes (“COVID-19”), the Chinese government directed exhibitors in China to temporarily close more than 70,000 movie theaters, including all of the approximately 700 IMAX theaters in mainland China. On March 11, 2020, due to the worsening public health crisis associated with the novel coronavirus, COVID-19 was characterized as a pandemic by the World Health Organization, and in the following weeks, local, state and national governments instituted stay-at-home orders and restrictions on large public gatherings which caused movie theaters in countries around the world to temporarily close, including substantially all of the IMAX theaters in those countries. As a result of the theater closures, Hollywood and Chinese movie studios have postponed the theatrical release of multiple films, including many scheduled to be shown in IMAX theaters, while other films have been released directly to streaming platforms. As of the date of this report, stay-at-home orders have been lifted in many countries and movie theaters are gradually reopening with reduced capacities, physical distancing requirements, and other safety measures. Subsequent to June 30, 2020, approximately 40% of the theaters in the IMAX commercial multiplex network have begun to report gross box office (“GBO”) results in July. These theaters span across 40 countries and include the Domestic, Greater China and Rest of World markets. The repercussions of the COVID-19 global pandemic have resulted in a significant decrease in the Company’s revenues, earnings and operating cash flows during the three and six months ended June 30, 2020 as GBO results declined significantly, the installation of certain theater systems was delayed, and maintenance services were generally suspended. During the time period when a significant number of theaters in the IMAX network are closed, the Company has and will continue to experience a significant decline in earnings and operating cash flows as it is generating significantly lower than normal levels of GBO-based revenue from its joint revenue sharing arrangements and digital remastering services, it is unable to provide normal maintenance services to any of the theaters that remain closed, and while some installation activity is continuing, certain theater system installations have, and may continue to be delayed. In addition, the Company has experienced and may continue to experience delays in collecting payments due under existing theater sale or lease arrangements from its exhibitor partners who are now facing financial difficulties as a result of the theater closures. T he Company may continue to be significantly impacted by the COVID-19 global pandemic even after some or all theaters are reopened. The global economic impact of COVID-19 has led to record levels of unemployment in certain countries, which has led to, and may continue to result in, lower consumer spending. The timing and extent of a recovery of consumer behavior and willingness to spend discretionary income on movie-going may delay the Company’s ability to generate significant GBO-based revenue until such time as consumer behavior normalizes and consumer spending recovers. In response to uncertainties associated with the COVID-19 pandemic, the Company has taken and is continuing to take significant steps to preserve cash by eliminating non-essential costs, reducing employee hours and deferring all non-essential capital expenditures to minimum levels. The Company has also implemented an active cash management process, which, among other things, requires senior management approval of all outgoing payments. In addition, in the first quarter of 2020, the Company drew down the $280.0 million in available borrowing capacity under its credit facility, which was then amended in June 2020 to, among other things, (see Note 7) . Furthermore, the Company has applied for wage subsidies , tax credits and other financial support under the newly enacted COVID-19 relief legislation in the countries in which it operates . The Company receive d approximately $ million in July 2020 under the Canada Emergency Wage Subsidy program and expects to receive approximately $ million under the U.S. CARES Act, both of which were recognized in the second quarter of 2020 as reduction s to S elling, G eneral and A dministrative E xpenses ( $2.9 million) and C osts and E xpenses A pplicable to R evenues ( $0.3 million) in the Condensed Consolidated Statements of Operations . The Company will continue to review and apply for additional subsidies and credits for the remaining terms of these programs , where applicable. Consistent with the first quarter of 2020, the Company performed a quantitative goodwill impairment test taking into account the latest available information and determined that its goodwill was not impaired as of June 30, 2020. As of that date, the Company’s total Goodwill was $39.0 million, of which $19.0 million relates to the IMAX Systems reporting unit, $13.6 million relates to the Joint Revenue Sharing Arrangement reporting unit, and $6.4 million relates to the IMAX Maintenance reporting unit These estimates and the likelihood of future changes in these estimates depend on a number of underlying variables and a range of possible outcomes. Actual results may materially differ from management’s estimates, especially due to the . (See Note 1.) In the second quarter of 2020, the Company also updated its recoverability tests of the carrying values of the theater system equipment supporting its joint revenue sharing arrangements, which are recorded within Property, Plant and Equipment . In performing its reviews of recoverability, the Company estimated the undiscounted future cash flows expected to result from the use of the assets and determined that there was no impairment as of the date of each test. The cash flow estimates used in these reviews are consistent with estimates are highly uncertain due to the COVID-19 pandemic, therefore management’s estimated cash flows factor in a number of underlying variables and ranges of possible cash flow scenarios. Actual results may materially differ from management’s estimates, especially due to the . (See Note 1.) If business conditions deteriorate further, or should they remain depressed for a prolonged period of time, management’s estimates of operating results and future cash flows for the IMAX Systems and Joint Revenue Sharing Arrangements reporting units may be insufficient to support the goodwill assigned to them, thus requiring impairment charges. The Company will continue to evaluate the recoverability of goodwill at the reporting unit level on an annual basis as of the beginning of its fourth fiscal quarter and whenever events or changes in circumstances indicate there may be a potential impairment. Estimates related to future expected credit losses (Note 4) and deferred tax assets (Note 11) could also be materially impacted by changes in estimates in the future. (See Note 1.)

Recently Issued Accounting Stan

Recently Issued Accounting Standards Not Yet Adopted	6 Months Ended
	Jun. 30, 2020
Accounting Changes And Error Corrections [Abstract]
Recently Issued Accounting Standards Not Yet Adopted	3. Recently Issued Accounting Standards Not Yet Adopted In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). The purpose of ASU 2019-05 is to provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. The Company is currently assessing the impact of ASU 2020-04 on its Condensed Consolidated Financial Statements. The Company considers the applicability and impact of all recently issued FASB accounting standard codification updates. Accounting standards updates that are not noted above were assessed and determined to be not applicable or not significant to the Company’s Condensed Consolidated Financial Statements for the period ended June 30, 2020.

Current Expected Credit Losses

Current Expected Credit Losses	6 Months Ended
	Jun. 30, 2020
Credit Loss [Abstract]
Current Expected Credit Losses	4. Current Expected Credit Losses In 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASC Topic 326”), which amends previously issued guidance regarding the impairment of financial instruments by creating an impairment model that is based on expected losses rather than incurred losses. The standard requires financial assets measured on the amortized cost basis to be presented at the net amount expected to be collected. The Company’s accounts receivable, financing receivables and variable consideration receivables are within the scope of ASU No. 2016-13. Accounts Receivable Accounts receivable principally includes amounts currently due to the Company under theater sale and sales-type lease arrangements, contingent fees earned from theaters operators as a result of box office performance, and fees for theater maintenance services. To a lesser extent, accounts receivable also includes amounts due from movie studios and other content creators for digitally remastering films into IMAX formats, as well as for film distribution and post-production services. In order to mitigate the credit risk associated with accounts receivable, management performs an initial credit evaluation prior to entering into an arrangement with a customer and then regularly monitors the credit quality of each customer through an analysis of collections history and aging. This monitoring process includes meetings on at least a monthly basis to identify credit concerns and potential changes in credit quality classification. A customer may improve their credit quality classification once a substantial payment is made on an overdue balance or when the customer has agreed to a payment plan and payments have commenced in accordance with that plan. Changes in credit quality classification are dependent upon management approval. The Company’s internal credit quality classifications for theater operators are as follows: • Good Standing — The theater operator continues to be in good standing as payments and reporting are up to date. • Credit Watch — The theater operator has demonstrated a delay in payments, but continues to be in active communication with the Company. Theater operators placed on Credit Watch are subject to enhanced monitoring. In addition, depending on the size of the outstanding balance, length of time in arrears and other factors, future transactions may need to be approved by management. These receivables are in better condition than those in the Pre-Approved Transactions Only category, but are not in as good condition as the receivables in the Good Standing category. • Pre-Approved Transactions Only — The theater operator has demonstrated a delay in payments with little or no communication with the Company. All services and shipments to the theater operator must be reviewed and approved by management. These receivables are in better condition than those in the All Transactions Suspended category, but are not in as good condition as the receivables in the Credit Watch category. In certain situation, depending on the individual facts and circumstances related to each customer, finance income recognition may be suspended for the net investment in lease and financed sale receivable balances for customers in the Pre-Approved Transactions Only category. See below for a discussion of the Company’s net investment in leases and financed sale receivables. • All Transactions Suspended — The theater operator is severely delinquent, non-responsive or not negotiating in good faith with the Company. Once a theater operator is classified within the All Transactions Suspended category, the theater is placed on nonaccrual status and all revenue recognitions related to the theater are stopped. The ability of the Company to collect its accounts receivable balances is heavily dependent on the viability and solvency of individual theater operators which is significantly influenced by consumer behavior and general economic conditions. Theater operators, or other customers, may experience financial difficulties that could cause them to be unable to fulfill their payment obligations to the Company. The Company develops its estimate of credit losses by class of receivable and customer type through a calculation that utilizes historical loss rates which are then adjusted for specific receivables that are judged to have a higher than normal risk profile after taking into account management’s internal credit quality classifications, as well as macro-economic and industry risk factors. The following table summarizes the activity in the allowance for credit losses related to accounts receivable for the three and six months ended June 30, 2020: Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Theater Operators Studios Other Total Theater Operators Studios Other Total Beginning balance $ 6,504 $ 3,983 $ 1,041 $ 11,528 $ 3,302 $ 893 $ 942 $ 5,137 Current period provision (107 ) 1,596 (203 ) 1,286 3,095 4,686 (104 ) 7,677 Write-offs — — — — — — — — Recoveries — — — — — — — — Foreign exchange (80 ) (124 ) — (204 ) (80 ) (124 ) — (204 ) Ending balance $ 6,317 $ 5,455 $ 838 $ 12,610 $ 6,317 $ 5,455 $ 838 $ 12,610 For the three and six months ended June 30, 2020, the Company recorded provisions for current expected credit losses of $1.3 million and $7.7 million, respectively, reflecting a reduction in the credit quality of its theater and studio related accounts receivable, Financing Receivables Financing receivables are due from theater operators and consist of the Company’s net investment in sales-type leases and receivables associated with financed sales of IMAX Theater Systems. Similar to accounts receivable, management performs an initial credit evaluation prior to entering into an arrangement with a customer and then regularly monitors the credit quality of each customer through an analysis of collections history and aging. This monitoring process includes meetings on at least a monthly basis to identify credit concerns and potential changes in credit quality classification. A customer may improve their credit quality classification once a substantial payment is made on an overdue balance or when the customer has agreed to a payment plan and payments have commenced in accordance with that plan. Changes in credit quality classification are dependent upon management approval. The internal credit quality classifications utilized by the Company for accounts receivable, as described above, are also used for financing receivables. The ability of the Company to collect its financing receivable balances is heavily dependent on the viability and solvency of individual theater operators which is significantly influenced by consumer behavior and general economic conditions. Theater operators may experience financial difficulties that could cause them to be unable to fulfill their payment obligations to the Company. The Company develops its estimate of credit losses by class of receivable and customer type through a calculation that utilizes historical loss rates which are then adjusted for specific receivables that are judged to have a higher than normal risk profile after taking into account management’s internal credit quality classifications, as well as macro-economic and industry risk factors. As at June 30, 2020 and December 31, 2019, financing receivables consist of the following: June 30, December 31, 2020 2019 Net investment in leases Gross minimum payments due under sales-type leases $ 17,142 $ 16,766 Unearned finance income (899 ) (1,005 ) Present value of minimum payments due under sales-type leases 16,243 15,761 Allowance for credit losses (459 ) (155 ) Net investment in leases 15,784 15,606 Financed sales receivables Gross minimum payments due under financed sales 142,380 146,660 Unearned finance income (30,590 ) (33,313 ) Present value of minimum payments due under financed sales 111,790 113,347 Allowance for credit losses (3,709 ) (915 ) Net financed sales receivables 108,081 112,432 Total financing receivables $ 123,865 $ 128,038 Net financed sales receivables due within one year $ 31,061 $ 27,595 Net financed sales receivables due after one year $ 77,020 $ 84,837 Total financed sales receivables $ 108,081 $ 112,432 As at June 30, 2020 and December 31, 2019, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s sales-type lease arrangements and financed sale receivables, as applicable, are as follows: June 30, December 31, 2020 2019 Weighted-average remaining lease term (in years) Sales-type lease arrangements 7.9 8.1 Weighted-average interest rate Sales-type lease arrangements 6.85 % 6.68 % Financed sales receivables 9.02 % 9.00 % The following tables provide information on the Company’s net investment in leases by credit quality indicator as at June 30, 2020 and December 31, 2019: By Origination Year As at June 30, 2020 2020 2019 2018 2017 2016 Prior Total Net investment in leases: Credit quality classification: In good standing $ 924 $ 7,804 $ 2,991 $ 942 $ — $ 2,786 $ 15,447 Credit Watch — — — — — 88 88 Pre-approved transactions — — — — — — — Transactions suspended — — — — — 708 708 Total net investment in leases $ 924 $ 7,804 $ 2,991 $ 942 $ — $ 3,582 $ 16,243 Current-period gross write-offs $ — $ — $ — $ — $ — $ — $ — Current-period recoveries — — — — — — — Current-period net write-offs $ — $ — $ — $ — $ — $ — $ — By Origination Year As at December 31, 2019 2019 2018 2017 2016 2015 Prior Total Net investment in leases: Credit quality classification: In good standing $ 7,874 $ 3,045 $ 989 $ — $ — $ 3,186 $ 15,094 Credit Watch — — — — — 667 667 Pre-approved transactions — — — — — — — Transactions suspended — — — — — — — Total net investment in leases $ 7,874 $ 3,045 $ 989 $ — $ — $ 3,853 $ 15,761 The following tables provide information on the Company’s financed sale receivables by credit quality indicator as at June 30, 2020 and December 31, 2019: By Origination Year As at June 30, 2020 2020 2019 2018 2017 2016 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 1,606 $ 11,474 $ 14,382 $ 15,381 $ 15,495 $ 47,551 $ 105,889 Credit Watch — 331 — — 304 1,171 1,806 Pre-approved transactions — — — — 585 671 1,256 Transactions suspended — — — 896 937 1,006 2,839 Total financed sales receivables $ 1,606 $ 11,805 $ 14,382 $ 16,277 $ 17,321 $ 50,399 $ 111,790 Current-period gross write-offs $ — $ — $ — $ — $ — $ — $ — Current-period recoveries — — — — — — — Current-period net write-offs $ — $ — $ — $ — $ — $ — $ — By Origination Year As at December 31, 2019 2019 2018 2017 2016 2015 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 11,981 $ 14,414 $ 16,556 $ 15,208 $ — $ 44,291 $ 102,450 Credit Watch — — 637 1,687 — 6,955 9,279 Pre-approved transactions — — 250 295 — 285 830 Transactions suspended — — — 165 — 623 788 Total financed sales receivables $ 11,981 $ 14,414 $ 17,443 $ 17,355 $ — $ 52,154 $ 113,347 The following tables provide an aging analysis for the Company’s net investment in leases and financed sale receivables as at June 30, 2020 and December 31, 2019: As at June 30, 2020 Accrued and Current 30-89 Days 90+ Days Billed Unbilled Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 11 $ 262 $ 735 $ 1,008 $ 15,235 $ 16,243 $ (459 ) $ 15,784 Financed sales receivables 688 2,941 10,166 13,795 97,995 111,790 (3,709 ) 108,081 Total $ 699 $ 3,203 $ 10,901 $ 14,803 $ 113,230 $ 128,033 $ (4,168 ) $ 123,865 As at December 31, 2019 Accrued and Current 30-89 Days 90+ Days Billed Unbilled Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 30 $ 68 $ 251 $ 349 $ 15,412 $ 15,761 $ (155 ) $ 15,606 Financed sales receivables 1,678 2,772 5,446 9,896 103,451 113,347 (915 ) 112,432 Total $ 1,708 $ 2,840 $ 5,697 $ 10,245 $ 118,863 $ 129,108 $ (1,070 ) $ 128,038 The Company considers financing receivables with an aging between 60-89 days as indications of theaters with potential collection concerns. The Company will begin to focus its review on these financing receivables and increase its discussions internally and with the theater regarding payment status. Once a theater’s aging exceeds 90 days, the Company’s policy is to perform an enhanced review to assess collectibility of the theater’s past due accounts. The over 90 days past due category may be an indicator of potential impairment as up to 90 days outstanding is considered to be a reasonable time to resolve any issues. Given the potential impacts of the COVID-19 global pandemic on the Company’s customers, management is enhancing its monitoring procedures with respect to overdue receivables. The following table provides information about the Company’s net investment in leases and financed sale receivables with billed amounts past due for which it continues to accrue finance income as at June 30, 2020 and December 31, 2019: As at June 30, 2020 Accrued and Current 30-89 Days 90+ Days Billed Unbilled Allowance for Credit Losses Net Net investment in leases $ 9 $ 255 $ 729 $ 993 $ 12,338 $ (264 ) $ 13,067 Financed sales receivables 570 2,862 10,187 13,619 64,654 (2,427 ) 75,846 Total $ 579 $ 3,117 $ 10,916 $ 14,612 $ 76,992 $ (2,691 ) $ 88,913 As at December 31, 2019 Accrued and Current 30-89 Days 90+ Days Billed Unbilled Allowance for Credit Losses Net Net investment in leases $ 9 $ 19 $ 251 $ 279 $ 578 $ — $ 857 Financed sales receivables 1,146 1,290 5,523 7,959 29,173 — 37,132 Total $ 1,155 $ 1,309 $ 5,774 $ 8,238 $ 29,751 $ — $ 37,989 The following table provides information about the Company’s net investment in leases and financed sale receivables that are on nonaccrual status as at June 30, 2020 and December 31, 2019: As at June 30, 2020 As at December 31, 2019 Recorded Receivable Allowance for Credit Losses Net Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 708 $ (10 ) $ 698 $ — $ — $ — Net financed sales receivables 2,839 (1,032 ) 1,807 788 (732 ) 56 Total $ 3,547 $ (1,042 ) $ 2,505 $ 788 $ (732 ) $ 56 A theater operator that is classified within the “All Transactions Suspended” category is placed on nonaccrual status and all revenue recognitions related to the theater are stopped. While the recognition of finance income is suspended, payments received by a customer are applied against the outstanding balance owed. If payments are sufficient to cover any unreserved receivables, a recovery of provision taken on the billed amount, if applicable, is recorded to the extent of the residual cash received. Once the collectibility issues are resolved and the customer has returned to being in good standing, the Company will resume recognition of finance income. For the three and six months ended June 30, 2020, the Company recognized $0.1 million and $0.2 million, respectively (2019 — $0.1 million and $0.2 million, respectively) in finance income related to the net investment in leases with billed amounts past due. For the three and six months ended June 30, 2020, the Company recognized $0.9 million and $3.0 million, respectively (2019 —$2.1 million and $4.6 million, respectively) in finance income related to the financed sale receivables with billed amounts past due. The following table summarizes the activity in the allowance for credit losses related to the Company’s net investment in leases and financed sale receivables for the three and six months ended June 30, 2020 and 2019: Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Net Investment Financed Net Investment Financed in Leases Sales Receivables in Leases Sales Receivables Beginning balance $ 464 $ 3,557 $ 155 $ 915 Current period provision (5 ) 171 304 2,813 Write-offs — — — — Recoveries — — — — Foreign exchange — (19 ) — (19 ) Ending balance $ 459 $ 3,709 $ 459 $ 3,709 Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 Net Investment Net Financed Net Investment Net Financed in Leases Sales Receivables in Leases Sales Receivables Beginning balance $ 155 $ 839 $ 155 $ 839 Charge-offs — — — — Recoveries — — — — Provision — — — — Ending balance $ 155 $ 839 $ 155 $ 839 For the three and six months ended June 30, 2020, the Company recorded a provision for current expected credit losses of $0.2 million and $3.1 million, respectively, reflecting a reduction in the credit quality of its theater related financing receivables, which management believes is primarily related to the COVID-19 global pandemic. Management’s judgments regarding expected credit losses are based on the facts available to management and involve estimates about the future. Due to the unprecedented nature of the COVID-19 pandemic, its effect on the Company’s customers and their ability to meet their financial obligations to the Company is difficult to predict. As a result, the Company’s judgments and associated estimates of credit losses may ultimately prove, with the benefit of hindsight, to be incorrect. (See Notes 1 and 2.) Variable Consideration Receivable In sale arrangements, variable consideration may become due to the Company from theater operators if certain annual minimum box office receipt thresholds are exceeded. Such variable consideration is recorded as revenue in the period when the sale is recognized and adjusted in future periods based on actual results and changes in estimates. Variable consideration is only recognized to the extent the Company believes there is not a risk of significant revenue reversal. The ability of the Company to collect its variable consideration receivables is heavily dependent on the viability and solvency of individual theater operators which is significantly influenced by consumer behavior and general economic conditions. Theater operators may experience financial difficulties that could cause them to be unable to fulfill their payment obligations to the Company. The Company develops its estimate of credit losses by class of receivable and customer type through a calculation utilizing historical loss rates for financed sale receivables which are then adjusted for specific receivables that are judged to have a higher than normal risk profile after taking into account management’s internal credit quality classifications, as well as macro-economic and industry risk factors. The following table summarizes the activity in the allowance for credit losses related to variable consideration receivables for the three and six months ended June 30, 2020 : Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Theater Operators Theater Operators Beginning balance $ 875 $ — Current period provision (12 ) 863 Write-offs — — Recoveries — — Ending balance $ 863 $ 863 For the six months ended June 30, 2020, the Company recorded a provision of $0.9 million for current expected credit losses, reflecting a reduction in the credit quality of its theater related variable consideration receivables, which management believes is primarily related to the COVID-19 global pandemic. Management’s judgments regarding expected credit losses are based on the facts available to management and involve estimates about the future. Due to the unprecedented nature of the COVID-19 pandemic, its effect on the Company’s customers and their ability to meet their financial obligations to the Company is difficult to predict. As a result, the Company’s judgments and associated estimates of credit losses may ultimately prove, with the benefit of hindsight, to be incorrect. (See Notes 1 and 2.)

Lease Arrangements

Lease Arrangements	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Lease Arrangements	5. Lease Arrangements IMAX Corporation as a Lessee The Company’s operating lease arrangements principally involve office and warehouse space. Office equipment is generally purchased outright. Leases with an initial term of less than 12 months are not recorded on the Condensed Consolidated Balance Sheets and the related lease expense is recognized on a straight-line basis over the lease term. Most of the Company’s leases include one or more options to renew, with renewal terms that can extend the lease term from one to five years or more. The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs and its level of investment in leasehold improvements, among other factors. The incremental borrowing rate used in the calculation of the Company’s lease liability is based on the location of each leased property. None of the Company’s leases include options to purchase the leased property. The depreciable lives of right-of-use assets and related leasehold improvements are limited by the expected lease term. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed. For three and six months ended June 30, 2020 and 2019, the components of lease expense recorded within Selling, General and Administrative expenses are as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Operating lease cost (1) $ 121 $ 220 $ 259 $ 463 Amortization of lease assets 701 664 1,449 1,195 Interest on lease liabilities 245 274 507 542 Total lease cost $ 1,067 $ 1,158 $ 2,215 $ 2,200 (1) Includes short-term leases and variable lease costs, which are not significant for the three and six months ended June 30, 2020 and 2019. For three and six months ended June 30, 2020 and 2019, supplemental cash flow information related to leases is as follows: Six Months Ended June 30, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities $ 1,730 $ 1,782 Right-of-use assets obtained in exchange for lease obligations 286 17,515 $ 2,016 $ 19,297 As at June 30, 2020 and December 31, 2019, supplemental balance sheet information related to leases is as follows: June 30, December 31, 2020 2019 Assets Right-of-Use Assets Property, plant and equipment $ 15,074 $ 16,262 Liabilities Operating Leases Accrued and other liabilities $ 17,791 $ 18,677 As at June 30, 2020 and December 31, 2019, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s operating leases are as follows: June 30, December 31, 2020 2019 Weighted-average remaining lease term (years) 7.8 8.1 Weighted-average discount rate 5.90 % 5.90 % As at June 30, 2020, the maturities of the Company’s operating lease liabilities are as follows: Operating Leases 2020 (six months remaining) $ 1,803 2021 3,318 2022 2,811 2023 2,247 2024 2,198 Thereafter 10,177 Total lease payments $ 22,554 Less: interest expense (4,763 ) Present value of operating lease liabilities $ 17,791 IMAX Corporation as a Lessor The Company provides IMAX Theater Systems to customers through long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX Theater System, the Company earns fixed upfront and ongoing consideration. Certain arrangements that are legal sales are also classified as sales-type leases as certain clauses within the arrangements limit transfer of title or provide the Company with conditional rights to the system. The customer’s rights under the Company’s sales-type lease arrangements are described in Note 2(n) in the Company’s 2019 Form 10-K. Under the Company’s sales-type lease arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s sales-type leases are typically non-cancellable for 10 to 20 years with renewal provisions from inception. Except for those sales arrangements that are classified as sales-type leases, the Company’s leases generally do not contain an automatic transfer of title at the end of the lease term. The Company’s sales-type lease arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and extended warranty generally after the first year of the lease until the end of the lease term. The customer is responsible for obtaining insurance coverage for the IMAX Theater System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX Theater System is returned to the Company. The Company also provides IMAX Theater systems to customers through joint revenue sharing arrangements. Under the traditional form of these arrangements, in exchange for providing the IMAX system under a long-term lease, the Company earns rent based on a percentage of contingent box office receipts and, in some cases, concession revenues, rather than requiring the customer to pay a fixed upfront fee or annual minimum payments. The Company has assessed the nature of its joint revenue sharing arrangements and concluded that the arrangements contain an operating lease. Under joint revenue sharing arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s joint revenue sharing arrangements are typically non-cancellable for 10 years or longer with renewal provisions. Title to equipment under joint revenue sharing arrangements does not transfer to the customer. The Company’s joint revenue sharing arrangements do not contain a guarantee of residual value at the end of the term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the IMAX Theater System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX Theater System is returned to the Company. The Company classifies its lease arrangements at inception of the arrangement and, if required, after a modification of the lease arrangement, to determine whether they are sales-type leases or operating leases. On April 10, 2020, the FASB staff issued a question-and-answer document to address stakeholder questions on the application of the lease accounting guidance for lease concessions related to the effects of the COVID-19 pandemic. The guidance allows concessions related to the timing of payments, where the total consideration has not changed, to not be accounted for as lease modifications. Instead, any such concessions can be accounted for as if no change was made to the contract or as variable lease payments. In the second quarter of 2020, the Company adopted the FASB relief guidance and elected to account for any such lease concessions as if no change was made to the underlying contracts. The adoption of this guidance did not have a material effect on the Company’s Condensed Consolidated Financial Statements.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Inventories	6. Inventories As at June 30, 2020 and December 31, 2019, inventories consist of the following: June 30, December 31, 2020 2019 Raw materials $ 34,139 $ 26,538 Work-in-process 5,839 4,608 Finished goods 20,201 11,843 $ 60,179 $ 42,989 When compared to December 31, 2019, inventories increased by $17.2 million due to delays in manufacturing, shipments and installation of IMAX Theater Systems at customer sites due to government restrictions in various countries limiting public gatherings as a result of the COVID-19 global pandemic. At June 30, 2020, inventories include finished goods of $4.0 million (December 31, 2019 — $0.7 million) for which title had passed to the customer, but the criteria for revenue recognition were not met as of the balance sheet date. During the three and six months ended June 30, 2020, the Company recognized write-downs of $0.1 million for excess and obsolete inventory based on current estimates of net realizable value. (2019 — $nil).

Credit Facility and Other Finan

Credit Facility and Other Financing Arrangements	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Credit Facility and Other Financing Arrangements	7. Credit Facility and Other Financing Arrangements As at June 30, 2020 and December 31, 2019, bank indebtedness includes the following: June 30, December 31, 2020 2019 Credit Facility $ 300,000 $ 20,000 Working Capital Facility 244 — Unamortized debt issuance costs (2,479 ) (1,771 ) $ 297,765 $ 18,229 Credit Agreement The Company has a credit agreement, the Fifth Amended and Restated Credit Agreement, with Wells Fargo Bank, National Association (“Wells Fargo”), as agent, and a syndicate of lenders party thereto (the “Credit Agreement”). The Company’s obligations under the Credit Agreement are guaranteed by certain of its subsidiaries (the “Guarantors”) and are secured by first-priority security interests in substantially all the assets of the Company and the Guarantors. The facility provided by the Credit Agreement (the “Credit Facility”) matures on June 28, 2023. The Credit Agreement has a revolving borrowing capacity of $300.0 million, and contains an uncommitted accordion feature allowing the Company to further expand its borrowing capacity to $440.0 million or greater, subject to certain conditions, depending on the mix of revolving and term loans comprising the incremental facility. In the first quarter of 2020, in response to uncertainties associated with the outbreak of the COVID-19 global pandemic and its impact on the Company’s business, the Company drew down the $280.0 million in available borrowing capacity under the Credit Facility, resulting in total outstanding borrowings of $300.0 million. The Credit Agreement contains a covenant that requires the Company to maintain a Senior Secured Net Leverage Ratio (as defined in the Credit Agreement), as at the last day of any Fiscal Quarter (as defined in the Credit Agreement) of no greater than 3.25:1.00. In addition, the Credit Agreement contains customary affirmative and negative covenants, including covenants that limit indebtedness, liens, capital expenditures, asset sales, investments and restricted payments, in each case subject to negotiated exceptions and baskets. The Credit Agreement also contains customary representations, warranties and event of default provisions. On June 10, 2020, the Company entered into the First Amendment to the Credit Agreement (the “Amendment”), which, among other things, (i) suspends the Senior Secured Net Leverage Ratio covenant through the first quarter of 2021, (ii) re-establishes the Senior Secured Net Leverage Ratio covenant thereafter, provided that for subsequent quarters that such covenant is tested, as applicable, the Company will be permitted to use its quarterly EBITDA (as defined in the Credit Agreement) from the third and fourth quarters of 2019 in lieu of the EBITDA for the corresponding quarters of 2020, (iii) adds a $75.0 million minimum liquidity covenant measured at the end of each calendar month and (iv) restricts the Company’s ability to make certain restricted payments, dispositions and investments, create or assume liens and incur debt that would otherwise have been permitted by the Credit Agreement. The modifications to the negative covenants, the minimum liquidity covenant and modifications to certain other provisions in the Credit Agreement pursuant to the Amendment were effective from the date of the Amendment until the earlier of the delivery of the compliance certificate for the fourth quarter of 2021 and the date on which the Company, in its sole discretion, elects to calculate its compliance with the Senior Secured Net Leverage Ratio by using either its actual EBITDA or annualized EBITDA (the “Designated Period”). The Company was in compliance with all of its requirements under the Credit Agreement, as amended, as at June 30, 2020, and based on current projections expects to be in compliance through at least the next year. Borrowings under the Credit Facility bear interest, at the Company’s option, at (i) LIBOR plus a margin ranging from 1.00% to 1.75% per annum; or (ii) the U.S. base rate plus a margin ranging from 0.25% to 1.00% per annum, in each case depending on the Company’s Total Leverage Ratio (as defined in the Credit Agreement); provided, however, that from the effective date of the Amendment until the Company delivers a compliance certificate under the Credit Facility following the end of the Designated Period, the applicable margin for LIBOR borrowings will be 2.50% per annum and the applicable margin for U.S. base rate borrowings will be 1.75% per annum. The effective interest rate for the three and six months ended June 30, 2020 was 1.83% and 1.86%, respectively (2019 — 3.52% and 3.55%, respectively). In addition, the Credit Facility has standby fees ranging from 0.25% to 0.38% per annum, based on the Company’s Total Leverage Ratio with respect to the unused portion of the Credit Facility; provided, however, that from the effective date of the Amendment until the Company delivers a compliance certificate under the Credit Facility following the end of the Designated Period, the standby fee will be 0.50 % per annum. The Company incurred fees of approximately $1.0 million in connection with the Amendment, which are being amortized on a straight-line basis through December 31, 2021. As at June 30, 2020 and December 31, 2019, the Company did not have any letters of credit or advance payment guarantees outstanding under the Credit Facility. Working Capital Facility On July 24, 2019, IMAX (Shanghai) Multimedia Technology Co., Ltd. (“IMAX Shanghai”), one of the Company’s majority-owned subsidiaries in China, renewed its unsecured revolving facility for up to 200.0 million Renminbi (approximately $30.0 million) to fund ongoing working capital requirements (the “Working Capital Facility”). As at June 30, 2020, there was 1.7 million Renminbi ($0.2 million) in borrowings outstanding under the Working Capital Facility and 198.3 million Renminbi ($29.8 million) was available for future borrowings. There were no amounts drawn under the Working Capital facility at December 31, 2019. The amounts available for borrowing under the Working Capital Facility are not subject to a standby fee. The effective interest rate for the three and six months ended June 30, 2020 was 4.35%, respectively. Subsequent to June 30, 2020, IMAX Shanghai renewed its Working Capital Facility. Wells Fargo Foreign Exchange Facility Within the Credit Facility, the Company is able to purchase foreign currency forward contracts and/or other swap arrangements. The net settlement loss on its foreign currency forward contracts was $0.3 million at June 30, 2020, as the notional value exceeded the fair value of the forward contracts (December 31, 2019 — $0.5 million net settlement gain). As at June 30, 2020, the Company has $36.0 million in notional value of such arrangements outstanding (December 31, 2019 — $36.1 million). NBC Facility On October 28, 2019, the Company entered into a $5.0 million facility with the National Bank of Canada (the “NBC Facility”) fully insured by Export Development Canada for use solely in conjunction with the issuance of performance guarantees and letters of credit. The Company did not have any letters of credit or advance payment guarantees outstanding as at June 30, 2020 and December 31, 2019 under the NBC Facility.

Commitments, Contingencies and

Commitments, Contingencies and Guarantees	6 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments, Contingencies and Guarantees	8. Commitments, Contingencies and Guarantees Commitments In the ordinary course of business, the Company enters into contractual agreements with third parties that include non-cancellable payment obligations, for which it is liable in future periods. These arrangements can include terms binding the Company to minimum payments and/or penalties if it terminates the agreement for any reason other than an event of default as described by the agreement. Contingencies and guarantees The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. Management is required to assess the likelihood of any adverse judgments or outcomes related to these legal contingencies, as well as potential ranges of probable or reasonably possible losses. The Company will record a provision for a liability when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The determination of the amount of any liability recorded or disclosed is reviewed at least quarterly based on a careful analysis of each individual exposure with, in some cases, the assistance of outside legal counsel, taking into account the impact of negotiations, settlements, rulings, and other pertinent information related to the case. The amount of liabilities recorded or disclosed for these contingencies may change in the future due to changes in management’s judgments resulting from new developments or changes in settlement strategy. Any resulting adjustment to the liabilities recorded by the Company could have a material adverse effect on its results of operations, cash flows, and financial position in the period or periods in which such changes in judgment occur. The Company believes it has adequate provisions for any such matters. (a) In January 2004, the Company and IMAX Theatre Services Ltd., a subsidiary of the Company, commenced an arbitration seeking damages before the International Court of Arbitration of the International Chamber of Commerce (the “ICC”) with respect to the breach by Electronic Media Limited (“EML”) of its December 2000 agreement with the Company. In June 2004, the Company commenced a related arbitration before the ICC against EML’s affiliate, E-City Entertainment (I) PVT Limited (“E-City”). On March 27, 2008, the arbitration panel issued a final award in favor of the Company in the amount of $11.3 million, consisting of past and future rents owed to the Company, plus interest and costs, as well as an additional $2,512 each day in interest from October 1, 2007 until the date the award is paid. In July 2008, E-City commenced a proceeding in Mumbai, India seeking an order that the ICC award may not be recognized in India and on June 10, 2013, the Bombay High Court ruled that it had jurisdiction over the proceeding filed by E-City. The Company appealed that ruling to the Supreme Court of India, and on March 10, 2017, the Supreme Court set aside the Bombay High Court’s judgement and dismissed E-City’s petition. On March 29, 2017, the Company filed an Execution Application in the Bombay High Court seeking to enforce the ICC award against E-City and several related parties. That matter is currently pending. The Company has also taken steps to enforce the ICC final award outside of India. In December 2011, the Ontario Superior Court of Justice issued an order recognizing the final award and requiring E-City to pay the Company $30,000 to cover the costs of the application, and in October 2015, the New York Supreme Court recognized the Canadian judgment and entered it as a New York judgment. The Company intends to continue pursuing its rights and seeking to enforce the award, although no assurances can be given with respect to the ultimate outcome. (b) On November 11, 2013, Giencourt Investments, S.A. (“Giencourt”) initiated arbitration before the International Centre for Dispute Resolution in Miami, Florida, based on alleged breaches by the Company of its theater agreement and related license agreement with Giencourt. An arbitration hearing for witness testimony was held during the week of December 14, 2015. At the hearing, Giencourt’s expert identified monetary damages of up to approximately $10.4 million, which Giencourt sought to recover from the Company. The Company asserted a counterclaim against Giencourt for breach of contract and sought to recover lost profits in excess of $24.0 million under the agreements. Subsequently, in December 2015, Giencourt made a motion to the panel seeking to enforce a purported settlement of the matter based on negotiations between Giencourt and the Company. The panel held a final hearing with closing arguments in October 2016. On February 7, 2017, the panel issued a Partial Final Award and on July 21, 2017, the panel issued a Final Award (collectively, the “Award”), which held that the parties had reached a binding settlement, and therefore the panel did not reach the merits of the dispute. The Company strongly disputes that discussions about a potential resolution of this matter amounted to an enforceable settlement. In October 2017, the Company filed a petition to vacate the arbitration award in the United States Court for the Southern District of Florida on various grounds, including that the panel exceeded its jurisdiction, and a hearing was held on June 27, 2019. On September 27, 2019, a Magistrate Judge filed a non-binding recommendation that the Company’s petition be dismissed. On October 14, 2019, the Company filed an objection to that recommendation. The Company’s petition to vacate the arbitration award was denied by the District Judge on January 10, 2020. The Company filed an appeal of this decision on February 7, 2020 with the Eleventh Circuit Court of Appeals, but such appeal was dismissed on May 29, 2020. At this time, the Company is unable to determine the amounts that it may ultimately owe pursuant to the Award, or the timing of any such payments, but believes it has adequate provisions recorded in its Condensed Consolidated Balance Sheets related to the Award. In addition to the above, the Company has initiated a claim against Giencourt in the Ontario Superior Court seeking damages from Giencourt with respect to contractual claims under various terminated agreements between the parties. These proceedings are in preliminary stages, and no assurances can be given with respect to the ultimate outcome of the matter, but any amounts, if awarded to the Company under these proceedings, may reduce the Company’s overall financial obligations to Giencourt. (c) In addition to the matters described above, the Company is currently involved in other legal proceedings or governmental inquiries which, in the opinion of the Company’s management, will not materially affect the Company’s financial position or future operating results, although no assurance can be given with respect to the ultimate outcome of any such proceedings. (d) In the normal course of business, the Company enters into agreements that may contain features that meet the definition of a guarantee. A guarantee is a contract (including an indemnity) that contingently requires the Company to make payments (either in cash, financial instruments, other assets, shares of its stock or provision of services) to a third party based on (a) changes in an underlying interest rate, foreign exchange rate, equity or commodity instrument, index or other variable, that is related to an asset, a liability or an equity security of the counterparty, (b) failure of another party to perform under an obligating agreement or (c) failure of another third party to pay its indebtedness when due. Financial Guarantees Certain subsidiaries of the Company have provided significant financial guarantees to third parties under the Credit Agreement. Product Warranties The Company’s accrual for product warranties, which was recorded as part of accrued and other liabilities in the Condensed Consolidated Balance Sheets, was less than $0.1 million and $0.2 million at June 30, 2020 and December 31, 2019 Director/Officer Indemnifications The Company’s General By-law contains an indemnification of its directors/officers, former directors/officers and persons who have acted at its request to be a director/officer of an entity in which the Company is a shareholder or creditor, to indemnify them, to the extent permitted by the Canada Business Corporations Act Other Indemnification Agreements In the normal course of the Company’s operations, the Company provides indemnifications to counterparties in transactions such as: IMAX Theater Systems lease and sale agreements and the supervision of installation or servicing of IMAX Theater Systems; film production, exhibition and distribution agreements; real property lease agreements; and employment agreements. These indemnification agreements require the Company to compensate the counterparties for costs incurred as a result of litigation claims that may be suffered by the counterparty as a consequence of the transaction or the Company’s breach or non-performance under these agreements. While the terms of these indemnification agreements vary based upon the contract, they normally extend for the life of the agreements. A small number of agreements do not provide for any limit on the maximum potential amount of indemnification; however, virtually all of the IMAX Theater System lease and sale agreements limit such maximum potential liability to the purchase price of the system. The fact that the maximum potential amount of indemnification required by the Company is not specified in some cases prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to counterparties. Historically, the Company has not made any significant payments under such indemnifications and no amounts have been accrued in the Condensed Consolidated Financial Statements with respect to the contingent aspect of these indemnities.

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Operations Supplemental Information	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Condensed Consolidated Statements of Operations Supplemental Information	9. Condensed Consolidated Statements of Operations Supplemental Information (a) Selling Expenses The Company defers direct selling costs such as sales commissions and other amounts related to its sales and sales-type lease arrangements until the related revenue is recognized. These costs and direct advertising and marketing, which are included in Costs and Expenses Applicable to Revenues – Technology Sales, totaled $0.2 million and $0.4 million for the three and six months ended June 30, 2020, respectively (2019 — $0.4 million and $0.9 million, respectively). Film exploitation costs, including advertising and marketing, totaled a recovery of less than $0.1 million and expense of $2.6 million for the three and six months ended June 30, 2020, respectively (2019 — expense of $9.6 million and $14.1 million, respectively), and are recorded as incurred in Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services. Commissions are recognized as Costs and Expenses Applicable to Revenues – Technology Rentals in the month they are earned. These costs totaled less than $0.1 million and $0.2 million for the three and six months ended June 30, 2020, respectively (2019 — recovery of $0.4 million and recovery of $0.6 million, respectively). Direct advertising and marketing costs for each theater are charged to Costs and Expenses Applicable to Revenues – Technology Rentals as incurred. These costs totaled less than $0.1 million and $0.4 million for the three and six months ended June 30, 2020, respectively (2019 — $0.7 million and $0.9 million, respectively). (b) Foreign Exchange Included in Selling, General and Administrative Expenses for the three and six months ended June 30, 2020 (c) Collaborative Arrangements Joint Revenue Sharing Arrangements In a joint revenue sharing arrangement, the Company receives a portion of a theater’s box office and in certain arrangements a portion of concession revenues and a small upfront or initial payment, in exchange for placing an IMAX Theater System at the theater operator’s venue. Under joint revenue sharing arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s joint revenue sharing arrangements are typically non-cancellable for 10 years or longer with renewal provisions. Title to equipment under joint revenue sharing arrangements generally does not transfer to the customer. The Company’s joint revenue sharing arrangements do not contain a guarantee of residual value at the end of the term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the IMAX Theater System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX Theater System is returned to the Company. The Company has signed traditional and hybrid joint revenue sharing agreements with 41 exhibitors for a total of 1,237 IMAX Theater Systems, of which 868 theaters were included in the IMAX network as at June 30, 2020, the terms of which are similar in nature, rights and obligations. The accounting policy for the Company’s joint revenue sharing arrangements is disclosed in Note 2(n) of the Company’s 2019 Form 10-K. Amounts attributable to transactions arising between the Company and its customers under joint revenue sharing arrangements are included in Revenues — Technology Sales and Revenues — Technology Rentals and for the three and six months ended June 30, 2020 amounted to $0.1 million and $6.9 million, respectively (2019 — $27.8 million and $48.2 million, respectively). IMAX DMR In an IMAX DMR arrangement, the Company transforms conventional motion pictures into the Company’s large screen format, allowing the release of Hollywood content to the global IMAX theater network. In a typical IMAX DMR film arrangement, the Company receives a percentage of the box office receipts from a movie studio in exchange for converting a commercial film into IMAX DMR format and distributing it through the IMAX network. In recent years, the percentage of gross box office receipts earned in IMAX DMR arrangements has averaged approximately 12.5%, except for within Greater China, where the Company receives a lower percentage of net box office receipts for certain Hollywood films. For the six months ended June 30, 2020, the majority of IMAX DMR revenue was earned from the exhibition of 14 IMAX DMR films (2019 – 39) throughout the IMAX theater network. The accounting policy for the Company’s IMAX DMR arrangements is disclosed in Note 2(n) of the Company’s 2019 Form 10-K. Amounts attributable to transactions arising between the Company and its customers under IMAX DMR arrangements are included in Revenues – Image Enhancement and Maintenance Services and for the three and six months ended June 30, 2020 amounted to $0.6 million and $11.2 million, respectively (2019 — $39.3 million and $67.2 million, respectively). Co-Produced Film Arrangements In certain film arrangements, the Company co-produces a film with a third party whereby the third party retains the copyright and rights to the film. In some cases, the Company obtains exclusive theatrical distribution rights to the film. Under these arrangements, both parties contribute funding to the Company’s partly-owned subsidiary for the production and distribution of the film and for associated exploitation costs. As at June 30, 2020, the Company has two significant co-produced film arrangements which represent the VIE total assets balance of $7.0 million and liabilities balance of $15.5 million and three other co-produced film arrangements, the terms of which are similar. The accounting policies relating to co-produced film arrangements are disclosed in Notes 2(a) and 2(n) of the Company’s 2019 Form 10-K. For the three and six months ended June 30, 2020, expenses totaling $1.2 million and $1.4 million, respectively (2019 — less than $0.1 million and $0.2 million, respectively) attributable to transactions between the Company and other parties involved in the production of the films have been included in Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services. For the three and six months ended June 30, 2020, revenue of $0.1 million and $0.1 million, respectively (2019 — $nil and less than $0.1 million, respectively) and Costs and Expenses Applicable to Revenues of $nil and $nil, respectively (2019 — $nil and less than $0.1 million, respectively) attributable to this collaborative arrangement have been recorded in Revenue – Image Enhancement and Maintenance Services and Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services.

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows Supplemental Information	6 Months Ended
	Jun. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Condensed Consolidated Statements of Cash Flows Supplemental Information	10. Condensed Consolidated Statements of Cash Flows Supplemental Information (a) Changes in other operating assets and liabilities as reported in the Condensed Consolidated Statements of Cash Flows are comprised of the following: Six Months Ended June 30, 2020 2019 Decrease (increase) in: Financing receivables $ 776 6,029 Prepaid expenses (2,332 ) (1,188 ) Variable consideration receivable (220 ) (362 ) Other assets (4,492 ) (2,189 ) Increase (decrease) in: Accounts payable (6,716 ) (9,817 ) Accrued and other liabilities 764 (4,910 ) $ (12,220 ) $ (12,437 ) (b) Depreciation and amortization are comprised of the following: Six Months Ended June 30, 2020 2019 Film assets $ 3,515 $ 8,492 Property, plant and equipment: Joint revenue sharing arrangements 13,178 11,295 Other property, plant and equipment 5,686 5,992 Other intangible assets 3,238 2,952 Other assets 1,266 829 Deferred financing costs 299 244 $ 27,182 $ 29,804 (c) Write-downs are comprised of the following: Six Months Ended June 30, 2020 2019 Film assets (1) $ 4,504 $ — Other assets (2) 1,151 — Joint revenue sharing arrangements (3) 929 404 Property, plant and equipment 58 81 Inventories 72 2 Other intangible assets 92 21 $ 6,806 $ 508 (1) In the six months ended June 30, 2020, the Company recorded an impairment loss of $4.5 million (2019 — $nil) to write-down the carrying value of certain documentary and alternative content film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments. As of , following the recording of these write-downs, the Company’s film assets totaled $13.1 million, which principally consists of documentary and DMR content. The recoverability of these assets assumes the return to historical levels of box office results as theaters reopen following the lifting of COVID-19 restrictions. (2) In the six months ended June 30, 2020, the Company recorded a $1.2 million (2019 - $ nil (3) In the six months ended June 30, 2020, the Company recorded charges of $0.9 million in Costs and Expenses Applicable to Technology Rentals principally related to the write-down of xenon-based digital systems which were upgraded by customers to laser-based digital systems and taken out of service. In the six months ended June 30, 2019, the Company recorded a charge of $0.1 million in Costs and Expenses Applicable to Technology Rentals and $0.1 million in Revenues -Technology Rentals upon the upgrade of xenon-based digital systems under joint revenue sharing arrangements to laser-based digital systems. (d) Significant non-cash investing activities are comprised of the following: Six Months Ended June 30, 2020 2019 Net (decrease) increase in accruals related to: Investment in joint revenue sharing arrangements $ (1,887 ) $ 3,651 Acquisition of other intangible assets (10 ) 13 Purchases of property, plant and equipment 158 (427 ) $ (1,739 ) $ 3,237

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes (a) Income Tax Expense The Company’s effective tax benefit rate for the three months ended June 30, 2020, is 25.4% and differs from the Canadian statutory tax rate of 26.2%, primarily due to permanent book to tax differences, investment and other tax credits, jurisdictional tax rate differences, management’s estimates of contingent liabilities related to the resolution of various tax examinations and withholding taxes associated with the reversal of the indefinite reinvestment assertion for certain foreign subsidiaries, as discussed below. In the first quarter of 2020, management completed a reassessment of its strategy with respect to the most efficient means of deploying the Company’s capital resources globally. Based on the results of this reassessment, management concluded that the historical earnings of certain foreign subsidiaries in excess of amounts required to sustain business operations would no longer be indefinitely reinvested. As a result, the Company recognized a deferred tax liability of $19.7 million repatriation of any such earnings. In the second quarter of 2020, the estimate of the applicable foreign withholding taxes was reduced by $ 1.2 million to $18.5 million due to a reduction in the amount of distributable historical earnings . Cash held outside of Canada as at June 30, 2020 was $75.0 million ( December 31, 2019 — $90.1 million ), of which $61.5 million was held in the People’s Republic of China (“PRC”) ( December 31, 2019 — $67.6 million ). For the three months ended June 30, 2020, the Company recorded income tax benefit of $10.2 million (2019 — tax expense of $5.3 million), which includes the $1.2 million reduction to the foreign withholding taxes discussed above. second quarter of 2020 The Company’s effective tax rate for the six months ended June 30, 2020 is -6.3% and differs from the Canadian statutory tax rate of 26.2%, primarily due to permanent book to tax differences, investment and other tax credits, jurisdictional tax rate differences, managements estimates of contingent liabilities related to the resolution of various tax examinations and withholding taxes associated with the reversal of the indefinite reinvestment assertion for certain foreign subsidiaries, as discussed above. For the six months ended June 30, 2020 , the Company recorded income tax expense of $5.3 million , which includes the foreign withholding taxes discussed above . In addition, in the six months ended June 30, 2020, the Company recognized income tax expense of $5.1 million ( 2019 — $0.5 million) related to the provision for uncertain tax positions and an expense of $0.7 million ( 2019 — $0.3 million) recognized to reduce the tax benefit available on share-based compensation costs recognized in the period. As at June 30, 2020, the Company’s Condensed Consolidated Balance Sheets include net deferred income tax assets of $46.8 million, which is net of a valuation allowance of $0.2 million (December 31, 2019 — $23.9 million). As at June 30, 2020, the Company’s Condensed Consolidated Balance Sheets include a deferred income tax liability of $18.5 million deferred tax assets increased by $8.9 million due to losses recognized in the period. The recoverability of these deferred tax assets is subject to certain levels of future taxable income and the uncertainties associated with accounting estimates, as discussed in Note 1. Based on a review of the projected future earnings of the Company there was no change in management’s estimates of the recoverability of the Company’s deferred tax assets. Should actual results differ from management’s estimates of future taxable income, an increased valuation allowance may be required. The Company’s Chinese subsidiary had taken a deduction for certain share-based compensation issued by its parent company in a prior period and had recognized a related deferred tax asset of $1.4 million (December 31, 2019 — $1.4 million). Chinese regulatory authorities responsible for capital and exchange controls will need to review and approve the proposed settlement of these transactions before they can be completed. There may be a requirement for future investment of funds into China in order to secure the deduction. Should the Company proceed, any such future investment would come from existing capital invested in the IMAX China group of companies being redeployed amongst the IMAX China group of companies, including the Chinese subsidiary. (b) Income Tax Effect on Other Comprehensive (Loss) Income The income tax (expense) benefit included in the Company’s other comprehensive (loss) income are related to the following items: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Unrealized change in cash flow hedging instruments $ (354 ) $ (99 ) $ 395 $ (182 ) Realized change in cash flow hedging instruments upon settlement (88 ) (78 ) (182 ) (96 ) Unrecognized actuarial gain on defined benefit plan — — 40 — $ (442 ) $ (177 ) $ 253 $ (278 )

Capital Stock

Capital Stock	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Capital Stock	12. Capital Stock (a) Share-Based Compensation For the three and six months ended June 30, 2020, share-based compensation expense totaled $6.5 million and $10.7 million, respectively (2019 — $7.0 million and $11.4 million, respectively) and is reflected in the following accounts in the Condensed Consolidated Statements of Operations: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Cost and expenses applicable to revenues $ — $ 447 $ 400 $ 821 Selling, general and administrative expenses 6,467 6,485 10,174 10,388 Research and development — 95 85 180 $ 6,467 $ 7,027 $ 10,659 $ 11,389 There were no share-based compensation expenses allocated to Costs and Expenses Applicable to Revenues or Research and Development in the three months ended June 30, 2020 due to the idling of the Company’s productive capacity and slowdown in business activities during the COVID-19 global pandemic. The following table summarizes the Company’s share-based compensation expense by each award type: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Stock Options $ 503 $ 2,177 $ 1,016 $ 4,084 Restricted Share Units 4,534 4,132 7,436 6,242 Performance Stock Units 467 — 746 — IMAX China Stock Options 15 77 101 143 IMAX China Long Term Incentive Plan Restricted Share Units 909 641 1,313 920 IMAX China Long Term Incentive Plan Performance Stock Units 39 — 47 — $ 6,467 $ 7,027 $ 10,659 $ 11,389 For the six months ended June 30, 2020, the above includes expense of $0.1 million and $0.1 million in the three and six months ended June 30, 2020, respectively (2019 — $ nil nil Stock Option Summary The following table summarizes the activity under the Company’s Stock Option Plan (“SOP”) and IMAX Amended and Restated Long Term Incentive Plan (“IMAX LTIP”) for the six months ended June 30: Number of Shares Weighted Average Exercise Price Per Share 2020 2019 2020 2019 Stock options outstanding, beginning of period 5,732,209 5,465,046 $ 26.82 $ 27.63 Granted — 1,016,882 — 20.66 Exercised — (85,746 ) — 20.15 Forfeited (23,633 ) (103,902 ) 22.35 23.70 Expired (772,665 ) (316,325 ) 27.03 26.08 Cancelled (18,483 ) (5,196 ) 27.97 32.80 Stock options outstanding, end of period 4,917,428 5,970,759 26.80 26.70 Stock options exercisable, end of period 4,313,890 4,104,443 27.32 28.35 Stock options are no longer granted under the Company’s previous approved SOP. Restricted Share Units (“RSU”) Summary The following table summarizes the activity in respect of RSUs issued under the IMAX LTIP for the six months ended June 30: Number of Awards Weighted Average Grant Date Fair Value Per Share 2020 2019 2020 2019 RSUs outstanding, beginning of period 1,065,347 1,033,871 $ 23.17 $ 25.70 Granted 1,047,369 618,181 15.36 22.40 Vested and settled (383,126 ) (302,232 ) 21.58 26.69 Forfeited (39,912 ) (124,527 ) 20.29 23.66 RSUs outstanding, end of period 1,689,678 1,225,293 18.76 23.99 Performance Stock Units Summary In the first quarter of 2020, the Company expanded its share-based compensation program to include performance stock units (“PSUs”). The Company grants two types of PSU awards, one which vests based on a combination of employee service and the achievement of certain EBITDA-based targets and one which vests based on a combination of employee service and the achievement of certain stock-price targets. These awards vest over a three-year performance period. The fair value of PSUs with EBITDA-based targets is equal to the closing price on date of grant or the average closing price of the Company’s common stock for five days prior to the date of grant. The fair value of PSUs with stock-price targets is determined on the grant date using a Monte Carlo simulation, which is a valuation model that takes into account the likelihood of achieving the stock-price targets embedded in the award (“Monte Carlo Model”). The compensation expense attributable to each type of PSU is recognized on a straight-line basis over the requisite service period. The fair value determined by the Monte Carlo Model is affected by the Company’s stock price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company’s expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. The compensation expense is fixed on the date of grant based on the dollar value granted. The amount and timing of compensation expense recognized for PSUs with EBITDA-based targets is dependent upon management's assessment of the likelihood and timing of achieving these targets. If, as a result of management’s assessment, it is projected that a greater number of PSUs will vest than previously anticipated, a life-to-date adjustment to increase compensation expense is recorded in the period such determination is made. Conversely, if, as a result of management’s assessment, it is projected that a lower number of PSUs will vest than previously anticipated, a life-to-date adjustment to decrease compensation expense is recorded in the period such determination is made. Compensation expense is not adjusted for estimated, forfeitures, but is instead adjusted based upon the actual forfeiture of the award. The following table summarizes the activity in respect of PSUs issued under the IMAX LTIP for the six months ended June 30: Number of Awards Weighted Average Grant Date Fair Value Per Share 2020 2019 2020 2019 Granted 369,260 — $ 15.67 $ — Forfeited (2,526 ) — 14.84 — PSUs outstanding, end of period 366,734 — 15.68 — Issuer Purchases of Equity Securities In 2017, the Company’s Board of Directors approved a new $200.0 million common stock share repurchase program, which would have expired on June 30, 2020. In June 2020, the Board of Directors approved a 12-month extension of this program which will now expire on June 30, 2021. The repurchases may be made either in the open market or through private transactions, subject to market conditions, applicable legal requirements and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time. There were no common stock repurchases during the three months ended June 30, 2020. During the six months ended June 30, 2020, the Company repurchased 2,484,123 shares of its common stock at an average price of $14.72 per share, excluding commissions. During the three and six months ended June 30, 2019, the Company repurchased 87,769 common shares at an average price of $19.45 per share, excluding commissions. In 2019, IMAX China announced that its shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase shares of IMAX China in an amount not to exceed 10% of the total number of issued shares as at June 6, 2019 (35,605,560 shares). The share repurchase program expired on the date of the 2020 Annual General Meeting of IMAX China on June 11, 2020. During the 2020 Annual General Meeting, shareholders approved the repurchase of shares of IMAX China not to exceed 10% of the total number of issued shares as of June 11, 2020 (34,848,398 shares). This program will be valid until the 2021 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time. During the three and six months ended June 30, 2020, IMAX China repurchased 425,800 and 906,400 shares of its common stock, respectively, at an average price of HKD 11.63 per share and HKD 13.13 per share, respectively (U.S. $1.50 and U.S. $1.69, respectively). During the three and six months ended June 30, 2019, IMAX China repurchased 6,315,900 and 7,025,700 of its common shares, respectively, at an average price of HKD 18.59 per share and HKD 18.68 per share, respectively (U.S. $2.37 and U.S. $2.38, respectively). The total number of shares purchased during the six months ended June 30, 2020 does not include 200,000 common shares (2019 — 400,000 common shares) purchased in the administration of employee share-based compensation plans, at an average price of $15.43 per share (2019 — $22.98 per share). There were no such purchases made during the three months ended June 30, 2020 and 2019. As at June 30, 2020, the IMAX LTIP trustee held 21,313 shares (December 31, 2019 — 187,020 shares) purchased for $0.3 million (December 31, 2019 — $4.0 million) in the open market to be issued upon the settlement of RSUs and certain stock options. The shares held with the trustee are recorded at cost and are reported as a reduction against capital stock on the Condensed Consolidated Balance Sheets. (b) Basic and Diluted Weighted Average Shares Outstanding The following table reconciles the denominator of the basic and diluted weighted average share computations: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Weighted average number of common shares (000's): Issued and outstanding, beginning of period 58,787 61,291 61,176 61,434 Weighted average number of shares repurchased, net of shares issued during the period 21 40 (1,563 ) (80 ) Weighted average number of shares used in computing basic income per share 58,808 61,331 59,613 61,354 Assumed exercise of stock options, RSUs and PSUs, net of shares assumed repurchased, if dilutive — 176 — 171 Weighted average number of shares used in computing diluted income per share 58,808 61,507 59,613 61,525 For three and six months ended June 30, 2020, the calculation of diluted weighted average shares outstanding excludes 6,973,840 and 6,973,840 shares, respectively (2019 — 6,153,795 and 6,226,887 shares, respectively) of common shares issuable upon the vesting of RSUs and PSUs and the exercise of stock options.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	6 Months Ended
	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	13. Revenue from Contracts with Customers (a) Disaggregated Information About Revenue The following tables summarize the Company’s revenues by type and reportable segment for the three and six months ended June 30, 2020: Three Months Ended June 30, 2020 Revenue from Contracts with Customers Revenue from Fixed Consideration Variable Consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems $ 1,278 $ 765 $ — $ — $ 2,043 Joint Revenue Sharing Arrangements, fixed fees — — 369 — 369 Other Theater Business (1) (309 ) — — — (309 ) Other sales (2) 505 79 — — 584 Sub-total 1,474 844 369 — 2,687 Image enhancement and maintenance services IMAX DMR — 546 — — 546 IMAX Maintenance — — — — — Film Post-Production 738 — — — 738 Film Distribution 2,250 194 — — 2,444 Other — 71 — — 71 Sub-total 2,988 811 — — 3,799 Technology rentals Joint Revenue Sharing Arrangements, contingent rent (3) — — (137 ) — (137 ) Sub-total — — (137 ) — (137 ) Finance income IMAX Systems — — — 2,506 2,506 Total $ 4,462 $ 1,655 $ 232 $ 2,506 $ 8,855 Six Months Ended June 30, 2020 Revenue from Contracts with Customers Revenue from Fixed consideration Variable consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems $ 3,521 $ 1,662 $ — $ — $ 5,183 Joint Revenue Sharing Arrangements, fixed fees — — 1,139 — 1,139 Other Theater Business 954 — — — 954 Other sales (2) 983 90 — — 1,073 Sub-total 5,458 1,752 1,139 — 8,349 Image enhancement and maintenance services IMAX DMR — 11,175 — — 11,175 IMAX Maintenance 7,370 — — — 7,370 Film Post-Production 2,349 — — — 2,349 Film Distribution 2,250 1,077 — — 3,327 Other — 299 — — 299 Sub-total 11,969 12,551 — — 24,520 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 5,834 — 5,834 Sub-total — — 5,834 — 5,834 Finance income IMAX Systems — — — 5,054 5,054 Total $ 17,427 $ 14,303 $ 6,973 $ 5,054 $ 43,757 (1) The Company is reporting negative revenue due to an adjustment to prior period revenue. (2) Other sales include New Business Initiatives. (3) The Company is reporting negative revenue due to the continued amortization of lessee incentives that are typically netted against lease revenues, which are abnormally low during the period due to the COVID-19 global pandemic, as discussed in Note 2. The following tables summarize the Company’s revenues by type and reportable segment for the three and six months ended June 30, 2019 : Three Months Ended June 30, 2019 Revenue from Contracts with Customers Revenue from Fixed Consideration Variable Consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems $ 13,074 $ 849 $ — $ — $ 13,923 Joint Revenue Sharing Arrangements, fixed fees — — 2,548 — 2,548 Other Theater Business 2,580 — — — 2,580 Other sales (1) 500 143 — — 643 Sub-total 16,154 992 2,548 — 19,694 Image enhancement and maintenance services IMAX DMR — 39,293 — — 39,293 IMAX Maintenance 13,207 — — — 13,207 Film Post-production 2,326 — — — 2,326 Film Distribution — 1,275 — — 1,275 Other (1) 561 — — 561 Sub-total 15,533 41,129 — — 56,662 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 25,540 — 25,540 Other (1) — 2 321 — 323 Sub-total — 2 25,861 — 25,863 Finance income IMAX Systems — — — 2,578 2,578 Total $ 31,687 $ 42,123 $ 28,409 $ 2,578 $ 104,797 Six Months Ended June 30, 2019 Revenue from Contracts with Customers Revenue from Fixed consideration Variable consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems $ 21,238 $ 3,030 $ — $ — $ 24,268 Joint Revenue Sharing Arrangements, fixed fees — — 5,087 — 5,087 Other Theater Business 4,206 — — — 4,206 Other sales (1) 1,188 145 — — 1,333 Sub-total 26,632 3,175 5,087 — 34,894 Image enhancement and maintenance services IMAX DMR — 67,243 — — 67,243 IMAX Maintenance 26,158 — — — 26,158 Film Post-production 4,273 — — — 4,273 Film Distribution — 1,990 — — 1,990 Other (1) 1,145 — — 1,145 Sub-total 30,431 70,378 — — 100,809 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 43,584 — 43,584 Other (1) — 26 423 — 449 Sub-total — 26 44,007 — 44,033 Finance income IMAX Systems — — — 5,259 5,259 Total $ 57,063 $ 73,579 $ 49,094 $ 5,259 $ 184,995 (1) Other sales include New Business Initiatives. (See Note 2 for information on the current impacts and uncertainties relating to the COVID-19 pandemic, which are impacting the Company’s revenues.) (b) Deferred Revenue The Company’s IMAX Theater System sale and lease arrangements include a requirement for it to provide maintenance services over the life of the arrangement, subject to a consumer price index adjustment each year. In circumstances where customers prepay the entire term’s maintenance fee, additional payments are due to the Company for the years after its extended warranty and maintenance obligations expire. Payments upon renewal each year are either prepaid or made in arrears and can vary in frequency from monthly to annually. At June 30, 2020, $17.2 million of consideration has been deferred in relation to outstanding maintenance services to be provided on existing maintenance contracts (December 31, 2019 — $17.7 million). The maintenance revenue is recognized evenly over the contract term which coincides with the maintenance services being provided. In the event of customer default, any payments made by the customer may be retained by the Company. In instances where the Company receives consideration prior to satisfying its performance obligations, the recognition of revenue is deferred. The majority of the deferred revenue balance relates to payments received by the Company for IMAX Theater Systems where control of the system has not transferred to the customer. The deferred revenue balance related to an individual theater increases as progress payments are made and is then derecognized when control of the system is transferred to the customer. Recognition dates are variable and depend on numerous factors, including some outside of the Company’s control. (See Note 2 for information on the current impacts of and uncertainties relating to the COVID-19 pandemic which are impacting Company’s revenues

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Segment Reporting	14. Segment Reporting The Company’s Chief Executive Officer (“CEO”) is its Chief Operating Decision Maker (“CODM”), as such term is defined under U.S. GAAP. The CODM, along with other members of management, assess segment performance based on segment revenues and gross margins. Selling, general and administrative expenses, research and development costs, the amortization of intangibles, provisions for (recoveries of) current expected credit losses, certain write-downs, interest income, interest expense and tax (expense) benefit are not allocated to the segments. The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements; (iii) IMAX Systems, (iv) IMAX Maintenance; (v) Other Theater Business; (vi) New Business Initiatives; (vii) Film Distribution; and (viii) Film Post-production. The Company organizes its reportable segments into the following four categories, identified by the nature of the product sold or service provided: (i) IMAX Technology Network, which earns revenue based on contingent box office receipts and includes the IMAX DMR segment and contingent rent from the Joint Revenue Sharing Arrangement (“JRSA”) segment; (ii) IMAX Technology Sales and Maintenance, which includes results from the IMAX Systems, IMAX Maintenance and Other Theater Business segments, as well as fixed revenues from the JRSA segment; (iii) New Business Initiatives, which is a segment that includes activities related to the exploration of new lines of business and new initiatives outside of the Company’s core business; and (iv) Film Distribution and Post-production, which includes activities related to the licensing of film content, and the distribution of films primarily for the Company’s institutional theater partners (through the Film Distribution segment) and the provision of film post-production and quality control services (through the Film Post-production segment). The Company is presenting information at a disaggregated level to provide more relevant information to readers. Transactions between the IMAX DMR segment and the Film Post-production segment are valued at exchange value. Inter-segment profits are eliminated upon consolidation, as well as for the disclosures below. The following table sets forth the breakdown of revenue and (margin loss) gross margin by category for the three months ended June 30, 2020: Revenue (Margin Loss) Gross Margin (3) 2020 2019 2020 2019 IMAX Technology Network IMAX DMR $ 546 $ 39,293 $ (30 ) $ 23,961 Joint revenue sharing arrangements, contingent rent (4) (137 ) 25,540 (6,501 ) 19,318 409 64,833 (6,531 ) 43,279 IMAX Technology Sales and Maintenance IMAX Systems (1) 4,549 16,501 2,650 8,019 Joint revenue sharing arrangements, fixed fees 369 2,548 48 870 IMAX Maintenance — 13,207 (1,908 ) 5,640 Other Theater Business (2)(5) (309 ) 2,580 (564 ) 841 4,609 34,836 226 15,370 New Business Initiatives 632 478 512 281 Film Distribution and Post-production Film Distribution 2,444 1,275 (1,541 ) 377 Post-production 738 2,326 145 81 3,182 3,601 (1,396 ) 458 8,832 103,748 (7,189 ) 59,388 Other 23 1,049 (499 ) 165 Total $ 8,855 $ 104,797 $ (7,688 ) $ 59,553 The following table sets forth the breakdown of revenue and (margin loss) gross margin by category for six months ended June 30, 2020: Revenue (Margin Loss) Gross Margin (3) 2020 2019 2020 2019 IMAX Technology Network IMAX DMR $ 11,175 $ 67,243 $ 4,413 $ 43,736 Joint revenue sharing arrangements, contingent rent 5,834 43,584 (8,119 ) 31,253 17,009 110,827 (3,706 ) 74,989 IMAX Technology Sales and Maintenance IMAX Systems (1) 10,237 29,527 5,826 15,071 Joint revenue sharing arrangements, fixed fees 1,139 5,087 227 1,165 IMAX Maintenance 7,370 26,158 (1,149 ) 10,921 Other Theater Business (2) 954 4,206 46 1,316 19,700 64,978 4,950 28,473 New Business Initiatives 1,110 1,312 873 900 Film Distribution and Post-production Film Distribution 3,327 1,990 (3,699 ) (333 ) Post-production 2,349 4,273 368 766 5,676 6,263 (3,331 ) 433 Sub-total 43,495 183,380 (1,214 ) 104,795 Other 262 1,615 (1,388 ) (102 ) Total $ 43,757 $ 184,995 $ (2,602 ) $ 104,693 (1) Includes initial upfront payments and the present value of fixed minimum payments from sales and sales-type lease arrangements of IMAX Theater Systems, and the present value of estimated variable consideration from sales of IMAX Theater Systems. To a lesser extent, also includes finance income associated with these revenue streams. ( 2 ) Principally includes after-market sales of IMAX projection system parts and 3D glasses ( 3 ) IMAX DMR gross margin includes marketing cost of $nil and $2.4 million for the three and six months ended June 30, 2020, respectively (2019 — $9.5 million and $13.4 million, respectively). JRSA gross margin includes advertising, marketing and commission expense of less than $0.1 million and $0.6 million for the three and six months ended June 30, 2020, respectively (2019 —$0.2 million and $0.3 million, respectively). IMAX Systems gross margin includes marketing and commission costs of $0.2 million and $0.4 million for the three and six months ended June 30, 2020, respectively, (2019 — $0.4 million and $0.9 million, respectively). Film Distribution segment gross margin includes marketing expense of less than $0.1 million and $0.2 million for the three and six months ended June 30, 2020, respectively (2019 — less than $0.1 million and $0.6 million, respectively). (4) The Company is reporting negative revenue due to the continued amortization of lessee incentives that are typically netted against lease revenues, which are abnormally low during the period due to the COVID-19 global pandemic, as discussed in Note 2. (5) The Company is reporting negative revenue due to an adjustment to prior period revenue. Geographic Information Revenue by geographic area is based on the location of the customer. Revenue related to IMAX DMR is presented based upon the geographic location of the theaters that exhibit the remastered films. IMAX DMR revenue is generated through contractual relationships with studios and other third parties and these may not be in the same geographical location as the theater. Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Revenue United States $ 3,812 $ 35,944 $ 16,777 $ 60,237 Asia (excluding Greater China) 1,868 9,963 7,728 18,753 Greater China 1,393 32,575 6,662 59,256 Russia & the CIS 658 5,619 2,224 7,307 Western Europe 631 11,933 5,188 20,376 Latin America 108 2,160 1,635 4,813 Canada 12 2,620 943 4,492 Rest of the World 373 3,983 2,600 9,761 Total $ 8,855 $ 104,797 $ 43,757 $ 184,995 No single country in the Rest of the World, Western Europe, Latin America and Asia (excluding Greater China) comprises more than 10% of the Company’s total revenue, except for Japan in the three months ended June 30, 2020.

Employees Pension and Postretir

Employees Pension and Postretirement Benefits	6 Months Ended
	Jun. 30, 2020
Compensation And Retirement Disclosure [Abstract]
Employees Pension and Postretirement Benefits	15. Employee's Pension and Postretirement Benefits (a) Defined Benefit Plan The Company has an unfunded defined benefit supplemental executive retirement plan (the “SERP”) covering Richard L. Gelfond, its CEO. The accounting for the SERP assumes that Mr. Gelfond will receive a lump sum payment of $20.3 million six months after retirement at the end of the current term of his employment agreement (December 31, 2022), although Mr. Gelfond has not informed the Company that he intends to retire at that time. As at June 30, 2020 and December 31, 2019 , the Company’s projected benefit obligation and unfunded status related to the SERP are as follows : June 30, December 31, 2020 2019 Projected benefit obligation: Obligation, beginning of period $ 18,840 $ 17,977 Prior Service cost — 456 Interest cost 189 564 Actuarial gain — (157 ) Obligation, end of period and unfunded status $ 19,029 $ 18,840 The accumulated benefit obligation for the SERP was $19.0 million at June 30, 2020 (December 31, 2019 —$18.8 million). For the three and six months ended June 30, 2020, the Company recorded interest costs of $0.1 million and $0.2 million, respectively, (2019 — $0.1 million and $0.3 million, respectively) related to the SERP. The Company expects to recognize interest costs of $0.2 million related to the SERP during the remainder of 2020. No contributions are expected to be made for the SERP during the remainder of 2020. (b) Defined Contribution Pension Plan The Company also maintains defined contribution plans for its employees, including its executive officers. The Company makes contributions to these plans on behalf of employees in an amount up to 5% of their base salary subject to certain prescribed maximums. During the three and six months ended June 30, 2020, the Company contributed and recorded expense of $0.2 million and $0.5 million, respectively, and $0.4 million, respectively, (c) Postretirement Benefits – Executives The Company has an unfunded postretirement plan for Mr. Gelfond and Bradley J. Wechsler, Chairman of the Company’s Board of Directors. The plan provides that the Company will maintain health benefits for Messrs. Gelfond and Wechsler until they become eligible for Medicare and, thereafter, the Company will provide Medicare supplement coverage as selected by Messrs. Gelfond and Wechsler. As at June 30, 2020, the Company’s postretirement benefits obligation under this plan is $0.6 million (December 31, 2019 — $0.7 million). For the three and six months ended June 30, 2020, the Company has recorded expense of less than $0.1 million and less than $0.1 million, respectively (2019 — less than $0.1 million and less than $0.1 million, respectively) related to this plan. (d) Postretirement Benefits – Canadian Employees The Company has an unfunded postretirement plan for its Canadian employees meeting specific eligibility requirements. The Company will provide eligible participants, upon retirement, with health and welfare benefits. As at June 30, 2020, the Company’s postretirement benefits obligation under this plan is $1.5 million (December 31, 2019 — $1.6 million). For the three and six months ended June 30, 2020, the Company has recorded expense of less than $0.1 million and $0.1 million, respectively (2019 — less than $0.1 million and less than $0.1 million, respectively) related to this plan. (e) Deferred Compensation Benefit Plan The Company maintained a nonqualified deferred compensation benefit plan (the “Retirement Plan”) covering the former CEO of IMAX Entertainment and Senior Executive Vice President of the Company. Under the terms of the Retirement Plan, the benefits were due to vest in full if he incurred a separation from service (as defined therein). In the fourth quarter of 2018, the executive incurred a separation from service, and as such, the Retirement Plan benefits became fully vested as at December 31, 2018 and the accelerated costs were recognized and reflected in Executive Transition Costs on the Consolidated Statement of Operations. As at June 30, 2020, the Company had a funded benefit obligation recorded of $3.6 million (December 31, 2019 — $3.6 million). The Company did not recognize any additional expenses in the three and six months ended June 30, 2020 and 2019

Financial Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2020
Investments All Other Investments [Abstract]
Financial Instruments	1 6 . Financial Instruments (a) Cash and Cash Equivalents The Company maintains cash with various major financial institutions. The Company’s cash is invested with highly rated financial institutions. (b) Fair Value Measurements The carrying values of the Company’s cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities due within one year approximate fair values due to the short-term maturity of these instruments. The Company’s other financial instruments are comprised of the following: As at June 30, 2020 As at December 31, 2019 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Level 1 Cash and cash equivalents (1) $ 318,986 $ 318,986 $ 109,484 $ 109,484 Equity securities (3) 13,192 13,192 15,685 15,685 Level 2 Net financed sales receivables (2) $ 108,081 $ 108,430 $ 112,432 $ 111,441 Net investment in sales-type leases (2) 15,784 15,516 15,606 15,309 Convertible loan receivable (2) — — 1,500 1,500 Equity securities (1) 1,000 1,000 1,000 1,000 Foreign exchange contracts — (3) (318 ) (318 ) 530 530 Foreign exchange contracts — (3) 27 27 — — Bank indebtedness - under the Working Capital Facility (1) (244 ) (244 ) — — Bank indebtedness - under the Credit Facility (1) (300,000 ) (300,000 ) (20,000 ) (20,000 ) (1) Recorded at cost, which approximates fair value. (2) Estimated based on discounting future cash flows at currently available interest rates with comparable terms. (3) Value determined using quoted prices in active markets. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. There were no significant transfers in or out of the Company’s Level 3 assets during the three and six months ended June 30, 2020 and 2019. (c) Foreign Exchange Risk Management The Company is exposed to market risk from changes in foreign currency rates. A majority of the Company’s revenues is denominated in U.S. dollars while a substantial portion of its costs and expenses is denominated in Canadian dollars. A portion of the net U.S. dollar cash flows of the Company is periodically converted to Canadian dollars to fund Canadian dollar expenses through the spot market. In China and Japan, the Company has ongoing operating expenses related to its operations in Chinese Renminbi and Japanese yen, respectively. Net cash flows are converted to and from U.S. dollars through the spot market. The Company also has cash receipts under leases denominated in Chinese Renminbi, Japanese yen, Canadian dollars and Euros which are converted to U.S. dollars through the spot market. In addition, because IMAX films generate box office in 81 different countries, unfavourable exchange rates between applicable local currencies and the U.S. dollar affect the Company’s reported gross box-office and revenues, further impacting the Company’s results of operations. The Company’s policy is to not use any financial instruments for trading or other speculative purposes. The Company entered into a series of foreign currency forward contracts to manage the Company’s risks associated with the volatility of foreign currencies. Certain of these foreign currency forward contracts met the criteria required for hedge accounting under the Derivatives and Hedging Topic of the FASB ASC at inception, and continue to meet hedge effectiveness tests at June 30, 2020 (the “Foreign Currency Hedges”), with settlement dates throughout 2020 and 2021. Foreign currency derivatives are recognized and measured in the Condensed Consolidated Balance Sheets at fair value. Changes in the fair value (gains or losses) are recognized in the Condensed Consolidated Statements of Operations except for derivatives designated and qualifying as foreign currency cash flow hedging instruments. The Company currently has cash flow hedging instruments associated with selling, general and administrative expenses and inventories . For foreign currency cash flow hedging instruments related to selling, general and administrative expenses, the effective portion of the gain or loss in a hedge of a forecasted transaction is reported in O ther C omprehensive I ncome and reclassified to the C ondensed C onsolidated St atements of O perations when the forecasted transaction occurs. For foreign currency cash flow hedging instruments related to inventories , the effective portion of the gain or loss in a hedge of a forecasted transaction is reported in O ther C omprehensive I ncome and reclassified to Inventories in the Condensed Consolidated B alance S heet s when the forecasted transaction occurs. Any ineffective portion is recognized immediately in the Condensed C onsolidated S tatement of O perations. On April 28, 2020, the FASB staff issued a question-and-answer document (Q&A) to respond to frequently asked questions about the disruptive effects of COVID-19 on cash flow hedge accounting. FASB Accounting Standards Codification Topic 815, Derivative and Hedging, provides guidance on when to discontinue cash flow hedge accounting and when and how to reclassify amounts deferred in accumulated other comprehensive income (AOCI) to earnings. The Q&A document addresses how the postponement or cancellation of forecasted transactions related to the effects of the COVID-19 pandemic should be considered when applying cash flow hedge accounting under Topic 815. The Company has considered the Q&A document when applying cash hedge flow accounting under Topic 815. The guidance did not have a material impact to the Company’s Condensed Consolidated Financial Statements. The following tabular disclosures reflect the impact that derivative instruments and hedging activities have on the Company’s Condensed Consolidated Financial Statements: Notional value of foreign exchange contracts: June 30, December 31, 2020 2019 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards $ 32,437 36,052 Derivatives not designated as hedging instruments: Foreign exchange contracts — Forwards 3,584 — $ 36,021 $ 36,052 Fair value of derivatives in foreign exchange contracts: June 30, December 31, Balance Sheet Location 2020 2019 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards Other assets $ 245 $ 602 Accrued and other liabilities (563 ) (72 ) Derivatives not designated as hedging instruments: Foreign exchange contracts — Forwards Other assets 57 — Accrued and other liabilities (30 ) — $ (291 ) $ 530 Derivatives in Foreign Currency Hedging relationships are as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Foreign exchange contracts Derivative Gain (Loss) — Forwards Recognized in OCI (Effective Portion) $ 1,334 $ 297 $ (1,526 ) $ 365 Location of Derivative Loss Reclassified from AOCI Three Months Ended June 30, Six months ended June 30, (Effective Portion) 2020 2019 2020 2019 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ (328 ) $ (355 ) $ (669 ) (661 ) Property, plant and equipment — (19 ) — (32 ) Inventory (9 ) — $ (26 ) — $ (337 ) $ (374 ) $ (695 ) $ (693 ) Three Months Ended June 30, Six months ended June 30, 2020 2019 2020 2019 Foreign exchange contracts Derivative Gain (Loss) Recognized In — Forwards and Out of OCI $ — $ 2 $ (88 ) $ 2 Non Designated Derivatives in Foreign Currency relationships are as follows: Three Months Ended June 30, Six months ended June 30, Location of Derivative Gain 2020 2019 2020 2019 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ 27 $ — $ 27 — $ 27 $ — $ 27 $ — The Company's estimated net amount of the existing losses as at June 30, 2020 is $0.4 million, which is expected to be reclassified to earnings within the next twelve months. (d) Investments in Equity Securities As at June 30, 2020, the Condensed Consolidated Balance Sheets includes $13.2 million (December 31, 2019 — $15.7 million) of investments in equity securities. On January 17, 2019, IMAX China (Hong Kong), Limited, a wholly-owned subsidiary of IMAX China, as an investor entered into a cornerstone investment agreement with Maoyan Entertainment (“Maoyan”) (as the issuer) and Morgan Stanley Asia Limited (as a sponsor, underwriter and the underwriters’ representative). Pursuant to this agreement, IMAX China (Hong Kong), Limited agreed to invest $15.2 million to subscribe for a certain number of shares of Maoyan at the final offer price pursuant to the global offering of the share capital of Maoyan, and this investment would be subject to a lock-up period of six months following the date of the global offering. On February 4, 2019, Maoyan completed its global offering, upon which, IMAX China (Hong Kong), Limited became a less than 1% shareholder in Maoyan. This investment is classified as an equity security, with a readily determinable market value through the Hong Kong Stock Exchange. The changes in fair value are recorded in gain (loss) in fair value of equity investment line item in the Company’s Condensed Consolidated Statement of Operations. As at June 30, 2020, the value of the Company’s investment in Maoyan was $12.1 million (December 31, 2019 — $14.6 million). For the three and six months ended June 30, 2020, the Company has recorded a net unrealized gain of $2.0 million and loss of $2.5 million, respectively ( 2019— loss of $4.5 million and $2.1 million, respectively). The Company has an investment of $1.1 million (December 31, 2019 — $1.0 million) in the shares of an exchange traded fund. This investment is classified as an equity investment. As at June 30, 2020 , the Company held investments in the preferred shares of enterprises which meet the criteria for classification as an equity security under FASB ASC 325, carried at historical cost, net of impairment charges. The carrying value of these equity security investments was $1.0 million at June 30, 2020 ( December 31, 2019 — $1.0 million ) and is recorded in Other Assets.

Non-Controlling Interests

Non-Controlling Interests	6 Months Ended
	Jun. 30, 2020
Temporary Equity Disclosure [Abstract]
Non-Controlling Interests	17. Non-Controlling Interests (a) IMAX China Non-Controlling Interest The Company indirectly owns approximately 69.81% of IMAX China Holding, Inc. (“IMAX China”), whose shares trade on the Hong Kong Stock Exchange. IMAX China is a consolidated subsidiary of the Company. The balance of the non-controlling interest in IMAX China as at June 30, 2020 is $74.7 million. The net loss attributable to the non-controlling interest in IMAX China for the three and six months ended June 30, 2020 is $2.8 million and $12.5 million, respectively (2019 — net income of $2.7 million and $7.0 million, respectively). (b) Other Non-Controlling Interest The Company’s Original Film Fund was established in 2014 to co-finance a portfolio of 10 original large-format films. The initial investment in the Original Film Fund was committed by a third party in the amount of $25.0 million, with the possibility of contributing additional funds. The Company has contributed $9.0 million to the Original Film Fund since 2014 and has reached its maximum contribution. As at June 30, 2020, the Original Film Fund has invested $22.3 million toward the development of original films. The related production, financing and distribution agreement includes put and call rights relating to change of control of the rights, title and interest in the co-financed pictures. The following table summarizes the movement of the non-controlling interest in temporary equity, in the Company’s subsidiary for the six months ended June 30, 2020: Balance as at December 31, 2019 $ 5,908 Net loss (1,671 ) Balance as at June 30, 2020 $ 4,237

Exit Costs, Restructuring Charg

Exit Costs, Restructuring Charges and Associated Impairments	6 Months Ended
	Jun. 30, 2020
Restructuring And Related Activities [Abstract]
Exit Costs, Restructuring Charges and Associated Impairments	18. Exit costs, restructuring charges and associated impairments In 2018, the Company performed a strategic review of its business and decided to exit from certain non-core businesses or initiatives, which included closing its VR locations. In addition, as part of management’s efforts to decrease costs, the Company reduced certain functions and realigned resources. During the six months ended June 30, 2019, the Company recognized charges of $0.9 million associated with these actions in its Condensed Consolidated Statements of Operations, consisting of restructuring charges and costs to exit leases. Restructuring charges relate to the Company’s corporate unit and are comprised of employee severance costs including benefits and share-based compensation, costs of consolidating facilities and contract termination costs.

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accounting Principles	Accounting Principles IMAX Corporation, together with its consolidated subsidiaries (the “Company”), prepares its financial statements in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. In the Company’s opinion, the unaudited Condensed Consolidated Financial Statements reflect all adjustments of a normal recurring nature that are necessary for a fair statement of the results for the interim periods presented. The interim results presented in the Company’s Condensed Consolidated Statements of Operations are not necessarily indicative of results for a full year, particularly in this interim period due to the impacts of the COVID-19 global pandemic. (See Note 2.) The Company’s Condensed Consolidated Financial Statements Condensed Consolidated Financial Statements In the first quarter of 2020, the Company updated certain account names within Revenues and Costs and Expenses Applicable to Revenues in its Condensed Consolidated Statements of Operations to better describe the nature of its revenue-generating activities and related costs.
Principles of Consolidation	Principles of Consolidation These Condensed Consolidated Financial Statements include the accounts of the Company, except for subsidiaries which have been identified as variable interest entities (“VIEs”) where the Company is not the primary beneficiary. All intercompany accounts and transactions, including all unrealized intercompany profits on transactions with equity method investees, have been eliminated. The Company has interests in ten film production companies, which have been identified as VIEs. The Company is the primary beneficiary of five of these entities as it has the power to direct the activities that most significantly impact the economic performance of the VIE, and it has the obligation to absorb losses or the right to receive benefits from the respective VIE that could potentially be significant. The majority of the assets relating to these production companies are held by the IMAX Original Film Fund (the “Original Film Fund”) as described in Note 17(b). The Company does not consolidate the other five film production companies because it does not have the power to direct their activities and does not have the obligation to absorb the majority of the expected losses or the right to receive expected residual returns. The Company uses the equity method of accounting for these entities, which are not material to the Company’s Condensed Consolidated Financial Statements. A loss in value of an investment that is other than temporary is recognized as a charge to the Condensed Consolidated Statements of Operations.
Estimates and Assumptions	Estimates and Assumptions In preparing the Company’s Condensed Consolidated Financial Statements, management makes judgments in applying various accounting policies. The areas of policy judgment are consistent with those reported in the Company’s 2019 Form 10-K, with the exception of the adoption of the estimate of current expected credit losses that became effective January 1, 2020, which also involves significant judgment and estimation, and is described in Note 4 below. In addition, management makes assumptions about the Company’s future operating results and cash flows in deriving critical accounting estimates used in preparing the Condensed Consolidated Financial Statements. As disclosed in the Company’s 2019 Form 10-K, such sources of estimation include estimates used to determine the recoverable amounts of receivables, inventory, film assets, long-lived assets (including assets used to support joint revenue sharing arrangements), goodwill and deferred tax assets, as well as estimates of variable consideration related to future box office performance. To date, the Company’s operations have been significantly impacted by the COVID-19 pandemic, as described in Note 2. There continues to be significant ongoing uncertainty surrounding the extent and duration of the impacts that the pandemic will have on box office results and the installation of IMAX Theater Systems, as well as the Company’s customers, suppliers, and employees. There is heightened potential for future credit losses on receivables, inventory write downs, impairments of film assets, impairments of long-lived assets (including the theater system equipment supporting the Company’s joint revenue sharing arrangements), impairments of goodwill, valuation allowances against deferred tax assets, and the reversal of variable consideration receivables that are based on future box office performance. In the current environment, assumptions about box office results, IMAX Theater System installations, and customer creditworthiness have greater variability than normal, which could in the future significantly affect the valuation of the Company’s assets, both financial and non-financial. The Company’s cash flow estimates for testing the recoverability of certain long-lived assets are based on a longer time horizon due to the long-term nature of its underlying contracts, allowing time for a recovery of the cash flows associated with the underlying assets groups, which management has factored into its estimates. The accuracy of management’s estimates is dependent, in part, on the timing of the reopening of theaters in the IMAX network, and on the release of new films by production studios. These theater reopening and film release scenarios are highly uncertain and have been factored into management’s cash flow estimates. As an understanding of the longer-term impacts of COVID-19 on the Company’s customers and business develops, there is a heightened potential for changes in management’s estimates over the remainder of 2020.
Credit Risk	The Company’s internal credit quality classifications for theater operators are as follows: • Good Standing — The theater operator continues to be in good standing as payments and reporting are up to date. • Credit Watch — The theater operator has demonstrated a delay in payments, but continues to be in active communication with the Company. Theater operators placed on Credit Watch are subject to enhanced monitoring. In addition, depending on the size of the outstanding balance, length of time in arrears and other factors, future transactions may need to be approved by management. These receivables are in better condition than those in the Pre-Approved Transactions Only category, but are not in as good condition as the receivables in the Good Standing category. • Pre-Approved Transactions Only — The theater operator has demonstrated a delay in payments with little or no communication with the Company. All services and shipments to the theater operator must be reviewed and approved by management. These receivables are in better condition than those in the All Transactions Suspended category, but are not in as good condition as the receivables in the Credit Watch category. In certain situation, depending on the individual facts and circumstances related to each customer, finance income recognition may be suspended for the net investment in lease and financed sale receivable balances for customers in the Pre-Approved Transactions Only category. See below for a discussion of the Company’s net investment in leases and financed sale receivables. • All Transactions Suspended — The theater operator is severely delinquent, non-responsive or not negotiating in good faith with the Company. Once a theater operator is classified within the All Transactions Suspended category, the theater is placed on nonaccrual status and all revenue recognitions related to the theater are stopped.
Financing Receivable, Allowance for Credit Losses	The Company considers financing receivables with an aging between 60-89 days as indications of theaters with potential collection concerns. The Company will begin to focus its review on these financing receivables and increase its discussions internally and with the theater regarding payment status. Once a theater’s aging exceeds 90 days, the Company’s policy is to perform an enhanced review to assess collectibility of the theater’s past due accounts. The over 90 days past due category may be an indicator of potential impairment as up to 90 days outstanding is considered to be a reasonable time to resolve any issues. Given the potential impacts of the COVID-19 global pandemic on the Company’s customers, management is enhancing its monitoring procedures with respect to overdue receivables.
Lessee Leases	IMAX Corporation as a Lessee The Company’s operating lease arrangements principally involve office and warehouse space. Office equipment is generally purchased outright. Leases with an initial term of less than 12 months are not recorded on the Condensed Consolidated Balance Sheets and the related lease expense is recognized on a straight-line basis over the lease term. Most of the Company’s leases include one or more options to renew, with renewal terms that can extend the lease term from one to five years or more. The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs and its level of investment in leasehold improvements, among other factors. The incremental borrowing rate used in the calculation of the Company’s lease liability is based on the location of each leased property. None of the Company’s leases include options to purchase the leased property. The depreciable lives of right-of-use assets and related leasehold improvements are limited by the expected lease term. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed.
Lessor Leases	IMAX Corporation as a Lessor The Company provides IMAX Theater Systems to customers through long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX Theater System, the Company earns fixed upfront and ongoing consideration. Certain arrangements that are legal sales are also classified as sales-type leases as certain clauses within the arrangements limit transfer of title or provide the Company with conditional rights to the system. The customer’s rights under the Company’s sales-type lease arrangements are described in Note 2(n) in the Company’s 2019 Form 10-K. Under the Company’s sales-type lease arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s sales-type leases are typically non-cancellable for 10 to 20 years with renewal provisions from inception. Except for those sales arrangements that are classified as sales-type leases, the Company’s leases generally do not contain an automatic transfer of title at the end of the lease term. The Company’s sales-type lease arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and extended warranty generally after the first year of the lease until the end of the lease term. The customer is responsible for obtaining insurance coverage for the IMAX Theater System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX Theater System is returned to the Company. The Company also provides IMAX Theater systems to customers through joint revenue sharing arrangements. Under the traditional form of these arrangements, in exchange for providing the IMAX system under a long-term lease, the Company earns rent based on a percentage of contingent box office receipts and, in some cases, concession revenues, rather than requiring the customer to pay a fixed upfront fee or annual minimum payments. The Company has assessed the nature of its joint revenue sharing arrangements and concluded that the arrangements contain an operating lease. Under joint revenue sharing arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s joint revenue sharing arrangements are typically non-cancellable for 10 years or longer with renewal provisions. Title to equipment under joint revenue sharing arrangements does not transfer to the customer. The Company’s joint revenue sharing arrangements do not contain a guarantee of residual value at the end of the term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the IMAX Theater System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX Theater System is returned to the Company. The Company classifies its lease arrangements at inception of the arrangement and, if required, after a modification of the lease arrangement, to determine whether they are sales-type leases or operating leases. On April 10, 2020, the FASB staff issued a question-and-answer document to address stakeholder questions on the application of the lease accounting guidance for lease concessions related to the effects of the COVID-19 pandemic. The guidance allows concessions related to the timing of payments, where the total consideration has not changed, to not be accounted for as lease modifications. Instead, any such concessions can be accounted for as if no change was made to the contract or as variable lease payments. In the second quarter of 2020, the Company adopted the FASB relief guidance and elected to account for any such lease concessions as if no change was made to the underlying contracts. The adoption of this guidance did not have a material effect on the Company’s Condensed Consolidated Financial Statements.
Commitments and Contingencies	The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. Management is required to assess the likelihood of any adverse judgments or outcomes related to these legal contingencies, as well as potential ranges of probable or reasonably possible losses. The Company will record a provision for a liability when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The determination of the amount of any liability recorded or disclosed is reviewed at least quarterly based on a careful analysis of each individual exposure with, in some cases, the assistance of outside legal counsel, taking into account the impact of negotiations, settlements, rulings, and other pertinent information related to the case. The amount of liabilities recorded or disclosed for these contingencies may change in the future due to changes in management’s judgments resulting from new developments or changes in settlement strategy. Any resulting adjustment to the liabilities recorded by the Company could have a material adverse effect on its results of operations, cash flows, and financial position in the period or periods in which such changes in judgment occur. The Company believes it has adequate provisions for any such matters.
Segment Reporting	The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements; (iii) IMAX Systems, (iv) IMAX Maintenance; (v) Other Theater Business; (vi) New Business Initiatives; (vii) Film Distribution; and (viii) Film Post-production. The Company organizes its reportable segments into the following four categories, identified by the nature of the product sold or service provided: (i) IMAX Technology Network, which earns revenue based on contingent box office receipts and includes the IMAX DMR segment and contingent rent from the Joint Revenue Sharing Arrangement (“JRSA”) segment; (ii) IMAX Technology Sales and Maintenance, which includes results from the IMAX Systems, IMAX Maintenance and Other Theater Business segments, as well as fixed revenues from the JRSA segment; (iii) New Business Initiatives, which is a segment that includes activities related to the exploration of new lines of business and new initiatives outside of the Company’s core business; and (iv) Film Distribution and Post-production, which includes activities related to the licensing of film content, and the distribution of films primarily for the Company’s institutional theater partners (through the Film Distribution segment) and the provision of film post-production and quality control services (through the Film Post-production segment). The Company is presenting information at a disaggregated level to provide more relevant information to readers. Transactions between the IMAX DMR segment and the Film Post-production segment are valued at exchange value. Inter-segment profits are eliminated upon consolidation, as well as for the disclosures below.
Fair Value of Financial Instruments	The carrying values of the Company’s cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities due within one year approximate fair values due to the short-term maturity of these instruments. The Company’s other financial instruments are comprised of the following: As at June 30, 2020 As at December 31, 2019 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Level 1 Cash and cash equivalents (1) $ 318,986 $ 318,986 $ 109,484 $ 109,484 Equity securities (3) 13,192 13,192 15,685 15,685 Level 2 Net financed sales receivables (2) $ 108,081 $ 108,430 $ 112,432 $ 111,441 Net investment in sales-type leases (2) 15,784 15,516 15,606 15,309 Convertible loan receivable (2) — — 1,500 1,500 Equity securities (1) 1,000 1,000 1,000 1,000 Foreign exchange contracts — (3) (318 ) (318 ) 530 530 Foreign exchange contracts — (3) 27 27 — — Bank indebtedness - under the Working Capital Facility (1) (244 ) (244 ) — — Bank indebtedness - under the Credit Facility (1) (300,000 ) (300,000 ) (20,000 ) (20,000 ) (1) Recorded at cost, which approximates fair value. (2) Estimated based on discounting future cash flows at currently available interest rates with comparable terms. (3) Value determined using quoted prices in active markets. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. There were no significant transfers in or out of the Company’s Level 3 assets during the three and six months ended June 30, 2020 and 2019.
Fair Value Transfer	When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
VIEs Total Assets and Liabilities	Total assets and liabilities of the Company’s consolidated VIEs are as follows: June 30, December 31, 2020 2019 Total assets $ 7,010 $ 9,677 Total liabilities $ 15,494 $ 15,528

Current Expected Credit Losses

Current Expected Credit Losses (Tables)	6 Months Ended
	Jun. 30, 2020
Credit Loss [Abstract]
Summary of Allowance For Credit Losses Related to Accounts Receivable	The following table summarizes the activity in the allowance for credit losses related to accounts receivable for the three and six months ended June 30, 2020: Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Theater Operators Studios Other Total Theater Operators Studios Other Total Beginning balance $ 6,504 $ 3,983 $ 1,041 $ 11,528 $ 3,302 $ 893 $ 942 $ 5,137 Current period provision (107 ) 1,596 (203 ) 1,286 3,095 4,686 (104 ) 7,677 Write-offs — — — — — — — — Recoveries — — — — — — — — Foreign exchange (80 ) (124 ) — (204 ) (80 ) (124 ) — (204 ) Ending balance $ 6,317 $ 5,455 $ 838 $ 12,610 $ 6,317 $ 5,455 $ 838 $ 12,610
Schedule of Financing Receivables	As at June 30, 2020 and December 31, 2019, financing receivables consist of the following: June 30, December 31, 2020 2019 Net investment in leases Gross minimum payments due under sales-type leases $ 17,142 $ 16,766 Unearned finance income (899 ) (1,005 ) Present value of minimum payments due under sales-type leases 16,243 15,761 Allowance for credit losses (459 ) (155 ) Net investment in leases 15,784 15,606 Financed sales receivables Gross minimum payments due under financed sales 142,380 146,660 Unearned finance income (30,590 ) (33,313 ) Present value of minimum payments due under financed sales 111,790 113,347 Allowance for credit losses (3,709 ) (915 ) Net financed sales receivables 108,081 112,432 Total financing receivables $ 123,865 $ 128,038 Net financed sales receivables due within one year $ 31,061 $ 27,595 Net financed sales receivables due after one year $ 77,020 $ 84,837 Total financed sales receivables $ 108,081 $ 112,432
Schedule of Weighted-average Remaining Lease Term and Weighted-average Interest Rate	As at June 30, 2020 and December 31, 2019, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s sales-type lease arrangements and financed sale receivables, as applicable, are as follows: June 30, December 31, 2020 2019 Weighted-average remaining lease term (in years) Sales-type lease arrangements 7.9 8.1 Weighted-average interest rate Sales-type lease arrangements 6.85 % 6.68 % Financed sales receivables 9.02 % 9.00 %
Schedule of Net Investment In Leases by Credit Quality Indicator	The following tables provide information on the Company’s net investment in leases by credit quality indicator as at June 30, 2020 and December 31, 2019: By Origination Year As at June 30, 2020 2020 2019 2018 2017 2016 Prior Total Net investment in leases: Credit quality classification: In good standing $ 924 $ 7,804 $ 2,991 $ 942 $ — $ 2,786 $ 15,447 Credit Watch — — — — — 88 88 Pre-approved transactions — — — — — — — Transactions suspended — — — — — 708 708 Total net investment in leases $ 924 $ 7,804 $ 2,991 $ 942 $ — $ 3,582 $ 16,243 Current-period gross write-offs $ — $ — $ — $ — $ — $ — $ — Current-period recoveries — — — — — — — Current-period net write-offs $ — $ — $ — $ — $ — $ — $ — By Origination Year As at December 31, 2019 2019 2018 2017 2016 2015 Prior Total Net investment in leases: Credit quality classification: In good standing $ 7,874 $ 3,045 $ 989 $ — $ — $ 3,186 $ 15,094 Credit Watch — — — — — 667 667 Pre-approved transactions — — — — — — — Transactions suspended — — — — — — — Total net investment in leases $ 7,874 $ 3,045 $ 989 $ — $ — $ 3,853 $ 15,761
Schedule of Financed Sale Receivables by Credit Quality Indicator	The following tables provide information on the Company’s financed sale receivables by credit quality indicator as at June 30, 2020 and December 31, 2019: By Origination Year As at June 30, 2020 2020 2019 2018 2017 2016 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 1,606 $ 11,474 $ 14,382 $ 15,381 $ 15,495 $ 47,551 $ 105,889 Credit Watch — 331 — — 304 1,171 1,806 Pre-approved transactions — — — — 585 671 1,256 Transactions suspended — — — 896 937 1,006 2,839 Total financed sales receivables $ 1,606 $ 11,805 $ 14,382 $ 16,277 $ 17,321 $ 50,399 $ 111,790 Current-period gross write-offs $ — $ — $ — $ — $ — $ — $ — Current-period recoveries — — — — — — — Current-period net write-offs $ — $ — $ — $ — $ — $ — $ — By Origination Year As at December 31, 2019 2019 2018 2017 2016 2015 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 11,981 $ 14,414 $ 16,556 $ 15,208 $ — $ 44,291 $ 102,450 Credit Watch — — 637 1,687 — 6,955 9,279 Pre-approved transactions — — 250 295 — 285 830 Transactions suspended — — — 165 — 623 788 Total financed sales receivables $ 11,981 $ 14,414 $ 17,443 $ 17,355 $ — $ 52,154 $ 113,347
Schedule of Aging Analysis for Net Investment in Leases and Financed Sale Receivables	The following tables provide an aging analysis for the Company’s net investment in leases and financed sale receivables as at June 30, 2020 and December 31, 2019: As at June 30, 2020 Accrued and Current 30-89 Days 90+ Days Billed Unbilled Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 11 $ 262 $ 735 $ 1,008 $ 15,235 $ 16,243 $ (459 ) $ 15,784 Financed sales receivables 688 2,941 10,166 13,795 97,995 111,790 (3,709 ) 108,081 Total $ 699 $ 3,203 $ 10,901 $ 14,803 $ 113,230 $ 128,033 $ (4,168 ) $ 123,865 As at December 31, 2019 Accrued and Current 30-89 Days 90+ Days Billed Unbilled Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 30 $ 68 $ 251 $ 349 $ 15,412 $ 15,761 $ (155 ) $ 15,606 Financed sales receivables 1,678 2,772 5,446 9,896 103,451 113,347 (915 ) 112,432 Total $ 1,708 $ 2,840 $ 5,697 $ 10,245 $ 118,863 $ 129,108 $ (1,070 ) $ 128,038
Schedule of Net Investment in Leases and Financed Sale Receivables with Billed Amounts Past Due Continues to Accrue Finance Income	The following table provides information about the Company’s net investment in leases and financed sale receivables with billed amounts past due for which it continues to accrue finance income as at June 30, 2020 and December 31, 2019: As at June 30, 2020 Accrued and Current 30-89 Days 90+ Days Billed Unbilled Allowance for Credit Losses Net Net investment in leases $ 9 $ 255 $ 729 $ 993 $ 12,338 $ (264 ) $ 13,067 Financed sales receivables 570 2,862 10,187 13,619 64,654 (2,427 ) 75,846 Total $ 579 $ 3,117 $ 10,916 $ 14,612 $ 76,992 $ (2,691 ) $ 88,913 As at December 31, 2019 Accrued and Current 30-89 Days 90+ Days Billed Unbilled Allowance for Credit Losses Net Net investment in leases $ 9 $ 19 $ 251 $ 279 $ 578 $ — $ 857 Financed sales receivables 1,146 1,290 5,523 7,959 29,173 — 37,132 Total $ 1,155 $ 1,309 $ 5,774 $ 8,238 $ 29,751 $ — $ 37,989
Schedule of Net Investment in Leases and Financed Sale Receivables on Nonaccrual Status	The following table provides information about the Company’s net investment in leases and financed sale receivables that are on nonaccrual status as at June 30, 2020 and December 31, 2019: As at June 30, 2020 As at December 31, 2019 Recorded Receivable Allowance for Credit Losses Net Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 708 $ (10 ) $ 698 $ — $ — $ — Net financed sales receivables 2,839 (1,032 ) 1,807 788 (732 ) 56 Total $ 3,547 $ (1,042 ) $ 2,505 $ 788 $ (732 ) $ 56
Summary of Allowance for Credit Losses Related to Net Investment in Leases and Financed Sale Receivables	The following table summarizes the activity in the allowance for credit losses related to the Company’s net investment in leases and financed sale receivables for the three and six months ended June 30, 2020 and 2019: Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Net Investment Financed Net Investment Financed in Leases Sales Receivables in Leases Sales Receivables Beginning balance $ 464 $ 3,557 $ 155 $ 915 Current period provision (5 ) 171 304 2,813 Write-offs — — — — Recoveries — — — — Foreign exchange — (19 ) — (19 ) Ending balance $ 459 $ 3,709 $ 459 $ 3,709 Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 Net Investment Net Financed Net Investment Net Financed in Leases Sales Receivables in Leases Sales Receivables Beginning balance $ 155 $ 839 $ 155 $ 839 Charge-offs — — — — Recoveries — — — — Provision — — — — Ending balance $ 155 $ 839 $ 155 $ 839
Summary of Allowance For Credit Losses Related to Variable Consideration Receivables	The following table summarizes the activity in the allowance for credit losses related to variable consideration receivables for the three and six months ended June 30, 2020 : Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Theater Operators Theater Operators Beginning balance $ 875 $ — Current period provision (12 ) 863 Write-offs — — Recoveries — — Ending balance $ 863 $ 863

Lease Arrangements (Tables)

Lease Arrangements (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Components of Lease Expense	For three and six months ended June 30, 2020 and 2019, the components of lease expense recorded within Selling, General and Administrative expenses are as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Operating lease cost (1) $ 121 $ 220 $ 259 $ 463 Amortization of lease assets 701 664 1,449 1,195 Interest on lease liabilities 245 274 507 542 Total lease cost $ 1,067 $ 1,158 $ 2,215 $ 2,200 (1) Includes short-term leases and variable lease costs, which are not significant for the three and six months ended June 30, 2020 and 2019.
Supplemental Cash Flow Information Related to Leases	For three and six months ended June 30, 2020 and 2019, supplemental cash flow information related to leases is as follows: Six Months Ended June 30, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities $ 1,730 $ 1,782 Right-of-use assets obtained in exchange for lease obligations 286 17,515 $ 2,016 $ 19,297
Lessee Operating Lease Balance Sheet Amounts and Lines	As at June 30, 2020 and December 31, 2019, supplemental balance sheet information related to leases is as follows: June 30, December 31, 2020 2019 Assets Right-of-Use Assets Property, plant and equipment $ 15,074 $ 16,262 Liabilities Operating Leases Accrued and other liabilities $ 17,791 $ 18,677
Lessee Operating Leases Weighted Average Remaining Lease Term and Weighted Average Interest Rate	As at June 30, 2020 and December 31, 2019, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s operating leases are as follows: June 30, December 31, 2020 2019 Weighted-average remaining lease term (years) 7.8 8.1 Weighted-average discount rate 5.90 % 5.90 %
Lessee Operating Lease, Maturity	As at June 30, 2020, the maturities of the Company’s operating lease liabilities are as follows: Operating Leases 2020 (six months remaining) $ 1,803 2021 3,318 2022 2,811 2023 2,247 2024 2,198 Thereafter 10,177 Total lease payments $ 22,554 Less: interest expense (4,763 ) Present value of operating lease liabilities $ 17,791

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Inventories	As at June 30, 2020 and December 31, 2019, inventories consist of the following: June 30, December 31, 2020 2019 Raw materials $ 34,139 $ 26,538 Work-in-process 5,839 4,608 Finished goods 20,201 11,843 $ 60,179 $ 42,989

Credit Facility and Other Fin_2

Credit Facility and Other Financing Arrangements (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Bank Indebtedness	As at June 30, 2020 and December 31, 2019, bank indebtedness includes the following: June 30, December 31, 2020 2019 Credit Facility $ 300,000 $ 20,000 Working Capital Facility 244 — Unamortized debt issuance costs (2,479 ) (1,771 ) $ 297,765 $ 18,229

Condensed Consolidated Statem_7

Condensed Consolidated Statements of Cash Flows Supplemental Information (Tables)	6 Months Ended
	Jun. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Summary of Changes in Other Operating Assets and Liabilities	Six Months Ended June 30, 2020 2019 Decrease (increase) in: Financing receivables $ 776 6,029 Prepaid expenses (2,332 ) (1,188 ) Variable consideration receivable (220 ) (362 ) Other assets (4,492 ) (2,189 ) Increase (decrease) in: Accounts payable (6,716 ) (9,817 ) Accrued and other liabilities 764 (4,910 ) $ (12,220 ) $ (12,437 )
Summary of Depreciation and Amortization	Six Months Ended June 30, 2020 2019 Film assets $ 3,515 $ 8,492 Property, plant and equipment: Joint revenue sharing arrangements 13,178 11,295 Other property, plant and equipment 5,686 5,992 Other intangible assets 3,238 2,952 Other assets 1,266 829 Deferred financing costs 299 244 $ 27,182 $ 29,804
Write-downs	Six Months Ended June 30, 2020 2019 Film assets (1) $ 4,504 $ — Other assets (2) 1,151 — Joint revenue sharing arrangements (3) 929 404 Property, plant and equipment 58 81 Inventories 72 2 Other intangible assets 92 21 $ 6,806 $ 508 (1) In the six months ended June 30, 2020, the Company recorded an impairment loss of $4.5 million (2019 — $nil) to write-down the carrying value of certain documentary and alternative content film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments. As of , following the recording of these write-downs, the Company’s film assets totaled $13.1 million, which principally consists of documentary and DMR content. The recoverability of these assets assumes the return to historical levels of box office results as theaters reopen following the lifting of COVID-19 restrictions. (2) In the six months ended June 30, 2020, the Company recorded a $1.2 million (2019 - $ nil (3) In the six months ended June 30, 2020, the Company recorded charges of $0.9 million in Costs and Expenses Applicable to Technology Rentals principally related to the write-down of xenon-based digital systems which were upgraded by customers to laser-based digital systems and taken out of service. In the six months ended June 30, 2019, the Company recorded a charge of $0.1 million in Costs and Expenses Applicable to Technology Rentals and $0.1 million in Revenues -Technology Rentals upon the upgrade of xenon-based digital systems under joint revenue sharing arrangements to laser-based digital systems.
Significant Non-cash Investing Activities	Six Months Ended June 30, 2020 2019 Net (decrease) increase in accruals related to: Investment in joint revenue sharing arrangements $ (1,887 ) $ 3,651 Acquisition of other intangible assets (10 ) 13 Purchases of property, plant and equipment 158 (427 ) $ (1,739 ) $ 3,237

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Tax (Expense) Benefit Included in the Company's Other Comprehensive (Loss) Income	The income tax (expense) benefit included in the Company’s other comprehensive (loss) income are related to the following items: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Unrealized change in cash flow hedging instruments $ (354 ) $ (99 ) $ 395 $ (182 ) Realized change in cash flow hedging instruments upon settlement (88 ) (78 ) (182 ) (96 ) Unrecognized actuarial gain on defined benefit plan — — 40 — $ (442 ) $ (177 ) $ 253 $ (278 )

Capital Stock (Tables)

Capital Stock (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Stock compensation	Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Cost and expenses applicable to revenues $ — $ 447 $ 400 $ 821 Selling, general and administrative expenses 6,467 6,485 10,174 10,388 Research and development — 95 85 180 $ 6,467 $ 7,027 $ 10,659 $ 11,389
Stock-based compensation by plan type	The following table summarizes the Company’s share-based compensation expense by each award type: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Stock Options $ 503 $ 2,177 $ 1,016 $ 4,084 Restricted Share Units 4,534 4,132 7,436 6,242 Performance Stock Units 467 — 746 — IMAX China Stock Options 15 77 101 143 IMAX China Long Term Incentive Plan Restricted Share Units 909 641 1,313 920 IMAX China Long Term Incentive Plan Performance Stock Units 39 — 47 — $ 6,467 $ 7,027 $ 10,659 $ 11,389
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes the activity under the Company’s Stock Option Plan (“SOP”) and IMAX Amended and Restated Long Term Incentive Plan (“IMAX LTIP”) for the six months ended June 30: Number of Shares Weighted Average Exercise Price Per Share 2020 2019 2020 2019 Stock options outstanding, beginning of period 5,732,209 5,465,046 $ 26.82 $ 27.63 Granted — 1,016,882 — 20.66 Exercised — (85,746 ) — 20.15 Forfeited (23,633 ) (103,902 ) 22.35 23.70 Expired (772,665 ) (316,325 ) 27.03 26.08 Cancelled (18,483 ) (5,196 ) 27.97 32.80 Stock options outstanding, end of period 4,917,428 5,970,759 26.80 26.70 Stock options exercisable, end of period 4,313,890 4,104,443 27.32 28.35
Restricted Stock Units activity under the IMAX LTIP	The following table summarizes the activity in respect of RSUs issued under the IMAX LTIP for the six months ended June 30: Number of Awards Weighted Average Grant Date Fair Value Per Share 2020 2019 2020 2019 RSUs outstanding, beginning of period 1,065,347 1,033,871 $ 23.17 $ 25.70 Granted 1,047,369 618,181 15.36 22.40 Vested and settled (383,126 ) (302,232 ) 21.58 26.69 Forfeited (39,912 ) (124,527 ) 20.29 23.66 RSUs outstanding, end of period 1,689,678 1,225,293 18.76 23.99
Performance Stock Units Activity under the IMAX LTIP	The following table summarizes the activity in respect of PSUs issued under the IMAX LTIP for the six months ended June 30: Number of Awards Weighted Average Grant Date Fair Value Per Share 2020 2019 2020 2019 Granted 369,260 — $ 15.67 $ — Forfeited (2,526 ) — 14.84 — PSUs outstanding, end of period 366,734 — 15.68 —
Basic and diluted per-share computations	The following table reconciles the denominator of the basic and diluted weighted average share computations: Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Weighted average number of common shares (000's): Issued and outstanding, beginning of period 58,787 61,291 61,176 61,434 Weighted average number of shares repurchased, net of shares issued during the period 21 40 (1,563 ) (80 ) Weighted average number of shares used in computing basic income per share 58,808 61,331 59,613 61,354 Assumed exercise of stock options, RSUs and PSUs, net of shares assumed repurchased, if dilutive — 176 — 171 Weighted average number of shares used in computing diluted income per share 58,808 61,507 59,613 61,525

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Disaggregation of Revenue by Segment	The following tables summarize the Company’s revenues by type and reportable segment for the three and six months ended June 30, 2020: Three Months Ended June 30, 2020 Revenue from Contracts with Customers Revenue from Fixed Consideration Variable Consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems $ 1,278 $ 765 $ — $ — $ 2,043 Joint Revenue Sharing Arrangements, fixed fees — — 369 — 369 Other Theater Business (1) (309 ) — — — (309 ) Other sales (2) 505 79 — — 584 Sub-total 1,474 844 369 — 2,687 Image enhancement and maintenance services IMAX DMR — 546 — — 546 IMAX Maintenance — — — — — Film Post-Production 738 — — — 738 Film Distribution 2,250 194 — — 2,444 Other — 71 — — 71 Sub-total 2,988 811 — — 3,799 Technology rentals Joint Revenue Sharing Arrangements, contingent rent (3) — — (137 ) — (137 ) Sub-total — — (137 ) — (137 ) Finance income IMAX Systems — — — 2,506 2,506 Total $ 4,462 $ 1,655 $ 232 $ 2,506 $ 8,855 Six Months Ended June 30, 2020 Revenue from Contracts with Customers Revenue from Fixed consideration Variable consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems $ 3,521 $ 1,662 $ — $ — $ 5,183 Joint Revenue Sharing Arrangements, fixed fees — — 1,139 — 1,139 Other Theater Business 954 — — — 954 Other sales (2) 983 90 — — 1,073 Sub-total 5,458 1,752 1,139 — 8,349 Image enhancement and maintenance services IMAX DMR — 11,175 — — 11,175 IMAX Maintenance 7,370 — — — 7,370 Film Post-Production 2,349 — — — 2,349 Film Distribution 2,250 1,077 — — 3,327 Other — 299 — — 299 Sub-total 11,969 12,551 — — 24,520 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 5,834 — 5,834 Sub-total — — 5,834 — 5,834 Finance income IMAX Systems — — — 5,054 5,054 Total $ 17,427 $ 14,303 $ 6,973 $ 5,054 $ 43,757 (1) The Company is reporting negative revenue due to an adjustment to prior period revenue. (2) Other sales include New Business Initiatives. (3) The Company is reporting negative revenue due to the continued amortization of lessee incentives that are typically netted against lease revenues, which are abnormally low during the period due to the COVID-19 global pandemic, as discussed in Note 2. The following tables summarize the Company’s revenues by type and reportable segment for the three and six months ended June 30, 2019 : Three Months Ended June 30, 2019 Revenue from Contracts with Customers Revenue from Fixed Consideration Variable Consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems $ 13,074 $ 849 $ — $ — $ 13,923 Joint Revenue Sharing Arrangements, fixed fees — — 2,548 — 2,548 Other Theater Business 2,580 — — — 2,580 Other sales (1) 500 143 — — 643 Sub-total 16,154 992 2,548 — 19,694 Image enhancement and maintenance services IMAX DMR — 39,293 — — 39,293 IMAX Maintenance 13,207 — — — 13,207 Film Post-production 2,326 — — — 2,326 Film Distribution — 1,275 — — 1,275 Other (1) 561 — — 561 Sub-total 15,533 41,129 — — 56,662 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 25,540 — 25,540 Other (1) — 2 321 — 323 Sub-total — 2 25,861 — 25,863 Finance income IMAX Systems — — — 2,578 2,578 Total $ 31,687 $ 42,123 $ 28,409 $ 2,578 $ 104,797 Six Months Ended June 30, 2019 Revenue from Contracts with Customers Revenue from Fixed consideration Variable consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems $ 21,238 $ 3,030 $ — $ — $ 24,268 Joint Revenue Sharing Arrangements, fixed fees — — 5,087 — 5,087 Other Theater Business 4,206 — — — 4,206 Other sales (1) 1,188 145 — — 1,333 Sub-total 26,632 3,175 5,087 — 34,894 Image enhancement and maintenance services IMAX DMR — 67,243 — — 67,243 IMAX Maintenance 26,158 — — — 26,158 Film Post-production 4,273 — — — 4,273 Film Distribution — 1,990 — — 1,990 Other (1) 1,145 — — 1,145 Sub-total 30,431 70,378 — — 100,809 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 43,584 — 43,584 Other (1) — 26 423 — 449 Sub-total — 26 44,007 — 44,033 Finance income IMAX Systems — — — 5,259 5,259 Total $ 57,063 $ 73,579 $ 49,094 $ 5,259 $ 184,995 (1) Other sales include New Business Initiatives.

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Breakdown of Revenue and (Margin Loss) Gross Margin by Category	The following table sets forth the breakdown of revenue and (margin loss) gross margin by category for the three months ended June 30, 2020: Revenue (Margin Loss) Gross Margin (3) 2020 2019 2020 2019 IMAX Technology Network IMAX DMR $ 546 $ 39,293 $ (30 ) $ 23,961 Joint revenue sharing arrangements, contingent rent (4) (137 ) 25,540 (6,501 ) 19,318 409 64,833 (6,531 ) 43,279 IMAX Technology Sales and Maintenance IMAX Systems (1) 4,549 16,501 2,650 8,019 Joint revenue sharing arrangements, fixed fees 369 2,548 48 870 IMAX Maintenance — 13,207 (1,908 ) 5,640 Other Theater Business (2)(5) (309 ) 2,580 (564 ) 841 4,609 34,836 226 15,370 New Business Initiatives 632 478 512 281 Film Distribution and Post-production Film Distribution 2,444 1,275 (1,541 ) 377 Post-production 738 2,326 145 81 3,182 3,601 (1,396 ) 458 8,832 103,748 (7,189 ) 59,388 Other 23 1,049 (499 ) 165 Total $ 8,855 $ 104,797 $ (7,688 ) $ 59,553 The following table sets forth the breakdown of revenue and (margin loss) gross margin by category for six months ended June 30, 2020: Revenue (Margin Loss) Gross Margin (3) 2020 2019 2020 2019 IMAX Technology Network IMAX DMR $ 11,175 $ 67,243 $ 4,413 $ 43,736 Joint revenue sharing arrangements, contingent rent 5,834 43,584 (8,119 ) 31,253 17,009 110,827 (3,706 ) 74,989 IMAX Technology Sales and Maintenance IMAX Systems (1) 10,237 29,527 5,826 15,071 Joint revenue sharing arrangements, fixed fees 1,139 5,087 227 1,165 IMAX Maintenance 7,370 26,158 (1,149 ) 10,921 Other Theater Business (2) 954 4,206 46 1,316 19,700 64,978 4,950 28,473 New Business Initiatives 1,110 1,312 873 900 Film Distribution and Post-production Film Distribution 3,327 1,990 (3,699 ) (333 ) Post-production 2,349 4,273 368 766 5,676 6,263 (3,331 ) 433 Sub-total 43,495 183,380 (1,214 ) 104,795 Other 262 1,615 (1,388 ) (102 ) Total $ 43,757 $ 184,995 $ (2,602 ) $ 104,693 (1) Includes initial upfront payments and the present value of fixed minimum payments from sales and sales-type lease arrangements of IMAX Theater Systems, and the present value of estimated variable consideration from sales of IMAX Theater Systems. To a lesser extent, also includes finance income associated with these revenue streams. ( 2 ) Principally includes after-market sales of IMAX projection system parts and 3D glasses ( 3 ) IMAX DMR gross margin includes marketing cost of $nil and $2.4 million for the three and six months ended June 30, 2020, respectively (2019 — $9.5 million and $13.4 million, respectively). JRSA gross margin includes advertising, marketing and commission expense of less than $0.1 million and $0.6 million for the three and six months ended June 30, 2020, respectively (2019 —$0.2 million and $0.3 million, respectively). IMAX Systems gross margin includes marketing and commission costs of $0.2 million and $0.4 million for the three and six months ended June 30, 2020, respectively, (2019 — $0.4 million and $0.9 million, respectively). Film Distribution segment gross margin includes marketing expense of less than $0.1 million and $0.2 million for the three and six months ended June 30, 2020, respectively (2019 — less than $0.1 million and $0.6 million, respectively). (4) The Company is reporting negative revenue due to the continued amortization of lessee incentives that are typically netted against lease revenues, which are abnormally low during the period due to the COVID-19 global pandemic, as discussed in Note 2. (5) The Company is reporting negative revenue due to an adjustment to prior period revenue.
Geographic Information	Revenue by geographic area is based on the location of the customer. Revenue related to IMAX DMR is presented based upon the geographic location of the theaters that exhibit the remastered films. IMAX DMR revenue is generated through contractual relationships with studios and other third parties and these may not be in the same geographical location as the theater. Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Revenue United States $ 3,812 $ 35,944 $ 16,777 $ 60,237 Asia (excluding Greater China) 1,868 9,963 7,728 18,753 Greater China 1,393 32,575 6,662 59,256 Russia & the CIS 658 5,619 2,224 7,307 Western Europe 631 11,933 5,188 20,376 Latin America 108 2,160 1,635 4,813 Canada 12 2,620 943 4,492 Rest of the World 373 3,983 2,600 9,761 Total $ 8,855 $ 104,797 $ 43,757 $ 184,995

Employees Pension and Postret_2

Employees Pension and Postretirement Benefits (Tables)	6 Months Ended
	Jun. 30, 2020
SERP Benefits [Member]
Defined Benefit Plan Disclosure [Line Items]
Amounts Accrued	As at June 30, 2020 and December 31, 2019 , the Company’s projected benefit obligation and unfunded status related to the SERP are as follows : June 30, December 31, 2020 2019 Projected benefit obligation: Obligation, beginning of period $ 18,840 $ 17,977 Prior Service cost — 456 Interest cost 189 564 Actuarial gain — (157 ) Obligation, end of period and unfunded status $ 19,029 $ 18,840

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2020
Derivative Instruments Gain Loss [Line Items]
Fair Value of Financial Instruments	The carrying values of the Company’s cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities due within one year approximate fair values due to the short-term maturity of these instruments. The Company’s other financial instruments are comprised of the following: As at June 30, 2020 As at December 31, 2019 Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Level 1 Cash and cash equivalents (1) $ 318,986 $ 318,986 $ 109,484 $ 109,484 Equity securities (3) 13,192 13,192 15,685 15,685 Level 2 Net financed sales receivables (2) $ 108,081 $ 108,430 $ 112,432 $ 111,441 Net investment in sales-type leases (2) 15,784 15,516 15,606 15,309 Convertible loan receivable (2) — — 1,500 1,500 Equity securities (1) 1,000 1,000 1,000 1,000 Foreign exchange contracts — (3) (318 ) (318 ) 530 530 Foreign exchange contracts — (3) 27 27 — — Bank indebtedness - under the Working Capital Facility (1) (244 ) (244 ) — — Bank indebtedness - under the Credit Facility (1) (300,000 ) (300,000 ) (20,000 ) (20,000 ) (1) Recorded at cost, which approximates fair value. (2) Estimated based on discounting future cash flows at currently available interest rates with comparable terms. (3) Value determined using quoted prices in active markets.
Notional Amount of Derivative	The following tabular disclosures reflect the impact that derivative instruments and hedging activities have on the Company’s Condensed Consolidated Financial Statements: Notional value of foreign exchange contracts: June 30, December 31, 2020 2019 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards $ 32,437 36,052 Derivatives not designated as hedging instruments: Foreign exchange contracts — Forwards 3,584 — $ 36,021 $ 36,052
Fair Value of Foreign Exchange Contracts	Fair value of derivatives in foreign exchange contracts: June 30, December 31, Balance Sheet Location 2020 2019 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards Other assets $ 245 $ 602 Accrued and other liabilities (563 ) (72 ) Derivatives not designated as hedging instruments: Foreign exchange contracts — Forwards Other assets 57 — Accrued and other liabilities (30 ) — $ (291 ) $ 530
Derivatives in Foreign Currency Hedging Relationships	Derivatives in Foreign Currency Hedging relationships are as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Foreign exchange contracts Derivative Gain (Loss) — Forwards Recognized in OCI (Effective Portion) $ 1,334 $ 297 $ (1,526 ) $ 365 Location of Derivative Loss Reclassified from AOCI Three Months Ended June 30, Six months ended June 30, (Effective Portion) 2020 2019 2020 2019 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ (328 ) $ (355 ) $ (669 ) (661 ) Property, plant and equipment — (19 ) — (32 ) Inventory (9 ) — $ (26 ) — $ (337 ) $ (374 ) $ (695 ) $ (693 ) Three Months Ended June 30, Six months ended June 30, 2020 2019 2020 2019 Foreign exchange contracts Derivative Gain (Loss) Recognized In — Forwards and Out of OCI $ — $ 2 $ (88 ) $ 2
Not Designated as Hedging Instrument [Member]
Derivative Instruments Gain Loss [Line Items]
Derivatives in Foreign Currency Hedging Relationships	Non Designated Derivatives in Foreign Currency relationships are as follows: Three Months Ended June 30, Six months ended June 30, Location of Derivative Gain 2020 2019 2020 2019 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ 27 $ — $ 27 — $ 27 $ — $ 27 $ —

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	6 Months Ended
	Jun. 30, 2020
Other Noncontrolling Interest [Member]
Non-controlling Interests
Summary of Movement of the Non-controlling Interest in Temporary Equity in Company's Subsidiary	The following table summarizes the movement of the non-controlling interest in temporary equity, in the Company’s subsidiary for the six months ended June 30, 2020: Balance as at December 31, 2019 $ 5,908 Net loss (1,671 ) Balance as at June 30, 2020 $ 4,237

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Details)	6 Months Ended
	Jun. 30, 2020Entity
Variable Interest Entity [Line Items]
Number of variable interest entities	10
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Number of variable interest entities primary beneficiary	5
Variable Interest Entity, Not Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Number of variable interest entities not a primary beneficiary	5

Basis of Presentation - VIEs To

Basis of Presentation - VIEs Total Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Variable Interest Entity [Line Items]
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	$ 1,061,465	$ 889,069
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	543,136	245,974
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	7,010	9,677
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	$ 15,494	$ 15,528

Impact of COVID-19 Pandemic - A

Impact of COVID-19 Pandemic - Additional Information (Details)	Jul. 28, 2020Country	Jul. 31, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Jun. 30, 2020USD ($)Theater	Dec. 31, 2019USD ($)
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Goodwill			$ 39,027,000		$ 39,027,000	$ 39,027,000
IMAX Systems Reporting Unit [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Goodwill			19,000,000		19,000,000
Joint Revenue Sharing Arrangements Reporting Unit [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Goodwill			13,600,000		13,600,000
IMAX Maintenance Reporting Unit [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Goodwill			6,400,000		6,400,000
Credit Facility [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Amount drew down in available borrowing capacity					280,000,000
Impact of COVID-19 Pandemic [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Goodwill impairment					0
Asset impairment					$ 0
Impact of COVID-19 Pandemic [Member] | Credit Facility [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Amount drew down in available borrowing capacity				$ 280,000,000
Impact of COVID-19 Pandemic [Member] | Selling, General and Administrative Expenses [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Proceeds from government subsidies			2,900,000
Impact of COVID-19 Pandemic [Member] | Costs and Expenses Applicable to Revenues [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Proceeds from government subsidies			$ 300,000
Impact of COVID-19 Pandemic [Member] | China [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Number of temporarily closed movie theatres | Theater					70,000
Impact of COVID-19 Pandemic [Member] | Canada [Member] | Emergency Wage Subsidy Program [Member] | Forecast [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Proceeds from government subsidies		$ 2,200,000
Impact of COVID-19 Pandemic [Member] | United States [Member] | CARES Act [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Proceeds from government subsidies					$ 1,000,000
IMAX [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Number of countries in which theaters began to report gross box office | Country	40
IMAX [Member] | Impact of COVID-19 Pandemic [Member] | Subsequent Event [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Percentage of theaters begun to report gross box office ("GBO")	40.00%
IMAX [Member] | Impact of COVID-19 Pandemic [Member] | Greater China [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Number of temporarily closed movie theatres | Theater					700

Current Expected Credit Losse_2

Current Expected Credit Losses - Summary of Allowance For Credit Losses Related to Accounts Receivable (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	$ 11,528	$ 5,137
Current period provision	1,286	7,677
Foreign exchange	(204)	(204)
Ending balance	12,610	12,610
Theatre Operators [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	6,504	3,302
Current period provision	(107)	3,095
Foreign exchange	(80)	(80)
Ending balance	6,317	6,317
Studios [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	3,983	893
Current period provision	1,596	4,686
Foreign exchange	(124)	(124)
Ending balance	5,455	5,455
Other [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	1,041	942
Current period provision	(203)	(104)
Ending balance	$ 838	$ 838

Current Expected Credit Losse_3

Current Expected Credit Losses - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Current Expected Credit Losses [Line Items]
Provisions for current expected credit losses	$ 1,286		$ 7,677
Finance income related to net investment in leases with billed amounts past due	100	$ 100	200	$ 200
Finance income related to financed sale receivables with billed amounts past due	900	$ 2,100	3,000	$ 4,600
Theatre And Studio [Member]
Current Expected Credit Losses [Line Items]
Provisions for current expected credit losses	1,300		7,700
Theatre Operators [Member]
Current Expected Credit Losses [Line Items]
Provisions for current expected credit losses	(107)		3,095
Provision for current expected credit losses	200		3,100
Provision for current expected credit losses	$ (12)		$ 863

Current Expected Credit Losse_4

Current Expected Credit Losses - Schedule of Financing Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Net investment in leases
Gross minimum payments due under sales-type leases	$ 17,142	$ 16,766
Unearned finance income	(899)	(1,005)
Present value of minimum payments due under sales-type leases	16,243	15,761
Allowance for credit losses	(459)	(155)
Net investment in leases	15,784	15,606
Financed sales receivables
Gross minimum payments due under financed sales	142,380	146,660
Unearned finance income	(30,590)	(33,313)
Present value of minimum payments due under financed sales	111,790	113,347
Allowance for credit losses	(3,709)	(915)
Net financed sales receivables	108,081	112,432
Total financing receivables	123,865	128,038
Net financed sales receivables due within one year	31,061	27,595
Net financed sales receivables due after one year	77,020	84,837
Net financed sales receivables	$ 108,081	$ 112,432

Current Expected Credit Losse_5

Current Expected Credit Losses - Schedule of Weighted-average Remaining Lease Term and Weighted-average Interest Rate (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Weighted-average remaining lease term (in years)
Sales-type lease arrangements	7 years 10 months 24 days	8 years 1 month 6 days
Weighted-average interest rate
Sales-type lease arrangements	6.85%	6.68%
Financed sales receivables	9.02%	9.00%

Current Expected Credit Losse_6

Current Expected Credit Losses - Schedule of Net Investment In Leases by Credit Quality Indicator (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Current fiscal year	$ 924	$ 7,874
Net investment leases, By Origination Year, Before latest fiscal year	7,804	3,045
Net investment leases, By Origination Year, Two years before latest fiscal year	2,991	989
Net investment leases, By Origination Year, Three years before latest fiscal year	942
Net investment leases, By Origination Year, Prior	3,582	3,853
Net Investment in Lease, Total	16,243	15,761
In Good Standing [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Current fiscal year	924	7,874
Net investment leases, By Origination Year, Before latest fiscal year	7,804	3,045
Net investment leases, By Origination Year, Two years before latest fiscal year	2,991	989
Net investment leases, By Origination Year, Three years before latest fiscal year	942
Net investment leases, By Origination Year, Prior	2,786	3,186
Net Investment in Lease, Total	15,447	15,094
Credit Watch [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Prior	88	667
Net Investment in Lease, Total	88	$ 667
Transactions Suspended [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Prior	708
Net Investment in Lease, Total	$ 708

Current Expected Credit Losse_7

Current Expected Credit Losses - Schedule of Financed Sale Receivables by Credit Quality Indicator (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Current fiscal year	$ 1,606	$ 11,981
Financed sales receivables, By Origination Year, Before lastest fiscal year	11,805	14,414
Financed sales receivables, By Origination Year, Two year before latest fiscal year	14,382	17,443
Financed sales receivables, By Origination Year, Three year before latest fiscal year	16,277	17,355
Financed sales receivables, By Origination Year, Four year before latest fiscal year	17,321
Financed sales receivables, By Origination Year, Prior	50,399	52,154
Financed sales receivables, Total	111,790	113,347
In Good Standing [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Current fiscal year	1,606	11,981
Financed sales receivables, By Origination Year, Before lastest fiscal year	11,474	14,414
Financed sales receivables, By Origination Year, Two year before latest fiscal year	14,382	16,556
Financed sales receivables, By Origination Year, Three year before latest fiscal year	15,381	15,208
Financed sales receivables, By Origination Year, Four year before latest fiscal year	15,495
Financed sales receivables, By Origination Year, Prior	47,551	44,291
Financed sales receivables, Total	105,889	102,450
Credit Watch [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Before lastest fiscal year	331
Financed sales receivables, By Origination Year, Two year before latest fiscal year		637
Financed sales receivables, By Origination Year, Three year before latest fiscal year		1,687
Financed sales receivables, By Origination Year, Four year before latest fiscal year	304
Financed sales receivables, By Origination Year, Prior	1,171	6,955
Financed sales receivables, Total	1,806	9,279
Pre-Approved Transactions [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Two year before latest fiscal year		250
Financed sales receivables, By Origination Year, Three year before latest fiscal year		295
Financed sales receivables, By Origination Year, Four year before latest fiscal year	585
Financed sales receivables, By Origination Year, Prior	671	285
Financed sales receivables, Total	1,256	830
Transactions Suspended [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Three year before latest fiscal year	896	165
Financed sales receivables, By Origination Year, Four year before latest fiscal year	937
Financed sales receivables, By Origination Year, Prior	1,006	623
Financed sales receivables, Total	$ 2,839	$ 788

Current Expected Credit Losse_8

Current Expected Credit Losses - Schedule of Aging Analysis for Net Investment in Leases and Financed Sale Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	$ 14,803		$ 10,245
Unbilled	113,230		118,863
Recorded Receivable	128,033		129,108
Allowance for Credit Losses	(4,168)		(1,070)
Total financing receivables	123,865		128,038
Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	1,008		349
Unbilled	15,235		15,412
Recorded Receivable	16,243		15,761
Allowance for Credit Losses	(459)	$ (464)	(155)	$ (155)	$ (155)	$ (155)
Total financing receivables	15,784		15,606
Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	13,795		9,896
Unbilled	97,995		103,451
Recorded Receivable	111,790		113,347
Allowance for Credit Losses	(3,709)	$ (3,557)	(915)	$ (839)	$ (839)	$ (839)
Total financing receivables	108,081		112,432
Accrued and Current [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	699		1,708
Accrued and Current [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	11		30
Accrued and Current [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	688		1,678
30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	3,203		2,840
30 to 89 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	262		68
30 to 89 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	2,941		2,772
Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	10,901		5,697
Equal To Greater Than 90 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	735		251
Equal To Greater Than 90 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	$ 10,166		$ 5,446

Current Expected Credit Losse_9

Current Expected Credit Losses - Schedule of Net Investment in Leases and Financed Sale Receivables with Billed Amounts Past Due Continues to Accrue Finance Income (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	$ 14,803		$ 10,245
Unbilled	113,230		118,863
Allowance for Credit Losses	(4,168)		(1,070)
Total financing receivables	123,865		128,038
Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,008		349
Unbilled	15,235		15,412
Allowance for Credit Losses	(459)	$ (464)	(155)	$ (155)	$ (155)	$ (155)
Total financing receivables	15,784		15,606
Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	13,795		9,896
Unbilled	97,995		103,451
Allowance for Credit Losses	(3,709)	$ (3,557)	(915)	$ (839)	$ (839)	$ (839)
Total financing receivables	108,081		112,432
Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	699		1,708
Accrued and Current [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	11		30
Accrued and Current [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	688		1,678
30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	3,203		2,840
30 to 89 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	262		68
30 to 89 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	2,941		2,772
Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	10,901		5,697
Equal To Greater Than 90 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	735		251
Equal To Greater Than 90 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	10,166		5,446
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	14,612		8,238
Unbilled	76,992		29,751
Allowance for Credit Losses	(2,691)
Total financing receivables	88,913		37,989
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	993		279
Unbilled	12,338		578
Allowance for Credit Losses	(264)
Total financing receivables	13,067		857
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	13,619		7,959
Unbilled	64,654		29,173
Allowance for Credit Losses	(2,427)
Total financing receivables	75,846		37,132
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	579		1,155
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Accrued and Current [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	9		9
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Accrued and Current [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	570		1,146
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | 30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	3,117		1,309
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | 30 to 89 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	255		19
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | 30 to 89 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	2,862		1,290
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	10,916		5,774
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Equal To Greater Than 90 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	729		251
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Equal To Greater Than 90 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	$ 10,187		$ 5,523

Current Expected Credit Loss_10

Current Expected Credit Losses - Schedule of Net Investment in Leases and Financed Sale Receivables on Nonaccrual Status (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	$ 3,547	$ 788
Allowance for Credit Losses	(1,042)	(732)
Net	2,505	56
Net Investment in Leases [Member]
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	708
Allowance for Credit Losses	(10)
Net	698
Net Financed Sales Receivables [Member]
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	2,839	788
Allowance for Credit Losses	(1,032)	(732)
Net	$ 1,807	$ 56

Current Expected Credit Loss_11

Current Expected Credit Losses - Summary of Allowance for Credit Losses Related to Net Investment in Leases and Financed Sale Receivables (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance		$ 1,070
Ending balance	$ 4,168	4,168
Net Investment in Leases [Member]
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance	464	155
Current period provision	(5)	304
Ending balance	459	459
Net Financed Sales Receivables [Member]
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance	3,557	915
Current period provision	171	2,813
Foreign exchange	(19)	(19)
Ending balance	$ 3,709	$ 3,709

Current Expected Credit Loss_12

Current Expected Credit Losses - Summary of Allowance For Credit Losses Related to Variable Consideration Receivables (Details) - Theatre Operators [Member] - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	$ 875
Current period provision	(12)	$ 863
Ending balance	$ 863	$ 863

Lease Arrangements - Additional

Lease Arrangements - Additional Information (Details)	6 Months Ended
	Jun. 30, 2020Lease
Leases [Line Items]
Lessee, operating lease description	The Company’s operating lease arrangements principally involve office and warehouse space. Office equipment is generally purchased outright. Leases with an initial term of less than 12 months are not recorded on the Condensed Consolidated Balance Sheets and the related lease expense is recognized on a straight-line basis over the lease term.
Lessee, operating lease, existence of option to extend term	true
Lessee, operating lease, existence of option to extend description	The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs and its level of investment in leasehold improvements, among other factors.
Lessee, operating lease, assumptions for discount rate	The incremental borrowing rate used in the calculation of the Company’s lease liability is based on the location of each leased property.
Leases include options to purchase leased property	0
Lessee, operating lease, existence of residual value	false
Lessee, operating lease, sublease options	The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed.
Lessor, sales-type lease description	The Company provides IMAX Theater Systems to customers through long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX Theater System, the Company earns fixed upfront and ongoing consideration. Certain arrangements that are legal sales are also classified as sales-type leases as certain clauses within the arrangements limit transfer of title or provide the Company with conditional rights to the system.
Sales-type lease, option to purchase asset description	the Company’s leases generally do not contain an automatic transfer of title at the end of the lease term
Minimum [Member]
Leases [Line Items]
Lessee, operating lease, renewal term	1 year
Sales-type lease, lease term	10 years
Non-cancellable term of joint revenue sharing arrangements	10 years
Maximum [Member]
Leases [Line Items]
Lessee, operating lease, renewal term	5 years
Sales-type lease, lease term	20 years
Non-cancellable term of joint revenue sharing arrangements	or longer

Lease Arrangements - Components

Lease Arrangements - Components of Lease Expense (Details) - Selling, General and Administrative Expenses [Member] - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2020		Jun. 30, 2019	Jun. 30, 2020		Jun. 30, 2019
Leases [Line Items]
Operating lease cost	$ 121	[1]	$ 220	$ 259	[1]	$ 463
Amortization of lease assets	701		664	1,449		1,195
Interest on lease liabilities	245		274	507		542
Total lease cost	$ 1,067		$ 1,158	$ 2,215		$ 2,200
[1]	Includes short-term leases and variable lease costs, which are not significant for the three and six months ended June 30, 2020 and 2019.

Lease Arrangements - Supplement

Lease Arrangements - Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 1,730	$ 1,782
Right-of-use assets obtained in exchange for lease obligations	286	17,515
Cash flow information related to leases	$ 2,016	$ 19,297

Lease Arrangements - Lessee Ope

Lease Arrangements - Lessee Operating Lease Balance Sheet Amounts and Lines (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Leases [Line Items]
Operating Leases	$ 17,791
Property, plant and equipment [Member]
Leases [Line Items]
Right-of-Use Assets	15,074	$ 16,262
Accrued and other liabilities [Member]
Leases [Line Items]
Operating Leases	$ 17,791	$ 18,677

Lease Arrangements - Lessee O_2

Lease Arrangements - Lessee Operating Leases Weighted Average Remaining Lease Term and Weighted Average Interest Rate (Details)	Jun. 30, 2020	Dec. 31, 2019
Lease Cost [Abstract]
Weighted-average remaining lease term (years)	7 years 9 months 18 days	8 years 1 month 6 days
Weighted-average discount rate	5.90%	5.90%

Lease Arrangements - Lessee O_3

Lease Arrangements - Lessee Operating Lease, Maturity (Details) $ in Thousands	Jun. 30, 2020USD ($)
Operating Lease Liabilities Payments Due [Abstract]
2020 (six months remaining)	$ 1,803
2021	3,318
2022	2,811
2023	2,247
2024	2,198
Thereafter	10,177
Total lease payments	22,554
Less: interest expense	(4,763)
Present value of operating lease liabilities	$ 17,791

Inventories - Inventories (Deta

Inventories - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Inventories
Raw materials	$ 34,139	$ 26,538
Work-in-process	5,839	4,608
Finished goods	20,201	11,843
Total	$ 60,179	$ 42,989

Inventories - Additional Inform

Inventories - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Inventories (Textuals) [Abstract]
Inventories increased		$ 17,200
Finished goods inventory with title passed to customer	$ 4,000	4,000		$ 700
Write-downs for excess and obsolete inventory	$ 100	$ 72	$ 2

Credit Facility and Other Fin_3

Credit Facility and Other Financing Arrangements - Bank Indebtedness (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Credit Facility	$ 300,000	$ 20,000
Working Capital Facility	244
Unamortized debt issuance costs	(2,479)	(1,771)
Total bank indebtedness	$ 297,765	$ 18,229

Credit Facility and Other Fin_4

Credit Facility and Other Financing Arrangements - Additional Information (Details)	Jun. 10, 2020	Jun. 30, 2020USD ($)	Jun. 30, 2019	Jun. 30, 2020USD ($)	Jun. 30, 2019	Jun. 30, 2020CNY (¥)	Dec. 31, 2019USD ($)	Dec. 31, 2019CNY (¥)	Oct. 28, 2019USD ($)	Jul. 24, 2019USD ($)	Jul. 24, 2019CNY (¥)
Credit Facility and Other Financing Arrangements (Textual) [Abstract]
Current borrowing capacity		$ 300,000,000		$ 300,000,000
Credit Facility Description				The Company has a credit agreement, the Fifth Amended and Restated Credit Agreement, with Wells Fargo Bank, National Association (“Wells Fargo”), as agent, and a syndicate of lenders party thereto (the “Credit Agreement”). The Company’s obligations under the Credit Agreement are guaranteed by certain of its subsidiaries (the “Guarantors”) and are secured by first-priority security interests in substantially all the assets of the Company and the Guarantors. The facility provided by the Credit Agreement (the “Credit Facility”) matures on June 28, 2023. The Credit Agreement has a revolving borrowing capacity of $300.0 million, and contains an uncommitted accordion feature allowing the Company to further expand its borrowing capacity to $440.0 million or greater, subject to certain conditions, depending on the mix of revolving and term loans comprising the incremental facility. In the first quarter of 2020, in response to uncertainties associated with the outbreak of the COVID-19 global pandemic and its impact on the Company’s business, the Company drew down the $280.0 million in available borrowing capacity under the Credit Facility, resulting in total outstanding borrowings of $300.0 million.
Credit Facility Maturity Date				Jun. 28, 2023
Line of credit facility covenant terms				The Credit Agreement contains a covenant that requires the Company to maintain a Senior Secured Net Leverage Ratio (as defined in the Credit Agreement), as at the last day of any Fiscal Quarter (as defined in the Credit Agreement) of no greater than 3.25:1.00.
Effective interest rate		1.83%	3.52%	1.86%	3.55%
Fees incurred with amendment				$ 959,000
Amounts Drawn		$ 244,000		$ 244,000
Working Capital Facility [Member]
Credit Facility and Other Financing Arrangements (Textual) [Abstract]
Current borrowing capacity										$ 30,000,000	¥ 200,000,000
Credit Facility Description				On July 24, 2019, IMAX (Shanghai) Multimedia Technology Co., Ltd. (“IMAX Shanghai”), one of the Company’s majority-owned subsidiaries in China, renewed its unsecured revolving facility for up to 200.0 million Renminbi (approximately $30.0 million) to fund ongoing working capital requirements (the “Working Capital Facility”).
Effective interest rate		4.35%		4.35%
Amounts Drawn		$ 200,000		$ 200,000		¥ 1,700,000	$ 0
Remaining borrowing capacity		29,800,000		29,800,000		¥ 198,300,000	29,800,000	¥ 198,300,000
Credit Facility [Member]
Credit Facility and Other Financing Arrangements (Textual) [Abstract]
Amount drew down in available borrowing capacity				$ 280,000,000
Line of credit facility covenant terms				On June 10, 2020, the Company entered into the First Amendment to the Credit Agreement (the “Amendment”), which, among other things, (i) suspends the Senior Secured Net Leverage Ratio covenant through the first quarter of 2021, (ii) re-establishes the Senior Secured Net Leverage Ratio covenant thereafter, provided that for subsequent quarters that such covenant is tested, as applicable, the Company will be permitted to use its quarterly EBITDA (as defined in the Credit Agreement) from the third and fourth quarters of 2019 in lieu of the EBITDA for the corresponding quarters of 2020, (iii) adds a $75.0 million minimum liquidity covenant measured at the end of each calendar month and (iv) restricts the Company’s ability to make certain restricted payments, dispositions and investments, create or assume liens and incur debt that would otherwise have been permitted by the Credit Agreement. The modifications to the negative covenants, the minimum liquidity covenant and modifications to certain other provisions in the Credit Agreement pursuant to the Amendment were effective from the date of the Amendment until the earlier of the delivery of the compliance certificate for the fourth quarter of 2021 and the date on which the Company, in its sole discretion, elects to calculate its compliance with the Senior Secured Net Leverage Ratio by using either its actual EBITDA or annualized EBITDA (the “Designated Period”).
Compliance with covenants				The Company was in compliance with all of its requirements under the Credit Agreement, as amended, as at June 30, 2020, and based on current projections expects to be in compliance through at least the next year.
Liquidity covenant minimum				$ 75,000,000
Interest rate description				Borrowings under the Credit Facility bear interest, at the Company’s option, at (i) LIBOR plus a margin ranging from 1.00% to 1.75% per annum; or (ii) the U.S. base rate plus a margin ranging from 0.25% to 1.00% per annum, in each case depending on the Company’s Total Leverage Ratio (as defined in the Credit Agreement); provided, however, that from the effective date of the Amendment until the Company delivers a compliance certificate under the Credit Facility following the end of the Designated Period, the applicable margin for LIBOR borrowings will be 2.50% per annum and the applicable margin for U.S. base rate borrowings will be 1.75% per annum. The effective interest rate for the three and six months ended June 30, 2020 was 1.83% and 1.86%, respectively (2019 — 3.52% and 3.55%, respectively).
Standby fees percentage	0.50%
Fees incurred with amendment				$ 1,000,000
Letters of credit or advance payment guarantees		0		0			0
Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Credit Facility and Other Financing Arrangements (Textual) [Abstract]
Interest rate margin percentage	2.50%
Credit Facility [Member] | Base Rate [Member]
Credit Facility and Other Financing Arrangements (Textual) [Abstract]
Interest rate margin percentage	1.75%
Wells Fargo Foreign Exchange Facility [Member]
Credit Facility and Other Financing Arrangements (Textual) [Abstract]
Settlement gain (loss) on its foreign currency forward contracts		(300,000)		(300,000)			500,000
Notional Amount of arrangements entered into		36,000,000		36,000,000			36,100,000
NBC Facility [Member]
Credit Facility and Other Financing Arrangements (Textual) [Abstract]
Current borrowing capacity									$ 5,000,000
Remaining borrowing capacity		0		0			$ 0
Minimum [Member]
Credit Facility and Other Financing Arrangements (Textual) [Abstract]
Borrowing capacity under uncommitted accordion feature		$ 440,000,000		$ 440,000,000
Minimum [Member] | Credit Facility [Member]
Credit Facility and Other Financing Arrangements (Textual) [Abstract]
Standby fees percentage				0.25%
Minimum [Member] | Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Credit Facility and Other Financing Arrangements (Textual) [Abstract]
Interest rate margin percentage				1.00%
Minimum [Member] | Credit Facility [Member] | Base Rate [Member]
Credit Facility and Other Financing Arrangements (Textual) [Abstract]
Interest rate margin percentage				0.25%
Maximum [Member] | Credit Facility [Member]
Credit Facility and Other Financing Arrangements (Textual) [Abstract]
Debt instrument net leverage ratio				3.25
Standby fees percentage				0.38%
Maximum [Member] | Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Credit Facility and Other Financing Arrangements (Textual) [Abstract]
Interest rate margin percentage				1.75%
Maximum [Member] | Credit Facility [Member] | Base Rate [Member]
Credit Facility and Other Financing Arrangements (Textual) [Abstract]
Interest rate margin percentage				1.00%

Commitments, Contingencies an_2

Commitments, Contingencies and Guarantees - Additional Information (Details) - USD ($)	6 Months Ended	25 Months Ended	51 Months Ended	95 Months Ended
	Jun. 30, 2020	Dec. 14, 2015	Mar. 27, 2008	Dec. 02, 2011	Dec. 31, 2019
Loss Contingencies [Line Items]
Final Award in favor of company			amount of $11.3 million, consisting of past and future rents owed to the Company, plus interest and costs, as well as an additional $2,512 each day in interest from October 1, 2007 until the date the award is paid	$30,000 to cover the costs of the application
Final Award amount issued			$ 11,300,000
Final Award additional interest			$ 2,512
Final Award settlement cost				$ 30,000
Damages sought		$ 10,400,000
Product Warranty Accrual					$ 200,000
Indemnification of its directors/officers	$ 0				$ 0
Other Indemnification	0
Minimum [Member]
Loss Contingencies [Line Items]
Counterclaim sought		$ 24,000,000
Maximum [Member]
Loss Contingencies [Line Items]
Product Warranty Accrual	$ 100,000

Condensed Consolidated Statem_8

Condensed Consolidated Statements of Operations Supplemental Information - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2020USD ($)TheaterexhibitorFilm	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)TheaterexhibitorFilm	Jun. 30, 2019USD ($)Film	Dec. 31, 2019USD ($)
Selling Expenses
Direct advertising and marketing costs included in costs and expenses applicable to revenues-technology rentals		$ 700,000	$ 400,000	$ 900,000
Film exploitation costs, including advertising and marketing included in costs and expenses applicable to revenues-image enhancement and maintenance services		9,600,000	2,600,000	14,100,000
Foreign Exchange
Foreign exchange translation loss	$ 300,000	200,000	$ 1,000,000	$ 400,000
Collaborative Arrangements
Total number of exhibitors under traditional and hybrid joint revenue sharing agreements | exhibitor	41		41
Total number of theater systems under traditional and hybrid joint revenue sharing agreements | Theater	1,237		1,237
Total number of operating theaters under traditional and hybrid joint revenue sharing agreement | Theater	868		868
Average percentage of the box-office receipts earned in exchange of converting commercial films	12.50%		12.50%
IMAX DMR films exhibited in the period | Film			14	39
Amounts attributable to transactions arising between the company and its customers under IMAX DMR arrangements	$ 600,000	39,300,000	$ 11,200,000	$ 67,200,000
Number of significant co-produced film arrangement | Film	2		2
Number of other co-produced film arrangements | Film	3		3
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	$ 1,061,465,000		$ 1,061,465,000		$ 889,069,000
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	543,136,000		543,136,000		245,974,000
Amounts attributable to transactions between the company and other parties involved in the production of films included in cost and expenses applicable to revenues-image enhancement and maintenance services	1,200,000	100,000	1,400,000	200,000
Co-produced television collaborative arrangement revenue	100,000		100,000
Variable Interest Entity, Primary Beneficiary [Member]
Collaborative Arrangements
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	7,010,000		7,010,000		9,677,000
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	15,494,000		15,494,000		$ 15,528,000
Retrospective adoption of ASC Topic 606, Revenue from Contracts with Customers [Member]
Collaborative Arrangements
Amounts attributable to transactions arising between the company and its customers under traditional and hybrid joint revenue sharing arrangements	100,000	27,800,000	$ 6,900,000	48,200,000
Maximum [Member]
Selling Expenses
Direct advertising and marketing costs included in costs and expenses applicable to revenues-technology rentals	100,000
Film exploitation costs, including advertising and marketing included in costs and expenses applicable to revenues-image enhancement and maintenance services	100,000
Collaborative Arrangements
Non-cancellable term of joint revenue sharing arrangements			or longer
Co-produced television collaborative arrangement revenue				100,000
Co-produced television collaborative arrangement costs and expenses				100,000
Minimum [Member]
Collaborative Arrangements
Non-cancellable term of joint revenue sharing arrangements			10 years
Technology Sales [Member]
Selling Expenses
Deferred direct selling costs and direct advertising and marketing included in costs and expenses applicable to revenues-technology sales	200,000	400,000	$ 400,000	900,000
Technology Rentals [Member]
Selling Expenses
Deferred direct selling costs and direct advertising and marketing included in costs and expenses applicable to revenues-technology sales		$ 400,000	$ 200,000	$ 600,000
Technology Rentals [Member] | Maximum [Member]
Selling Expenses
Deferred direct selling costs and direct advertising and marketing included in costs and expenses applicable to revenues-technology sales	$ 100,000

Condensed Consolidated Statem_9

Condensed Consolidated Statements of Cash Flows Supplemental Information - Summary of Changes in Other Operating Assets and Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Decrease (increase) in:
Financing receivables	$ 776	$ 6,029
Prepaid expenses	(2,332)	(1,188)
Variable consideration receivable	(220)	(362)
Other assets	(4,492)	(2,189)
Increase (decrease) in:
Accounts payable	(6,716)	(9,817)
Accrued and other liabilities	764	(4,910)
Changes in other operating assets and liabilities	$ (12,220)	$ (12,437)

Condensed Consolidated State_10

Condensed Consolidated Statements of Cash Flows Supplemental Information - Summary of Depreciation and Amortization (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Summary of Depreciation and amortization
Film assets	$ 3,515	$ 8,492
Property, plant and equipment:
Joint revenue sharing arrangements	13,178	11,295
Other property, plant and equipment	5,686	5,992
Other intangible assets	3,238	2,952
Other assets	1,266	829
Deferred financing costs	299	244
Depreciation and amortization	$ 27,182	$ 29,804

Condensed Consolidated State_11

Condensed Consolidated Statements of Cash Flows Supplemental Information - Write-downs (Details) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
		Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019
Write-downs
Film assets	[1]		$ 4,504	$ 0
Other assets	[2]		1,151	0
Joint revenue sharing arrangements	[3]		929	404
Property, plant and equipment			58	81
Inventories		$ 100	72	2
Other intangible assets			92	21
Write-downs			$ 6,806	$ 508
[1]	In the six months ended June 30, 2020, the Company recorded an impairment loss of $4.5 million (2019 — $nil) to write-down the carrying value of certain documentary and alternative content film assets due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments. As of , following the recording of these write-downs, the Company’s film assets totaled $13.1 million, which principally consists of documentary and DMR content. The recoverability of these assets assumes the return to historical levels of box office results as theaters reopen following the lifting of COVID-19 restrictions.
[2]	In the six months ended June 30, 2020, the Company recorded a $1.2 million (2019 - $ nil
[3]	In the six months ended June 30, 2020, the Company recorded charges of $0.9 million in Costs and Expenses Applicable to Technology Rentals principally related to the write-down of xenon-based digital systems which were upgraded by customers to laser-based digital systems and taken out of service. In the six months ended June 30, 2019, the Company recorded a charge of $0.1 million in Costs and Expenses Applicable to Technology Rentals and  $0.1 million in Revenues -Technology Rentals upon the upgrade of xenon-based digital systems under joint revenue sharing arrangements to laser-based digital systems.

Condensed Consolidated State_12

Condensed Consolidated Statements of Cash Flows Supplemental Information - Write-downs (Parenthetical) (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Supplemental Cash Flow Elements [Abstract]
Film assets write downs on impairment loss	$ 4,500,000
Film assets	13,100,000
Film assets additional write downs	0
Other assets write down on impairment	1,200,000
Write-down of content-related assets	1,000,000
Theater system components written off in Costs and expenses	$ 900,000	100,000
Theater system components written off in revenues		$ 100,000

Condensed Consolidated State_13

Condensed Consolidated Statements of Cash Flows Supplemental Information - Significant Non-cash Investing Activities - (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Net (decrease) increase in accruals related to:
Investment in joint revenue sharing arrangements	$ (1,887)	$ 3,651
Acquisition of other intangible assets	(10)	13
Purchases of property, plant and equipment	158	(427)
Net accruals	$ (1,739)	$ 3,237

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020	Dec. 31, 2019
Income Tax Contingency [Line Items]
Effective tax rate	25.40%		(6.30%)
Canadian statutory tax rate	26.20%		26.20%
Deferred income tax liabilities	$ 18,500		$ 18,500		$ 19,700
Cash held outside of Canada	75,000		75,000			$ 90,100
Reduction in foreign withholding taxes	1,200		1,200
Income tax expense (benefit)	(10,248)	$ 5,308	5,257	$ 8,956
Tax expense related to uncertain tax positions	300	$ 100	5,100	500
Reduce tax benefit to employee share compensation plans			700	$ 300
Deferred income tax asset after valuation allowance	46,800		46,800			23,900
Increase in deferred tax assets	8,900
Deferred tax asset, share-based compensation	1,400		1,400			1,400
Republic of China [Member]
Income Tax Contingency [Line Items]
Cash held/undistributed earnings intended to be permanently reinvested	$ 61,500		$ 61,500			$ 67,600

Income Taxes - Income Tax (Expe

Income Taxes - Income Tax (Expense) Benefit Included in the Company's Other Comprehensive (Loss) Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Unrealized change in cash flow hedging instruments	$ (354)	$ (99)	$ 395	$ (182)
Realized change in cash flow hedging instruments upon settlement	(88)	(78)	(182)	(96)
Unrecognized actuarial gain on defined benefit plan			40
Income tax effect on other comprehensive (loss) income	$ (442)	$ (177)	$ 253	$ (278)

Capital Stock - Additional Info

Capital Stock - Additional Information (Details)	3 Months Ended				6 Months Ended				12 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / shares	Jun. 30, 2019USD ($)$ / sharesshares	Jun. 30, 2019$ / shares	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / shares	Jun. 30, 2019USD ($)$ / sharesshares	Jun. 30, 2019$ / shares	Dec. 31, 2019USD ($)shares	Jun. 11, 2020shares	Jun. 06, 2019shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation costs recorded for the period	$ 6,500,000		$ 7,000,000		$ 10,700,000		$ 11,400,000
Stock-based compensation expense	$ 6,467,000		$ 7,027,000		$ 10,659,000		$ 11,389,000
Common shares purchased in open market by trustee in connection with RSUs | shares	0		0		200,000		400,000
Weighted average price of common shares purchased in open market by trustee in connection with RSUs | $ / shares					$ 15.43		$ 22.98
Number of treasury shares held in trust for future settlement of share based awards | shares					21,313				187,020
Value of treasury shares held in trust for future settlement of RSUs and stock options	$ 329,000	$ 329,000			$ 329,000	$ 329,000			$ 4,038,000
Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units | shares	6,973,840		6,153,795		6,973,840		6,226,887
IMAX China
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Details of the share repurchase program					In 2019, IMAX China announced that its shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase shares of IMAX China in an amount not to exceed 10% of the total number of issued shares as at June 6, 2019 (35,605,560 shares). The share repurchase program expired on the date of the 2020 Annual General Meeting of IMAX China on June 11, 2020. During the 2020 Annual General Meeting, shareholders approved the repurchase of shares of IMAX China not to exceed 10% of the total number of issued shares as of June 11, 2020 (34,848,398 shares). This program will be valid until the 2021 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time.
Stock Repurchase Program Expiration Date					Jun. 11, 2020
Repurchase of common shares | shares	425,800		6,315,900		906,400		7,025,700
Stock Acquired, Average Cost per Share | (per share)	$ 1.50	$ 11.63	$ 2.37	$ 18.59	$ 1.69	$ 13.13	$ 2.38	$ 18.68
Stock Repurchase Program, maximum percentage of shares to be repurchased										10.00%	10.00%
Stock Repurchase Program, Authorized number of shares | shares										34,848,398	35,605,560
Stock repurchase program expiration year					2021
Parent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Details of the share repurchase program					In 2017, the Company’s Board of Directors approved a new $200.0 million common stock share repurchase program, which would have expired on June 30, 2020. In June 2020, the Board of Directors approved a 12-month extension of this program which will now expire on June 30, 2021. The repurchases may be made either in the open market or through private transactions, subject to market conditions, applicable legal requirements and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time.
Stock Repurchase Program, Authorized Amount	$ 200,000,000	$ 200,000,000			$ 200,000,000	$ 200,000,000
Stock Repurchase Program Expiration Date					Jun. 30, 2021
Repurchase of common shares | shares	0		87,769		2,484,123		87,769
Stock Acquired, Average Cost per Share | $ / shares			$ 19.45		$ 14.72		$ 19.45
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 4,534,000		$ 4,132,000		$ 7,436,000		$ 6,242,000
Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units | shares	6,973,840		6,153,795		6,973,840		6,226,887
Restricted Share Units [Member] | Certain Advisor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 100,000				$ 100,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 503,000		$ 2,177,000		$ 1,016,000		$ 4,084,000
Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units | shares	6,973,840		6,153,795		6,973,840		6,226,887
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 467,000				$ 746,000
Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units | shares	6,973,840		6,153,795		6,973,840		6,226,887
Cost and Expenses Applicable to Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 0		$ 447,000		$ 400,000		$ 821,000
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 0		$ 95,000		$ 85,000		$ 180,000

Capital Stock - Stock Compensat

Capital Stock - Stock Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 6,467	$ 7,027	$ 10,659	$ 11,389
Cost and Expenses Applicable to Revenues [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	0	447	400	821
Selling, general and administrative expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	6,467	6,485	10,174	10,388
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 0	$ 95	$ 85	$ 180

Capital Stock - Stock-based Com

Capital Stock - Stock-based Compensation by Plan Type (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	$ 6,467	$ 7,027	$ 10,659	$ 11,389
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	503	2,177	1,016	4,084
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	4,534	4,132	7,436	6,242
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	467		746
IMAX China Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	15	77	101	143
IMAX China Long Term Incentive Plan Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	909	$ 641	1,313	$ 920
IMAX China Long Term Incentive Plan Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	$ 39		$ 47

Capital Stock - Schedule of Sha

Capital Stock - Schedule of Share-based Compensation, Stock Options, Activity (Details) - Employee Stock Option [Member] - $ / shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding, beginning of period	5,732,209	5,465,046
Granted		1,016,882
Exercised		(85,746)
Forfeited	(23,633)	(103,902)
Expired	(772,665)	(316,325)
Cancelled	(18,483)	(5,196)
Stock options outstanding, end of period	4,917,428	5,970,759
Stock options exercisable, end of period	4,313,890	4,104,443
Stock options outstanding, weighted average exercise price per share	$ 26.82	$ 27.63
Granted, weighted average exercise price per share		20.66
Exercised, weighted average exercise price per share		20.15
Forfeited, weighted average exercise price per share	22.35	23.70
Expired, weighted average exercise price per share	27.03	26.08
Cancelled, weighted average exercise price per share	27.97	32.80
Stock options outstanding, weighted average exercise price per share	26.80	26.70
Stock options exercisable, weighted average exercise price per share, end of period	$ 27.32	$ 28.35

Capital Stock - Restricted Stoc

Capital Stock - Restricted Stock Units Activity under the IMAX LTIP (Details) - Restricted Share Units [Member] - $ / shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs outstanding, beginning of period	1,065,347	1,033,871
Granted	1,047,369	618,181
Vested and settled	(383,126)	(302,232)
Forfeited	(39,912)	(124,527)
RSUs outstanding, end of period	1,689,678	1,225,293
RSUs outstanding, weighted average grant date fair value per share, beginning of period	$ 23.17	$ 25.70
Granted, weighted average grant date fair value per share	15.36	22.40
Vested and settled, weighted average grant date fair value per share	21.58	26.69
Forfeited, weighted average grant date fair value per share	20.29	23.66
RSUs outstanding, weighted average grant date fair value per share, end of period	$ 18.76	$ 23.99

Capital Stock - Performance Sto

Capital Stock - Performance Stock Units Activity under the IMAX LTIP (Details) - Performance Stock Units [Member]	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted | shares	369,260
Forfeited | shares	(2,526)
PSUs outstanding, end of period | shares	366,734
Granted, weighted average grant date fair value per share | $ / shares	$ 15.67
Forfeited, weighted average grant date fair value per share | $ / shares	14.84
PSUs outstanding, weighted average grant date fair value per share, end of period | $ / shares	$ 15.68

Capital Stock - Basic and Dilut

Capital Stock - Basic and Diluted Per-share Computations (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2018
Equity [Abstract]
Issued and outstanding, beginning of period	58,857,436		58,857,436		58,787,000	61,175,852	61,434,000	61,291,000
Weighted average number of shares repurchased, net of shares issued during the period	21,000	40,000	(1,563,000)	(80,000)
Weighted average number of shares used in computing basic income per share	58,808,000	61,331,000	59,613,000	61,354,000
Assumed exercise of stock options, RSUs and PSUs, net of shares assumed repurchased, if dilutive		176,000		171,000
Weighted average number of shares used in computing diluted income per share	58,808,000	61,507,000	59,613,000	61,525,000

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregation of Revenue by Segment (Details) - USD ($) $ in Thousands		3 Months Ended				6 Months Ended
		Jun. 30, 2020		Jun. 30, 2019		Jun. 30, 2020	Jun. 30, 2019
Revenue from Contracts with Customers [Line Items]
Revenues		$ 8,855		$ 104,797		$ 43,757	$ 184,995
Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		4,462		31,687		17,427	57,063
Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		1,655		42,123		14,303	73,579
Lease Arrangements [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		232		28,409		6,973	49,094
Finance Income [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		2,506		2,578		5,054	5,259
Technology Sales [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		2,687		19,694		8,349	34,894
Technology Sales [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		1,474		16,154		5,458	26,632
Technology Sales [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		844		992		1,752	3,175
Technology Sales [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		2,043		13,923		5,183	24,268
Technology Sales [Member] | IMAX Systems [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		1,278		13,074		3,521	21,238
Technology Sales [Member] | IMAX Systems [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		765		849		1,662	3,030
Technology Sales [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		369		2,548		1,139	5,087
Technology Sales [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Technology Sales [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Technology Sales [Member] | Other Theater Business [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		(309)	[1]	2,580		954	4,206
Technology Sales [Member] | Other Theater Business [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		(309)	[1]	2,580		954	4,206
Technology Sales [Member] | Other Theater Business [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	[1]	0		0	0
Technology Sales [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	584		643		1,073	1,333
Technology Sales [Member] | Other [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	505		500		983	1,188
Technology Sales [Member] | Other [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	79		143		90	145
Technology Sales [Member] | Lease Arrangements [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		369		2,548		1,139	5,087
Technology Sales [Member] | Lease Arrangements [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Technology Sales [Member] | Lease Arrangements [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		369		2,548		1,139	5,087
Technology Sales [Member] | Lease Arrangements [Member] | Other Theater Business [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	[1]	0		0	0
Technology Sales [Member] | Lease Arrangements [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	0		0		0	0
Technology Sales [Member] | Finance Income [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Technology Sales [Member] | Finance Income [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Technology Sales [Member] | Finance Income [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Technology Sales [Member] | Finance Income [Member] | Other Theater Business [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	[1]	0		0	0
Technology Sales [Member] | Finance Income [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	0		0		0	0
Image Enhancement And Maintenance Services [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		3,799		56,662		24,520	100,809
Image Enhancement And Maintenance Services [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		2,988		15,533		11,969	30,431
Image Enhancement And Maintenance Services [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		811		41,129		12,551	70,378
Image Enhancement And Maintenance Services [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		71		561	[2]	299	1,145	[2]
Image Enhancement And Maintenance Services [Member] | Other [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0	[2]	0	0	[2]
Image Enhancement And Maintenance Services [Member] | Other [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		71		561	[2]	299	1,145	[2]
Image Enhancement And Maintenance Services [Member] | IMAX DMR [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		546		39,293		11,175	67,243
Image Enhancement And Maintenance Services [Member] | IMAX DMR [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Image Enhancement And Maintenance Services [Member] | IMAX DMR [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		546		39,293		11,175	67,243
Image Enhancement And Maintenance Services [Member] | IMAX Maintenance Segment [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		13,207		7,370	26,158
Image Enhancement And Maintenance Services [Member] | IMAX Maintenance Segment [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		13,207		7,370	26,158
Image Enhancement And Maintenance Services [Member] | IMAX Maintenance Segment [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Image Enhancement And Maintenance Services [Member] | Film Post-Production [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		738		2,326		2,349	4,273
Image Enhancement And Maintenance Services [Member] | Film Post-Production [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		738		2,326		2,349	4,273
Image Enhancement And Maintenance Services [Member] | Film Post-Production [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Image Enhancement And Maintenance Services [Member] | Film Distribution [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		2,444		1,275		3,327	1,990
Image Enhancement And Maintenance Services [Member] | Film Distribution [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		2,250		0		2,250	0
Image Enhancement And Maintenance Services [Member] | Film Distribution [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		194		1,275		1,077	1,990
Image Enhancement And Maintenance Services [Member] | Lease Arrangements [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Image Enhancement And Maintenance Services [Member] | Lease Arrangements [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0	[2]	0	0	[2]
Image Enhancement And Maintenance Services [Member] | Lease Arrangements [Member] | IMAX DMR [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Image Enhancement And Maintenance Services [Member] | Lease Arrangements [Member] | IMAX Maintenance Segment [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Image Enhancement And Maintenance Services [Member] | Lease Arrangements [Member] | Film Post-Production [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Image Enhancement And Maintenance Services [Member] | Lease Arrangements [Member] | Film Distribution [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Image Enhancement And Maintenance Services [Member] | Finance Income [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Image Enhancement And Maintenance Services [Member] | Finance Income [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0	[2]	0	0	[2]
Image Enhancement And Maintenance Services [Member] | Finance Income [Member] | IMAX DMR [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Image Enhancement And Maintenance Services [Member] | Finance Income [Member] | IMAX Maintenance Segment [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Image Enhancement And Maintenance Services [Member] | Finance Income [Member] | Film Post-Production [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Image Enhancement And Maintenance Services [Member] | Finance Income [Member] | Film Distribution [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Technology Rentals [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		(137)	[3]	25,863		5,834	44,033
Technology Rentals [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	[3]	0		0	0
Technology Rentals [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	[3]	2		0	26
Technology Rentals [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]			323			449
Technology Rentals [Member] | Other [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]			0			0
Technology Rentals [Member] | Other [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]			2			26
Technology Rentals [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		(137)		25,540		5,834	43,584
Technology Rentals [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Technology Rentals [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Technology Rentals [Member] | Lease Arrangements [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		(137)	[3]	25,861		5,834	44,007
Technology Rentals [Member] | Lease Arrangements [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]			321			423
Technology Rentals [Member] | Lease Arrangements [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		(137)		25,540		5,834	43,584
Technology Rentals [Member] | Finance Income [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	[3]	0		0	0
Technology Rentals [Member] | Finance Income [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]			0			0
Technology Rentals [Member] | Finance Income [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Finance Income [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		2,506		2,578		5,054	5,259
Finance Income [Member] | IMAX Systems [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Finance Income [Member] | IMAX Systems [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Finance Income [Member] | Lease Arrangements [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0		0		0	0
Finance Income [Member] | Finance Income [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		$ 2,506		$ 2,578		$ 5,054	$ 5,259
[1]	The Company is reporting negative revenue due to an adjustment to prior period revenue.
[2]	Other sales include New Business Initiatives.
[3]	The Company is reporting negative revenue due to the continued amortization of lessee incentives that are typically netted against lease revenues, which are abnormally low during the period due to the COVID-19 global pandemic, as discussed in Note 2.

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Additional Information (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Revenue From Contract With Customer [Abstract]
Revenue Remaining Performance Obligation	$ 17.2	$ 17.7

Segment Reporting - Additional

Segment Reporting - Additional Information (Details)	6 Months Ended
	Jun. 30, 2020
Segment Reporting (Textual) [Abstract]
Description of products and services from which each reportable segment derives its revenues	The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements; (iii) IMAX Systems, (iv) IMAX Maintenance; (v) Other Theater Business; (vi) New Business Initiatives; (vii) Film Distribution; and (viii) Film Post-production.
Disclosure on geographic areas, description of revenue from external customers	No single country in the Rest of the World, Western Europe, Latin America and Asia (excluding Greater China) comprises more than 10% of the Company’s total revenue, except for Japan in the three months ended June 30, 2020

Segment Reporting - Breakdown o

Segment Reporting - Breakdown of Revenue and (Margin Loss) Gross Margin by Category (Details) - USD ($) $ in Thousands		3 Months Ended				6 Months Ended
		Jun. 30, 2020		Jun. 30, 2019		Jun. 30, 2020	Jun. 30, 2019
Revenues
Revenue		$ 8,855		$ 104,797		$ 43,757	$ 184,995
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1]	(7,688)		59,553		(2,602)	104,693
IMAX DMR [Member]
Revenues
Revenue		546		39,293		11,175	67,243
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1]	(30)		23,961		4,413	43,736
Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Revenues
Revenue		(137)	[2]	25,540	[2]	5,834	43,584
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1]	(6,501)	[2]	19,318	[2]	(8,119)	31,253
IMAX Technology Network [Member]
Revenues
Revenue		409		64,833		17,009	110,827
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1]	(6,531)		43,279		(3,706)	74,989
Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Revenues
Revenue		369		2,548		1,139	5,087
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1]	48		870		227	1,165
IMAX Systems [Member]
Revenues
Revenue	[3]	4,549		16,501		10,237	29,527
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1],[3]	2,650		8,019		5,826	15,071
IMAX Maintenance Segment [Member]
Revenues
Revenue				13,207		7,370	26,158
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1]	(1,908)		5,640		(1,149)	10,921
Other Theater Business [Member]
Revenues
Revenue	[4]	(309)	[5]	2,580	[5]	954	4,206
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1],[4]	(564)	[5]	841	[5]	46	1,316
IMAX Technology Sales and Maintenance [Member]
Revenues
Revenue		4,609		34,836		19,700	64,978
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1]	226		15,370		4,950	28,473
New Business Initiatives [Member]
Revenues
Revenue		632		478		1,110	1,312
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1]	512		281		873	900
Film Distribution [Member]
Revenues
Revenue		2,444		1,275		3,327	1,990
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1]	(1,541)		377		(3,699)	(333)
Post-production [Member]
Revenues
Revenue		738		2,326		2,349	4,273
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1]	145		81		368	766
Reportable Segments [Member]
Revenues
Revenue		3,182		3,601		5,676	6,263
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1]	(1,396)		458		(3,331)	433
Reportable Segments [Member]
Revenues
Revenue		8,832		103,748		43,495	183,380
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1]	(7,189)		59,388		(1,214)	104,795
Other [Member]
Revenues
Revenue		23		1,049		262	1,615
(Margin Loss) Gross Margin
(Margin Loss) Gross Margin	[1]	$ (499)		$ 165		$ (1,388)	$ (102)
[1]	IMAX DMR gross margin includes marketing cost of $nil and $2.4 million for the three and six months ended June 30, 2020, respectively (2019 — $9.5 million and $13.4 million, respectively). JRSA gross margin includes advertising, marketing and commission expense of less than $0.1 million and $0.6 million for the three and six months ended June 30, 2020, respectively (2019 —$0.2 million and $0.3 million, respectively). IMAX Systems gross margin includes marketing and commission costs of $0.2 million and $0.4 million for the three and six months ended June 30, 2020, respectively, (2019 — $0.4 million and $0.9 million, respectively). Film Distribution segment gross margin includes marketing expense of less than $0.1 million and $0.2 million for the three and six months ended June 30, 2020, respectively (2019 — less than $0.1 million and $0.6 million, respectively).
[2]	The Company is reporting negative revenue due to the continued amortization of lessee incentives that are typically netted against lease revenues, which are abnormally low during the period due to the COVID-19 global pandemic, as discussed in Note 2.
[3]	Includes initial upfront payments and the present value of fixed minimum payments from sales and sales-type lease arrangements of IMAX Theater Systems, and the present value of estimated variable consideration from sales of IMAX Theater Systems. To a lesser extent, also includes finance income associated with these revenue streams.
[4]	Principally includes after-market sales of IMAX projection system parts and 3D glasses
[5]	The Company is reporting negative revenue due to an adjustment to prior period revenue.

Segment Reporting - Breakdown_2

Segment Reporting - Breakdown of Revenue and (Margin Loss) Gross Margin by Category (Parenthetical) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
IMAX DMR [Member]
Segment Reporting (Textual) [Abstract]
Marketing costs (recovery)	$ 0	$ 9,500,000	$ 2,400,000	$ 13,400,000
Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Segment Reporting (Textual) [Abstract]
Advertising, marketing and commission costs		200,000	600,000	300,000
IMAX systems [Member]
Segment Reporting (Textual) [Abstract]
Advertising, marketing and commission costs	200,000	400,000	400,000	900,000
Film Distribution [Member]
Segment Reporting (Textual) [Abstract]
Marketing costs (recovery)			$ 200,000	$ 600,000
Maximum [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Segment Reporting (Textual) [Abstract]
Advertising, marketing and commission costs	100,000
Maximum [Member] | Film Distribution [Member]
Segment Reporting (Textual) [Abstract]
Marketing costs (recovery)	$ 100,000	$ 100,000

Segment Reporting - Geographic

Segment Reporting - Geographic Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Geographical Information
Revenues, total	$ 8,855	$ 104,797	$ 43,757	$ 184,995
United States [Member]
Geographical Information
Revenues, total	3,812	35,944	16,777	60,237
Asia (excluding Greater China) [Member]
Geographical Information
Revenues, total	1,868	9,963	7,728	18,753
Greater China [Member]
Geographical Information
Revenues, total	1,393	32,575	6,662	59,256
Russia & the CIS [Member]
Geographical Information
Revenues, total	658	5,619	2,224	7,307
Western Europe [Member]
Geographical Information
Revenues, total	631	11,933	5,188	20,376
Latin America [Member]
Geographical Information
Revenues, total	108	2,160	1,635	4,813
Canada [Member]
Geographical Information
Revenues, total	12	2,620	943	4,492
Rest of the World [Member]
Geographical Information
Revenues, total	$ 373	$ 3,983	$ 2,600	$ 9,761

Employees Pension and Postret_3

Employees Pension and Postretirement Benefits - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Deferred Compensation Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Deferred compensation plan description			The Company maintained a nonqualified deferred compensation benefit plan (the “Retirement Plan”) covering the former CEO of IMAX Entertainment and Senior Executive Vice President of the Company. Under the terms of the Retirement Plan, the benefits were due to vest in full if he incurred a separation from service (as defined therein).
Benefit obligation recorded	$ 3,600,000		$ 3,600,000		$ 3,600,000
Compensation expense recognized	0	$ 0	0	$ 0
Richard L. Gelfond [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Lump sump payment			$ 20,300,000
SERP Benefits [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
SERP assumptions			The accounting for the SERP assumes that Mr. Gelfond will receive a lump sum payment of $20.3 million six months after retirement at the end of the current term of his employment agreement (December 31, 2022), although Mr. Gelfond has not informed the Company that he intends to retire at that time.
Benefit Obligation	19,029,000		$ 19,029,000		18,840,000	$ 17,977,000
Interest costs	100,000	100,000	189,000	300,000	564,000
Expected interest costs in the remainder of the year	200,000		200,000
Companies contribution and expenses during the remainder of 2020	0		$ 0
Defined Contribution Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Defined contribution pension plans for employees			The Company also maintains defined contribution plans for its employees, including its executive officers. The Company makes contributions to these plans on behalf of employees in an amount up to 5% of their base salary subject to certain prescribed maximums.
Maximum percentage of base salary contributed to Defined Contribution Pension Plan by Company			5.00%
Canadian Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Contribution and recorded expense	200,000	300,000	$ 500,000	600,000
Us Internal Revenue Code [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Contribution and recorded expense	100,000	100,000	400,000	300,000
Postretirement Benefits Executives [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Benefit Obligation	600,000		600,000		700,000
Postretirement Benefits Executives [Member] | Maximum [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Maximum amount of Postretirement benefit recorded expense	100,000	100,000	100,000	100,000
Postretirement Benefits Canadian Employees [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Benefit Obligation	1,500,000		1,500,000		$ 1,600,000
Postretirement Benefits Canadian Employees [Member] | Maximum [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Maximum amount of Postretirement benefit recorded expense	$ 100,000	$ 100,000	$ 100,000	$ 100,000

Employee's Pension and Postreti

Employee's Pension and Postretirement Benefits - Amounts Accrued and Unfunded Status (Details) - Pension Plans, Defined Benefit [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Amounts Accrued
Obligation, beginning of period			$ 18,840	$ 17,977	$ 17,977
Prior Service cost					456
Interest cost	$ 100	$ 100	189	$ 300	564
Actuarial gain			0		(157)
Obligation, end of period and unfunded status	$ 19,029		$ 19,029		$ 18,840

Financial Instruments - Fair Va

Financial Instruments - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands		Jun. 30, 2020	Dec. 31, 2019
Other Financial Instrument
Cash and cash equivalents		$ 318,986	$ 109,484
Investment in equity securities		13,192	15,685
Net financed sales receivables		108,081	112,432
Net investment in sales-type leases		15,784	15,606
Foreign exchange contracts — designated forwards		291	(530)
Bank indebtedness - under the Credit Facility		(300,000)	(20,000)
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]
Other Financial Instrument
Cash and cash equivalents	[1]	318,986	109,484
Investment in equity securities	[2]	13,192	15,685
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Investment in equity securities	[1]	1,000	1,000
Net financed sales receivables	[3]	108,081	112,432
Net investment in sales-type leases	[3]	15,784	15,606
Bank indebtedness - under the Working Capital Facility	[1]	(244)	0
Bank indebtedness - under the Credit Facility	[1]	(300,000)	(20,000)
Convertible loan receivable	[3]	0	1,500
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Foreign exchange contracts — designated forwards	[2]	(318)	530
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Not Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Foreign exchange contracts — designated forwards	[2]	27	0
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]
Other Financial Instrument
Cash and cash equivalents	[1]	318,986	109,484
Investment in equity securities	[2]	13,192	15,685
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Investment in equity securities	[1]	1,000	1,000
Net financed sales receivables	[3]	108,430	111,441
Net investment in sales-type leases	[3]	15,516	15,309
Bank indebtedness - under the Working Capital Facility	[1]	(244)	0
Bank indebtedness - under the Credit Facility	[1]	(300,000)	(20,000)
Convertible loan receivable	[3]	0	1,500
Estimate of Fair Value, Fair Value Disclosure [Member] | Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Foreign exchange contracts — designated forwards	[2]	(318)	530
Estimate of Fair Value, Fair Value Disclosure [Member] | Not Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Foreign exchange contracts — designated forwards	[2]	$ 27	$ 0
[1]	Recorded at cost, which approximates fair value.
[2]	Value determined using quoted prices in active markets.
[3]	Estimated based on discounting future cash flows at currently available interest rates with comparable terms.

Financial Instruments - Additio

Financial Instruments - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2020USD ($)Country	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)Country	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)
Financial Instruments (Textual) [Abstract]
Significant transfers into/out of Level 3	$ 0	$ 0	$ 0	$ 0
Number of countries that generate box office | Country	81		81
Foreign Exchange contract settlement date range			settlement dates throughout 2020 and 2021
Estimated losses to be reclassified to earnings within the next twelve months			$ (400,000)
Investment in equity securities	$ 13,192,000		13,192,000		$ 15,685,000
Investment in equity securities - cost	15,200,000		$ 15,200,000
Equity securities restrictions			lock-up period of six months
Gain (loss) in fair value of equity securities	2,025,000	$ (4,544,000)	$ (2,514,000)	$ (2,053,000)
Maoyan [Member]
Financial Instruments (Textual) [Abstract]
Investment in equity securities	12,100,000		12,100,000		14,600,000
Fixed Income Securities [Member]
Financial Instruments (Textual) [Abstract]
Equity Investment, Debt Securities	1,100,000		1,100,000		1,000,000
Preferred Stock [Member] | Other Assets [Member]
Financial Instruments (Textual) [Abstract]
Investment in equity securities	$ 1,000,000		$ 1,000,000		$ 1,000,000
Maximum [Member]
Financial Instruments (Textual) [Abstract]
Equity securities percentage ownership			1.00%

Financial Instruments - Notiona

Financial Instruments - Notional Amount of Derivative (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Derivatives Fair Value [Line Items]
Foreign exchange contracts — Forwards	$ 36,021	$ 36,052
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Foreign exchange contracts — Forwards	32,437	$ 36,052
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Foreign exchange contracts — Forwards	$ 3,584

Financial Instruments - Fair _2

Financial Instruments - Fair Value of Foreign Exchange Contracts (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Derivatives Fair Value [Line Items]
Foreign exchange contracts - designated forwards	$ (291)	$ 530
Other Assets [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Derivative Asset, Fair Value	245	602
Other Assets [Member] | Not Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Derivative Asset, Fair Value	57
Accrued and other liabilities [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Derivative Liability, Fair Value	(563)	$ (72)
Accrued and other liabilities [Member] | Not Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Derivative Liability, Fair Value	$ (30)

Financial Instruments - Derivat

Financial Instruments - Derivatives in Foreign Currency Hedging Relationships (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Derivative Instruments Gain Loss [Line Items]
Derivative Gain (Loss) Recognized in OCI (Effective Portion)	$ 1,334	$ 297	$ (1,526)	$ 365
Location of Derivative Loss Reclassified from AOCI into Income (Effective Portion)	(337)	(374)	(695)	(693)
Derivative Gain (Loss) Recognized In and Out of OCI (Effective Portion)		2	(88)	2
Fair Value Hedging [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative Gain (Loss) Recognized in OCI (Effective Portion)	1,334	297	(1,526)	365
Selling, general and administrative expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Location of Derivative Loss Reclassified from AOCI into Income (Effective Portion)	(328)	(355)	(669)	(661)
Property, plant and equipment [Member]
Derivative Instruments Gain Loss [Line Items]
Location of Derivative Loss Reclassified from AOCI into Income (Effective Portion)		$ (19)		$ (32)
Inventories [Member]
Derivative Instruments Gain Loss [Line Items]
Location of Derivative Loss Reclassified from AOCI into Income (Effective Portion)	$ (9)		$ (26)

Financial Instruments - Non Des

Financial Instruments - Non Designated Derivatives in Foreign Currency Relationships (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Derivative Instruments Gain Loss [Line Items]
Location of Derivative Gain	$ 27	$ 27
Selling, general and administrative expenses [Member] | Foreign Exchange Contracts - Forwards [Member]
Derivative Instruments Gain Loss [Line Items]
Location of Derivative Gain	$ 27	$ 27

Non-Controlling Interests - Add

Non-Controlling Interests - Additional Information (Details) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2014USD ($)Film	Dec. 31, 2019USD ($)
Non-controlling Interests
Non-controlling interest	$ 74,723		$ 74,723			$ 89,493
Net (loss) income attributable to non-controlling interests	$ (4,080)	$ 2,439	(14,137)	$ 6,661
Investment in film assets			$ 4,057	8,214
IMAX China Noncontrolling Interest
Non-controlling Interests
Minority Interest Ownership Percentage By Company	69.81%		69.81%
IMAX China
Non-controlling Interests
Non-controlling interest	$ 74,700		$ 74,700
Net (loss) income attributable to non-controlling interests	$ (2,800)	$ 2,700	(12,500)	$ 7,000
Other Noncontrolling Interest [Member]
Non-controlling Interests
Net (loss) income attributable to non-controlling interests			$ (1,671)
Non-controlling interest description			The Company’s Original Film Fund was established in 2014 to co-finance a portfolio of 10 original large-format films. The initial investment in the Original Film Fund was committed by a third party in the amount of $25.0 million, with the possibility of contributing additional funds. The Company has contributed $9.0 million to the Original Film Fund since 2014 and has reached its maximum contribution.
Number Of Expected Original Films | Film					10
Investment in film assets			$ 22,300
Other Noncontrolling Interest [Member] | Third Party [Member]
Non-controlling Interests
Film Fund Expected Capital Contribution					$ 25,000
Other Noncontrolling Interest [Member] | IMAX [Member]
Non-controlling Interests
Film fund contributions paid			$ 9,000

Non-Controlling Interests - Sum

Non-Controlling Interests - Summary of Movement of the Non-controlling Interest in Temporary Equity in Company's Subsidiary (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Non-controlling Interests
Net loss	$ (4,080)	$ 2,439	$ (14,137)	$ 6,661
Other Noncontrolling Interest [Member]
Non-controlling Interests
Balance as at December 31, 2019			5,908
Net loss			(1,671)
Balance as at June 30, 2020	$ 4,237		$ 4,237

Exit Costs, Restructuring Cha_2

Exit Costs, Restructuring Charges and Associated Impairments - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Restructuring And Related Activities [Abstract]
Restructuring charges and costs to exit leases	$ 0	$ 0	$ 0	$ 850